[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftPH_ljBUSJbYyXpKMkQ1kCsq292surrYGMnBXgAAOpA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"University Hospital, Basel, Switzerland",[4],970,false,213,36,849250,68,721,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Healthy",48,{"name":18,"count":19},"Obesity",15,{"name":21,"count":22},"Multiple Sclerosis",10,{"name":24,"count":22},"Atrial Fibrillation",{"name":26,"count":27},"Breast Cancer",9,{"name":29,"count":27},"Pain",{"name":31,"count":27},"Glaucoma",{"name":33,"count":34},"Hyponatremia",8,[36,41,46,51,56,60,65,70,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03735901","Enhancement of Stroke Rehabilitation With Levodopa","2024-08-27","IMP Levodopa 100mg\u002FCarbidopa 25mg",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05684055","\"Community-based, eHealth Supported Management of Cardiovascular Risk Factors by Lay Village Health Workers (ComBaCaL aHT TwiC 1 & ComBaCaL aHT TwiC 2)","2025-05-04","First-line antihypertensive single-pill combination",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04095572","Alternative Prophylaxis in Female Recurrent Urinary Tract Infections","2025-06","intravesical instillation with HA-CS",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03781128","Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache","2025-12","Lysergic Acid Diethylamide",{"nctId":57,"briefTitle":58,"date":54,"intervention":59},"NCT05655091","Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection","FLU or CZO as continuous",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05869539","ACT-TIL and ANV419 for Advanced Melanoma.","2026-04","Combination of Tumor-infiltrating lymphocyte transfer with ANV419",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05401578","Canakinumab for the Treatment of Postprandial Hypoglycemia","2026-05-31","Canakinumab",{"nctId":71,"briefTitle":72,"date":68,"intervention":73},"NCT06978777","Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity","Caffeine",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06884514","Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects","2026-07-01","Psilocybin",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06796361","Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness","2026-08","Ketanserin 40mg plus Psilocybin 40mg",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,182,208,234,252,277,301,319,347,374,410,453,477,503,521,545,579,631,657,675,702,720,744,769,794,819,843,869,890,908,941,965,990,1053,1154,1191,1209,1227,1254,1274,1292,1320,1338,1356,1374,1397,1415,1433,1451,1469,1494,1512,1530,1557,1575,1593,1699,1725,1743,1816,1859,1885,1903,1921,1946,1970,1988,2009,2031,2058,2099,2135,2170,2205,2223,2241,2259,2277,2302,2320,2345,2369,2387,2412,2430,2458,2476,2494,2512,2537,2555,2579,2603,2627,2645,2671,2689,2707,2725,2743,2769,2787,2805,2831,2855,2881,2899,2924,2950,2968,2994,3021,3046,3064,3088,3113,3138,3156,3174,3200,3218,3236,3260,3278,3307,3325,3343,3361,3387,3405,3429,3453,3471,3494,3512,3535,3557,3583,3601,3619,3658,3692,3729,3753,3771,3789,3814,3832,3857,3881,3907,3932,3950,3973,3998,4016,4034,4056,4074,4092,4116,4134,4152,4177,4201,4223,4248,4273,4291,4314,4339,4357,4375,4393,4419,4478,4516,4538,4560,4578,4596,4620,4644,4667,4694,4717,4741,4765,4783,4812,4830,4853,4871,4895,4921,4939,4957,4980,5005,5023,5046,5070,5094,5118,5144,5177,5203,5225,5243,5261,5287,5305,5323,5346,5364,5389,5407,5431,5449,5471,5493,5516,5541,5559,5577,5595,5613,5634,5661,5679,5697,5715,5733,5751,5774,5797,5815,5833,5856,5874,5892,5916,5940,5958,5976,5994,6020,6038,6056,6074,6097,6121,6144,6168,6191,6214,6232,6250,6274,6292,6316,6334,6352,6370,6395,6413,6431,6449,6475,6493,6516,6540,6558,6576,6601,6619,6637,6660,6684,6709,6777,6813,6845,6863,6881,6906,6924,6948,6972,6997,7020,7045,7072,7090,7108,7131,7156,7179,7205,7231,7249,7274,7299,7317,7342,7360,7384,7402,7420,7438,7463,7481,7499,7522,7540,7563,7587,7615,7633,7660,7678,7703,7727,7751,7769,7793,7821,7843,7867,7890,7914,7937,7962,7986],{"intervention":93,"totalTrials":94,"cells":95},"Prednisone",6,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":117,"NA":180},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT00973154","Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial","COMPLETED",[88],"2014-07","2014-12","2009-12",800,[115],"Community-acquired Pneumonia",[93],{"trials":118,"activeCount":179,"soonestReadout":172},[119,132,146,157,167],{"nctId":120,"briefTitle":121,"status":108,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":129},"NCT01183247","An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens",[89],"2010-06","2008-07",63,[127,128],"Comparative Study","Immunosuppressive Agents",[130,131,93],"Rapamycin","Everolimus",{"nctId":133,"briefTitle":134,"status":108,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":142},"NCT00812123","Calcineurin Free Immunosuppression in Renal Transplant Recipients",[89],"2005-07","2001-01",127,[140,141],"Kidney Transplantation","Chronic Kidney Disease",[143,144,93,145],"Sirolimus","Cyclosporine A","Mycophenolate mofetil",{"nctId":147,"briefTitle":148,"status":108,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},"NCT00975078","Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment",[89],"2009-10","2009-05",39,[154],"Adrenal Gland Hypofunction",[156],"prednisone",{"nctId":158,"briefTitle":159,"status":108,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"NCT03269747","Short Term Effect of Glucocorticoids on Brown Adipose Tissue Thermogenesis in Humans",[89],"2019-04-16","2017-12-06",16,[165],"Brown Adipose Tissue",[93],{"nctId":168,"briefTitle":169,"status":170,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":178},"NCT03153527","Taper Or Abrupt Steroid Stop: TOASSTtrial","RECRUITING",[89],"2027-06","2017-05-31",530,[176,177],"Inflammatory Disorder","Autoimmune",[93],1,{"trials":181,"activeCount":98},[],{"intervention":183,"totalTrials":179,"cells":184},"Wilate",{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":206},{"trials":186,"activeCount":98},[],{"trials":188,"activeCount":98},[],{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":179,"soonestReadout":199},[195],{"nctId":196,"briefTitle":197,"status":170,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":205},"NCT04555785","Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor",[89],"2027-11","2028-11","2022-04-01",120,[204],"Bleeding",[183],{"trials":207,"activeCount":98},[],{"intervention":209,"totalTrials":179,"cells":210},"Immune checkpoint inhibitors plus Iscador® Qu.",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":232},{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":98},[],{"trials":218,"activeCount":98},[],{"trials":220,"activeCount":179,"soonestReadout":225},[221],{"nctId":222,"briefTitle":223,"status":170,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT06408688","Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors",[89],"2026-11","2024-06-24",100,[229],"Advanced Solid Tumor",[209,231],"Immune Checkpoint Inhibitors",{"trials":233,"activeCount":98},[],{"intervention":231,"totalTrials":179,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":250},{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":98},[],{"trials":243,"activeCount":98},[],{"trials":245,"activeCount":179,"soonestReadout":225},[246],{"nctId":222,"briefTitle":223,"status":170,"phases":247,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":248,"interventions":249},[89],[229],[209,231],{"trials":251,"activeCount":98},[],{"intervention":253,"totalTrials":179,"cells":254},"Cabergoline",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":275},{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":98},[],{"trials":264,"activeCount":179,"soonestReadout":269},[265],{"nctId":266,"briefTitle":267,"status":170,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT07045935","Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment",[89],"2029-12-31","2025-09-16",60,[273],"Prolactinoma",[253],{"trials":276,"activeCount":98},[],{"intervention":50,"totalTrials":179,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":299},{"trials":280,"activeCount":98},[],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":179,"soonestReadout":49},[289],{"nctId":47,"briefTitle":48,"status":170,"phases":290,"primaryCompletion":49,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},[89],"2026-06","2020-10-27",50,[295,296],"Urinary Tract Infections","Urinary Tract Infection (UTI)",[50,298],"intravesical instillation of sterile purified water",{"trials":300,"activeCount":98},[],{"intervention":298,"totalTrials":179,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":317},{"trials":304,"activeCount":98},[],{"trials":306,"activeCount":98},[],{"trials":308,"activeCount":98},[],{"trials":310,"activeCount":98},[],{"trials":312,"activeCount":179,"soonestReadout":49},[313],{"nctId":47,"briefTitle":48,"status":170,"phases":314,"primaryCompletion":49,"completion":291,"start":292,"enrollment":293,"conditions":315,"interventions":316},[89],[295,296],[50,298],{"trials":318,"activeCount":98},[],{"intervention":320,"totalTrials":179,"cells":321},"Empagliflozin 25 MG",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":345},{"trials":323,"activeCount":98},[],{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"trials":331,"activeCount":179,"soonestReadout":336},[332],{"nctId":333,"briefTitle":334,"status":170,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":344},"NCT04447911","Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia",[89],"2027-01","2027-02","2021-02-04",172,[33,341,342,343],"SIADH","Liver Failure","Kidney Failure",[320],{"trials":346,"activeCount":98},[],{"intervention":348,"totalTrials":179,"cells":349},"Lorazepam 1 mg",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":372},{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":98},[],{"trials":355,"activeCount":98},[],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":179,"soonestReadout":365},[360],{"nctId":361,"briefTitle":362,"status":363,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":371},"NCT07428681","Lorazepam for Delirium Prevention in Critically Ill Patients With High Anttila-Index","NOT_YET_RECRUITING",[89],"2028-02","2029-02","2027-03",260,[370],"Delirium Confusional State",[348],{"trials":373,"activeCount":98},[],{"intervention":375,"totalTrials":376,"cells":377},"Melatonin",2,{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":399},{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":179,"soonestReadout":392},[388],{"nctId":389,"briefTitle":390,"status":170,"phases":391,"primaryCompletion":392,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":398},"NCT03438526","The Basel BOMP-AID Randomized Trial",[89],"2026-12","2027-12","2022-01-03",190,[397],"Hypoactive Delirium",[375],{"trials":400,"activeCount":98},[401],{"nctId":402,"briefTitle":403,"status":108,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":163,"conditions":407,"interventions":409},"NCT00675181","Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow",[90],"2010-01","2008-05",[408],"Vasospastic Syndrome",[375],{"intervention":69,"totalTrials":411,"cells":412},3,{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":429,"PHASE4":449,"NA":451},{"trials":414,"activeCount":98},[],{"trials":416,"activeCount":98},[],{"trials":418,"activeCount":98},[419],{"nctId":420,"briefTitle":421,"status":422,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT01805960","Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF","TERMINATED",[87],"2016-12","2013-06",24,[24],[69],{"trials":430,"activeCount":179,"soonestReadout":68},[431,438],{"nctId":66,"briefTitle":67,"status":170,"phases":432,"primaryCompletion":68,"completion":68,"start":433,"enrollment":434,"conditions":435,"interventions":437},[88],"2023-04-17",56,[436],"Postprandial Hypoglycemia",[69],{"nctId":439,"briefTitle":440,"status":108,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":448},"NCT04510493","Canakinumab in Patients With COVID-19 and Type 2 Diabetes",[88],"2021-08-17","2020-10-23",116,[446,447],"Coronavirus Infection","Diabetes Mellitus, Type 2",[69],{"trials":450,"activeCount":98},[],{"trials":452,"activeCount":98},[],{"intervention":40,"totalTrials":179,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":473,"NA":475},{"trials":456,"activeCount":98},[],{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":179,"soonestReadout":39},[463],{"nctId":37,"briefTitle":38,"status":464,"phases":465,"primaryCompletion":39,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":472},"ACTIVE_NOT_RECRUITING",[88],"2029-06-30","2019-06-14",610,[470,471],"Acute Stroke","Stroke Rehabilitation",[40],{"trials":474,"activeCount":98},[],{"trials":476,"activeCount":98},[],{"intervention":478,"totalTrials":179,"cells":479},"DEB-DoxNic-TACE",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":499,"NA":501},{"trials":481,"activeCount":98},[],{"trials":483,"activeCount":98},[],{"trials":485,"activeCount":98},[],{"trials":487,"activeCount":179,"soonestReadout":492},[488],{"nctId":489,"briefTitle":490,"status":170,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT07302919","Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma",[87,88],"2028-06","2026-02-16",152,[496],"Hepato Cellular Carcinoma (HCC)",[478,498],"current standard of care",{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"intervention":498,"totalTrials":179,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":517,"NA":519},{"trials":506,"activeCount":98},[],{"trials":508,"activeCount":98},[],{"trials":510,"activeCount":98},[],{"trials":512,"activeCount":179,"soonestReadout":492},[513],{"nctId":489,"briefTitle":490,"status":170,"phases":514,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":515,"interventions":516},[87,88],[496],[478,498],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"intervention":522,"totalTrials":179,"cells":523},"Colchicine",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":541,"NA":543},{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":179,"soonestReadout":367},[532],{"nctId":533,"briefTitle":534,"status":170,"phases":535,"primaryCompletion":367,"completion":367,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT05890664","Colchicine After Electrocardioversion for Atrial Fibrillation",[88],"2024-04-14",416,[24,539],"Cardiac Arrhythmia",[522],{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"intervention":546,"totalTrials":376,"cells":547},"Oxytocin nasal spray",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":549,"activeCount":98},[],{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":376,"soonestReadout":392},[554,564],{"nctId":555,"briefTitle":556,"status":170,"phases":557,"primaryCompletion":337,"completion":337,"start":558,"enrollment":559,"conditions":560,"interventions":563},"NCT06676774","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls",[87],"2025-05-16",42,[561,562],"Arginine Vasopressin Deficiency","Diabetes Insipidus",[546],{"nctId":565,"briefTitle":566,"status":170,"phases":567,"primaryCompletion":392,"completion":392,"start":568,"enrollment":559,"conditions":569,"interventions":572},"NCT06808516","Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls",[87],"2025-07-01",[561,570,571],"Central Diabetes Insipidus","Oxytocin Deficiency",[546],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"intervention":55,"totalTrials":580,"cells":581},4,{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":616,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":98},[586,596,605],{"nctId":587,"briefTitle":588,"status":108,"phases":589,"primaryCompletion":590,"completion":591,"start":592,"enrollment":426,"conditions":593,"interventions":594},"NCT05175430","Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects",[86],"2024-02-20","2024-03-07","2022-10-24",[15],[595,55],"Paroxetine",{"nctId":597,"briefTitle":598,"status":108,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":426,"conditions":602,"interventions":603},"NCT04516902","Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects",[86],"2022-08-22","2021-01-01",[15],[55,604],"3,4-methylenedioxymethamphetamine",{"nctId":606,"briefTitle":607,"status":108,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":426,"conditions":612,"interventions":613},"NCT04558294","Effect of Ketanserin After LSD Administration",[86],"2021-08-28","2021-09-29","2020-10-16",[15],[55,614,615],"Ketanserin Placebo","Ketanserin",{"trials":617,"activeCount":179,"soonestReadout":54},[618],{"nctId":52,"briefTitle":53,"status":170,"phases":619,"primaryCompletion":54,"completion":54,"start":620,"enrollment":621,"conditions":622,"interventions":624},[87],"2019-01-02",30,[623],"Cluster Headache",[55],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[],{"intervention":632,"totalTrials":179,"cells":633},"177Lu-DOTA-JR11",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":98},[],{"trials":639,"activeCount":179,"soonestReadout":644},[640],{"nctId":641,"briefTitle":642,"status":170,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":649},"NCT04997317","Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide",[86,87],"2026-12-31","2021-04-21",18,[648],"Meningioma",[632,650,632],"177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4",{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"intervention":650,"totalTrials":179,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":660,"activeCount":98},[],{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":179,"soonestReadout":644},[665],{"nctId":641,"briefTitle":642,"status":170,"phases":666,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":667,"interventions":668},[86,87],[648],[632,650,632],{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"intervention":676,"totalTrials":179,"cells":677},"N-TEC",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":179,"soonestReadout":688},[684],{"nctId":685,"briefTitle":686,"status":170,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT06163573","Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.",[87],"2028-09","2029-09","2024-06-06",75,[693],"Patellofemoral Osteoarthritis",[676,695],"Platelet rich plasma",{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[],{"trials":701,"activeCount":98},[],{"intervention":695,"totalTrials":179,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":179,"soonestReadout":688},[710],{"nctId":685,"briefTitle":686,"status":170,"phases":711,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":712,"interventions":713},[87],[693],[676,695],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"intervention":721,"totalTrials":179,"cells":722},"indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":724,"activeCount":98},[],{"trials":726,"activeCount":98},[],{"trials":728,"activeCount":179,"soonestReadout":337},[729],{"nctId":730,"briefTitle":731,"status":363,"phases":732,"primaryCompletion":337,"completion":337,"start":733,"enrollment":27,"conditions":734,"interventions":737},"NCT07368153","Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors",[87],"2026-02",[735,736],"EBV Infections","Kidney Transplant",[721],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":98},[],{"intervention":745,"totalTrials":179,"cells":746},"Engineered cartilage graft",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":748,"activeCount":98},[],{"trials":750,"activeCount":98},[],{"trials":752,"activeCount":179,"soonestReadout":757},[753],{"nctId":754,"briefTitle":755,"status":170,"phases":756,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":762},"NCT06576583","Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.",[87],"2029-01","2030-01","2025-07-15",150,[693],[745],{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":98},[],{"intervention":770,"totalTrials":179,"cells":771},"Nintedanib",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":773,"activeCount":98},[],{"trials":775,"activeCount":98},[],{"trials":777,"activeCount":179,"soonestReadout":392},[778],{"nctId":779,"briefTitle":780,"status":170,"phases":781,"primaryCompletion":392,"completion":392,"start":782,"enrollment":783,"conditions":784,"interventions":787},"NCT03805477","Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation",[87],"2019-03-20",20,[785,786],"Bronchiolitis Obliterans Syndrome (BOS)","Bronchiolitis Obliterans (BO)",[770],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"intervention":795,"totalTrials":179,"cells":796},"TILs（Tumor Infiltrating Lymphocytes）",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":798,"activeCount":98},[],{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":179,"soonestReadout":807},[803],{"nctId":804,"briefTitle":805,"status":170,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":621,"conditions":809,"interventions":812},"NCT06455917","TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients",[87],"2029-12","2025-01-22",[810,811],"Non-Small Cell Lung Cancer","Lung Cancer (NSCLC)",[795],{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"intervention":820,"totalTrials":179,"cells":821},"Donor-derived ex-vivo expanded EBV Tscm CTL",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":823,"activeCount":98},[],{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":179,"soonestReadout":832},[828],{"nctId":829,"briefTitle":830,"status":363,"phases":831,"primaryCompletion":832,"completion":832,"start":225,"enrollment":22,"conditions":833,"interventions":836},"NCT05688241","EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas\u002F Diseases",[86,87],"2031-12",[834,835],"EBV Lymphoma","Post-transplant Lymphoproliferative Disease (PTLD)",[820],{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":98},[],{"trials":842,"activeCount":98},[],{"intervention":844,"totalTrials":179,"cells":845},"IFN-γ positive selected T-cells",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":863,"PHASE4":865,"NA":867},{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[],{"trials":851,"activeCount":179,"soonestReadout":392},[852],{"nctId":853,"briefTitle":854,"status":170,"phases":855,"primaryCompletion":392,"completion":392,"start":111,"enrollment":621,"conditions":856,"interventions":862},"NCT02007356","A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®",[87],[857,858,859,860,861],"Adenovirus Infection","EBV","Cytomegalovirus Infections","Cytokine Capture System","Allogenic Disease",[844],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[],{"intervention":59,"totalTrials":179,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":872,"activeCount":98},[],{"trials":874,"activeCount":98},[],{"trials":876,"activeCount":179,"soonestReadout":54},[877],{"nctId":57,"briefTitle":58,"status":170,"phases":878,"primaryCompletion":54,"completion":54,"start":879,"enrollment":9,"conditions":880,"interventions":882},[87],"2023-10-26",[881],"Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)",[59,883],"standard FLU or CZO intermittent bolus administration",{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[],{"intervention":883,"totalTrials":179,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[],{"trials":897,"activeCount":179,"soonestReadout":54},[898],{"nctId":57,"briefTitle":58,"status":170,"phases":899,"primaryCompletion":54,"completion":54,"start":879,"enrollment":9,"conditions":900,"interventions":901},[87],[881],[59,883],{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[],{"trials":907,"activeCount":98},[],{"intervention":909,"totalTrials":179,"cells":910},"Lysergic Acid Diethylamide Tartrate",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":179,"soonestReadout":921},[917],{"nctId":918,"briefTitle":919,"status":170,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":271,"conditions":924,"interventions":934},"NCT05883540","Lysergic Acid Diethylamide (LSD) in Palliative Care",[87],"2027-09","2028-05","2024-06-09",[925,29,926,927,928,929,930,931,932,933],"Palliative Care","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress",[909,909],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":98},[],{"intervention":942,"totalTrials":179,"cells":943},"61Cu-NODAGA-LM3",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":945,"activeCount":98},[],{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":179,"soonestReadout":492},[950],{"nctId":951,"briefTitle":952,"status":170,"phases":953,"primaryCompletion":492,"completion":492,"start":954,"enrollment":955,"conditions":956,"interventions":958},"NCT06455358","61Cu-NODAGA-LM3 PET\u002FCT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)",[86,87],"2025-02-05",27,[957],"Neuroendocrine Tumors",[942],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[],{"trials":964,"activeCount":98},[],{"intervention":966,"totalTrials":179,"cells":967},"Intranasal OXT",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":179,"soonestReadout":978},[974],{"nctId":975,"briefTitle":976,"status":170,"phases":977,"primaryCompletion":978,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT06036004","Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus",[87],"2026-10","2024-01-08",112,[982],"Central Diabetes Insipidus (cDI)",[966],{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":98},[],{"trials":989,"activeCount":98},[],{"intervention":78,"totalTrials":991,"cells":992},5,{"EARLY_PHASE1":993,"PHASE1":1006,"PHASE2":1045,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":994,"activeCount":98},[995],{"nctId":996,"briefTitle":997,"status":108,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT03604744","Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin",[85],"2021-04-10","2021-04-15","2019-03-27",28,[15],[1005,1005,78,78],"LSD",{"trials":1007,"activeCount":376,"soonestReadout":77},[1008,1016,1025,1035],{"nctId":75,"briefTitle":76,"status":170,"phases":1009,"primaryCompletion":77,"completion":77,"start":1010,"enrollment":426,"conditions":1011,"interventions":1012},[86],"2025-04-03",[15],[78,1013,1014,1015],"3,4-Methylenedioxymethamphetamine","Psilocybin placebo","3,4-Methylenedioxymethamphetamine placebo",{"nctId":1017,"briefTitle":1018,"status":170,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":426,"conditions":1022,"interventions":1023},"NCT06899334","Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants",[86],"2026-08-01","2025-04-01",[15],[1005,78,1024],"DMT",{"nctId":1026,"briefTitle":1027,"status":108,"phases":1028,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT04227756","Comparative Acute Effects of LSD, Psilocybin and Mescaline",[86],"2022-09-02","2020-05-19",32,[15],[1005,78,1034],"Mescaline",{"nctId":1036,"briefTitle":1037,"status":108,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":426,"conditions":1042,"interventions":1043},"NCT05523401","Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects",[86],"2024-10-20","2024-11-05","2023-08-16",[15],[1044,1044,1044,604,78],"4-bromo-2,5-dimethoxyphenethylamine",{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":98},[],{"trials":1050,"activeCount":98},[],{"trials":1052,"activeCount":98},[],{"intervention":1005,"totalTrials":1054,"cells":1055},11,{"EARLY_PHASE1":1056,"PHASE1":1096,"PHASE2":1115,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1057,"activeCount":98},[1058,1065,1074,1085,1092],{"nctId":1059,"briefTitle":1060,"status":108,"phases":1061,"primaryCompletion":1062,"completion":111,"start":425,"enrollment":163,"conditions":1063,"interventions":1064},"NCT01878942","Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",[85],"2014-02",[15],[1005],{"nctId":1066,"briefTitle":1067,"status":108,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":163,"conditions":1072,"interventions":1073},"NCT03321136","Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)",[85],"2019-07-05","2019-07-11","2017-11-28",[15],[1005,1005,1005,1005,1005],{"nctId":1075,"briefTitle":1076,"status":108,"phases":1077,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1002,"conditions":1081,"interventions":1082},"NCT03019822","Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing",[85],"2018-08-11","2018-09-04","2017-02-01",[15],[1005,1083,1084],"MDMA","Amphetamine",{"nctId":1086,"briefTitle":1087,"status":108,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":111,"enrollment":426,"conditions":1090,"interventions":1091},"NCT02308969","Neuronal Correlates of Altered States of Consciousness",[85],"2015-09",[15],[1005],{"nctId":996,"briefTitle":997,"status":108,"phases":1093,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1094,"interventions":1095},[85],[15],[1005,1005,78,78],{"trials":1097,"activeCount":179,"soonestReadout":1020},[1098,1102,1111],{"nctId":1017,"briefTitle":1018,"status":170,"phases":1099,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":426,"conditions":1100,"interventions":1101},[86],[15],[1005,78,1024],{"nctId":1103,"briefTitle":1104,"status":108,"phases":1105,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":783,"conditions":1108,"interventions":1109},"NCT05964647","Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects",[86],"2025-06-30","2024-02-01",[15],[1005,1005,1005,1110],"LSD (150 µg) + placebo",{"nctId":1026,"briefTitle":1027,"status":108,"phases":1112,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":1031,"conditions":1113,"interventions":1114},[86],[15],[1005,78,1034],{"trials":1116,"activeCount":98},[1117,1128],{"nctId":1118,"briefTitle":1119,"status":108,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1127},"NCT03153579","LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders",[87],"2021-12-15","2017-06-23",46,[1125,1126],"Patients","Anxiety Disorders",[1005],{"nctId":1129,"briefTitle":1130,"status":108,"phases":1131,"primaryCompletion":1132,"completion":1133,"start":1134,"enrollment":271,"conditions":1135,"interventions":1137},"NCT03866252","LSD Therapy for Persons Suffering From Major Depression",[87],"2022-09-29","2022-12-01","2019-11-01",[1136],"Major Depressive Disorder",[1005],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":179,"soonestReadout":1148},[1144],{"nctId":1145,"briefTitle":1146,"status":170,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":426,"conditions":1150,"interventions":1152},"NCT07309471","Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD",[90],"2028-07","2026-03-06",[1151],"LSD Reaction",[1153,1005],"DDH-LSD",{"intervention":1155,"totalTrials":376,"cells":1156},"177Lu-PP-F11N",{"EARLY_PHASE1":1157,"PHASE1":1169,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1158,"activeCount":98},[1159],{"nctId":1160,"briefTitle":1161,"status":108,"phases":1162,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":34,"conditions":1165,"interventions":1167},"NCT03647657","177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer",[85],"2021-12-14","2018-12-13",[1166],"Thyroid Cancer, Medullary",[1155,1168],"Sacuitril",{"trials":1170,"activeCount":179,"soonestReadout":1175},[1171],{"nctId":1172,"briefTitle":1173,"status":464,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":426,"conditions":1178,"interventions":1182},"NCT02088645","177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.",[86],"2027-04","2028-04","2015-04",[1166,1179,1180,1181],"Neuroendocrine Tumor of the Lung Grade 1 and 2","Neuroendocrine Tumor of the Thymus Grade 1 and 2","Neuroendocrine Tumor GEP Grade 1-3",[1155],{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"intervention":1014,"totalTrials":179,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":179,"soonestReadout":77},[1197],{"nctId":75,"briefTitle":76,"status":170,"phases":1198,"primaryCompletion":77,"completion":77,"start":1010,"enrollment":426,"conditions":1199,"interventions":1200},[86],[15],[78,1013,1014,1015],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"intervention":1015,"totalTrials":179,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1219,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":179,"soonestReadout":77},[1215],{"nctId":75,"briefTitle":76,"status":170,"phases":1216,"primaryCompletion":77,"completion":77,"start":1010,"enrollment":426,"conditions":1217,"interventions":1218},[86],[15],[78,1013,1014,1015],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"intervention":1228,"totalTrials":179,"cells":1229},"Experimental Intervention",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1246,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":179,"soonestReadout":200},[1234],{"nctId":1235,"briefTitle":1236,"status":363,"phases":1237,"primaryCompletion":200,"completion":200,"start":291,"enrollment":1238,"conditions":1239,"interventions":1245},"NCT07166549","Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",[86],12,[1240,1241,1242,1243,1244],"B Cell Malignancies","B-cell Leukemia","B Cell Lymphoma","Bispecific Chimeric Antigen Receptor (CAR) T Cells","Relapsed or Refractory (r\u002Fr) B-cell Malignancies",[1228],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[],{"intervention":64,"totalTrials":179,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":179,"soonestReadout":63},[1260],{"nctId":61,"briefTitle":62,"status":464,"phases":1261,"primaryCompletion":63,"completion":291,"start":1262,"enrollment":22,"conditions":1263,"interventions":1265},[86],"2023-06-21",[1264],"Advanced Melanoma",[64],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"intervention":1024,"totalTrials":179,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1284,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":179,"soonestReadout":1020},[1280],{"nctId":1017,"briefTitle":1018,"status":170,"phases":1281,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":426,"conditions":1282,"interventions":1283},[86],[15],[1005,78,1024],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[],{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"intervention":1293,"totalTrials":179,"cells":1294},"0.2 mg\u002Fmin 5-MeO-DMT",{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":179,"soonestReadout":1303},[1299],{"nctId":1300,"briefTitle":1301,"status":170,"phases":1302,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1308},"NCT07444788","Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants",[86],"2028-03-01","2026-03-31",40,[1307],"5-methoxy-dimethyltryptamine (5-MeO-DMT)",[1293,1309,1310,1311],"0.4 mg\u002Fmin 5-MeO-DMT","0.6 mg\u002Fmin 5-MeO-DMT","0.8 mg\u002Fmin 5-MeO-DMT",{"trials":1313,"activeCount":98},[],{"trials":1315,"activeCount":98},[],{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":98},[],{"intervention":1309,"totalTrials":179,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":179,"soonestReadout":1303},[1326],{"nctId":1300,"briefTitle":1301,"status":170,"phases":1327,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1328,"interventions":1329},[86],[1307],[1293,1309,1310,1311],{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"trials":1337,"activeCount":98},[],{"intervention":1310,"totalTrials":179,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1348,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":179,"soonestReadout":1303},[1344],{"nctId":1300,"briefTitle":1301,"status":170,"phases":1345,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1346,"interventions":1347},[86],[1307],[1293,1309,1310,1311],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"intervention":1311,"totalTrials":179,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1366,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1359,"activeCount":98},[],{"trials":1361,"activeCount":179,"soonestReadout":1303},[1362],{"nctId":1300,"briefTitle":1301,"status":170,"phases":1363,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1364,"interventions":1365},[86],[1307],[1293,1309,1310,1311],{"trials":1367,"activeCount":98},[],{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"intervention":83,"totalTrials":179,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1389,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1377,"activeCount":98},[],{"trials":1379,"activeCount":179,"soonestReadout":82},[1380],{"nctId":80,"briefTitle":81,"status":170,"phases":1381,"primaryCompletion":82,"completion":82,"start":1382,"enrollment":163,"conditions":1383,"interventions":1384},[86],"2025-04-21",[15],[83,1385,1386,1387,1388],"40mg Psilocybin","20mg Psilocybin","10mg Psilocybin","5mg Psilocybin",{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"intervention":1385,"totalTrials":179,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1407,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":179,"soonestReadout":82},[1403],{"nctId":80,"briefTitle":81,"status":170,"phases":1404,"primaryCompletion":82,"completion":82,"start":1382,"enrollment":163,"conditions":1405,"interventions":1406},[86],[15],[83,1385,1386,1387,1388],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"intervention":1386,"totalTrials":179,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":179,"soonestReadout":82},[1421],{"nctId":80,"briefTitle":81,"status":170,"phases":1422,"primaryCompletion":82,"completion":82,"start":1382,"enrollment":163,"conditions":1423,"interventions":1424},[86],[15],[83,1385,1386,1387,1388],{"trials":1426,"activeCount":98},[],{"trials":1428,"activeCount":98},[],{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"intervention":1387,"totalTrials":179,"cells":1434},{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":179,"soonestReadout":82},[1439],{"nctId":80,"briefTitle":81,"status":170,"phases":1440,"primaryCompletion":82,"completion":82,"start":1382,"enrollment":163,"conditions":1441,"interventions":1442},[86],[15],[83,1385,1386,1387,1388],{"trials":1444,"activeCount":98},[],{"trials":1446,"activeCount":98},[],{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":98},[],{"intervention":1388,"totalTrials":179,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1454,"activeCount":98},[],{"trials":1456,"activeCount":179,"soonestReadout":82},[1457],{"nctId":80,"briefTitle":81,"status":170,"phases":1458,"primaryCompletion":82,"completion":82,"start":1382,"enrollment":163,"conditions":1459,"interventions":1460},[86],[15],[83,1385,1386,1387,1388],{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[],{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":98},[],{"intervention":1470,"totalTrials":179,"cells":1471},"Injection, 161Tb-SibuDAB,1GBq",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":179,"soonestReadout":492},[1476],{"nctId":1477,"briefTitle":1478,"status":170,"phases":1479,"primaryCompletion":492,"completion":492,"start":590,"enrollment":1480,"conditions":1481,"interventions":1483},"NCT06343038","Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification\u002FEscalation Phase Ia\u002Fb Study",[86],25,[1482],"Castration-resistant Prostate Cancer",[1470,1484,1485],"Injection, 177Lu-PSMA-I&T, 1GBq","Injection, 161Tb-SibuDAB, Dose Escalation",{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"intervention":1484,"totalTrials":179,"cells":1495},{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":179,"soonestReadout":492},[1500],{"nctId":1477,"briefTitle":1478,"status":170,"phases":1501,"primaryCompletion":492,"completion":492,"start":590,"enrollment":1480,"conditions":1502,"interventions":1503},[86],[1482],[1470,1484,1485],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":98},[],{"intervention":1485,"totalTrials":179,"cells":1513},{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":179,"soonestReadout":492},[1518],{"nctId":1477,"briefTitle":1478,"status":170,"phases":1519,"primaryCompletion":492,"completion":492,"start":590,"enrollment":1480,"conditions":1520,"interventions":1521},[86],[1482],[1470,1484,1485],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[],{"intervention":1531,"totalTrials":179,"cells":1532},"MDMA 25 mg",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1534,"activeCount":98},[],{"trials":1536,"activeCount":179,"soonestReadout":1541},[1537],{"nctId":1538,"briefTitle":1539,"status":170,"phases":1540,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":783,"conditions":1544,"interventions":1546},"NCT07494214","Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants",[86],"2027-03-09","2027-04-09","2026-03-09",[1545],"Healhty",[1531,1547,1548],"MDMA 75 mg","MDMA 125 mg",{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[],{"trials":1554,"activeCount":98},[],{"trials":1556,"activeCount":98},[],{"intervention":1547,"totalTrials":179,"cells":1558},{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":179,"soonestReadout":1541},[1563],{"nctId":1538,"briefTitle":1539,"status":170,"phases":1564,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":783,"conditions":1565,"interventions":1566},[86],[1545],[1531,1547,1548],{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":98},[],{"trials":1574,"activeCount":98},[],{"intervention":1548,"totalTrials":179,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1591},{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":179,"soonestReadout":1541},[1581],{"nctId":1538,"briefTitle":1539,"status":170,"phases":1582,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":783,"conditions":1583,"interventions":1584},[86],[1545],[1531,1547,1548],{"trials":1586,"activeCount":98},[],{"trials":1588,"activeCount":98},[],{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[],{"intervention":1013,"totalTrials":1054,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1608,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1596,"activeCount":98},[1597],{"nctId":1598,"briefTitle":1599,"status":108,"phases":1600,"primaryCompletion":1601,"completion":1602,"start":1603,"enrollment":621,"conditions":1604,"interventions":1606},"NCT01616407","Effects of MDMA and Methylphenidate on Social Cognition",[85],"2012-12","2013-04","2012-08",[1605],"Social Cognition",[1013,1607],"Methylphenidate",{"trials":1609,"activeCount":179,"soonestReadout":77},[1610,1614,1626,1630,1639,1651,1659,1669,1678],{"nctId":75,"briefTitle":76,"status":170,"phases":1611,"primaryCompletion":77,"completion":77,"start":1010,"enrollment":426,"conditions":1612,"interventions":1613},[86],[15],[78,1013,1014,1015],{"nctId":1615,"briefTitle":1616,"status":108,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":163,"conditions":1620,"interventions":1624},"NCT00990067","Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)",[86],"2010-05","2009-11",[1621,1622,1623],"Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders",[1013,1625],"Duloxetine",{"nctId":597,"briefTitle":598,"status":108,"phases":1627,"primaryCompletion":600,"completion":600,"start":601,"enrollment":426,"conditions":1628,"interventions":1629},[86],[15],[55,604],{"nctId":1631,"briefTitle":1632,"status":108,"phases":1633,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":163,"conditions":1636,"interventions":1637},"NCT01136278","Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)",[86],"2010-12","2010-07",[1621,1622,1623],[1013,1638],"Clonidine",{"nctId":1640,"briefTitle":1641,"status":108,"phases":1642,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1647},"NCT04847206","Effects of MDMA-like Substances in Healthy Subjects",[86],"2024-06-18","2021-12-01",23,[15],[604,1648,1649,1650],"3,4-methylenedioxyamphetamine","lysine-3,4-methylenedioxymethamphetamine","lysine-3,4-methylenedioxyamphetamine",{"nctId":1652,"briefTitle":1653,"status":108,"phases":1654,"primaryCompletion":1601,"completion":1655,"start":1656,"enrollment":163,"conditions":1657,"interventions":1658},"NCT01465685","Emotional Effects of Methylphenidate and MDMA in Healthy Subjects",[86],"2013-01","2011-12",[15],[1013,1607],{"nctId":1660,"briefTitle":1661,"status":108,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":426,"conditions":1665,"interventions":1666},"NCT05277636","Acute Effects of R- and S-MDMA in Healthy Subjects",[86],"2024-01-13","2022-10-01",[15],[604,1667,1668,1668],"S-3,4-methylenedioxymethamphetamine","R-3,4-methylenedioxymethamphetamine",{"nctId":1670,"briefTitle":1671,"status":108,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":163,"conditions":1675,"interventions":1676},"NCT01386177","Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)",[86],"2012-01","2011-07",[1621,1622,1623],[1013,1677],"Doxazosin",{"nctId":1036,"briefTitle":1037,"status":108,"phases":1679,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":426,"conditions":1680,"interventions":1681},[86],[15],[1044,1044,1044,604,78],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[1690],{"nctId":1691,"briefTitle":1692,"status":108,"phases":1693,"primaryCompletion":1694,"completion":1694,"start":1695,"enrollment":163,"conditions":1696,"interventions":1697},"NCT01270672","Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)",[90],"2011-05","2011-01",[1621,1622,1623],[1013,1698],"carvedilol",{"intervention":1700,"totalTrials":179,"cells":1701},"Inhalation - Natural Odour",{"EARLY_PHASE1":1702,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1723},{"trials":1703,"activeCount":179,"soonestReadout":1708},[1704],{"nctId":1705,"briefTitle":1706,"status":170,"phases":1707,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1031,"conditions":1711,"interventions":1713},"NCT06370845","ABUNDANCE of A NATURAL ODOUR in HUMAN CEREBROSPINAL FLUID AFTER OLFACTORY EXPOSURE - the OLFO-Brain Study",[85],"2027-08-31","2027-10-30","2026-04-14",[1712],"Overweight and Obesity",[1700,1714],"Inhalation - Placebo",{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[],{"trials":1720,"activeCount":98},[],{"trials":1722,"activeCount":98},[],{"trials":1724,"activeCount":98},[],{"intervention":1714,"totalTrials":179,"cells":1726},{"EARLY_PHASE1":1727,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1728,"activeCount":179,"soonestReadout":1708},[1729],{"nctId":1705,"briefTitle":1706,"status":170,"phases":1730,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1031,"conditions":1731,"interventions":1732},[85],[1712],[1700,1714],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":98},[],{"intervention":1083,"totalTrials":1744,"cells":1745},7,{"EARLY_PHASE1":1746,"PHASE1":1770,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1747,"activeCount":98},[1748,1752,1761],{"nctId":1075,"briefTitle":1076,"status":108,"phases":1749,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1002,"conditions":1750,"interventions":1751},[85],[15],[1005,1083,1084],{"nctId":1753,"briefTitle":1754,"status":108,"phases":1755,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":621,"conditions":1759,"interventions":1760},"NCT03527316","Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction",[85],"2020-12-10","2020-12-24","2019-10-18",[15],[1083],{"nctId":1762,"briefTitle":1763,"status":108,"phases":1764,"primaryCompletion":111,"completion":111,"start":1765,"enrollment":426,"conditions":1766,"interventions":1768},"NCT01951508","Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",[85],"2013-10",[15,1767,1621],"Substance-related Disorder",[1607,1769,1083],"Modafinil",{"trials":1771,"activeCount":98},[1772,1781,1791],{"nctId":1773,"briefTitle":1774,"status":108,"phases":1775,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":163,"conditions":1778,"interventions":1779},"NCT00895804","Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)",[86],"2002-03","2001-06",[1621,1622,1623],[1083,1780],"Pindolol",{"nctId":1782,"briefTitle":1783,"status":108,"phases":1784,"primaryCompletion":1785,"completion":1786,"start":1655,"enrollment":163,"conditions":1787,"interventions":1789},"NCT01771874","Influence of Bupropion on the Effects of MDMA",[86],"2013-05","2013-09",[15,1788],"Substance-related Disorders",[1083,1790],"Bupropion",{"nctId":1792,"briefTitle":1793,"status":108,"phases":1794,"primaryCompletion":112,"completion":1795,"start":1796,"enrollment":163,"conditions":1797,"interventions":1799},"NCT00886886","Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)",[86],"2010-03","2009-04",[1621,1788,1798],"Amphetamine-related Disorders",[1083,1800],"Reboxetine, 8 mg",{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":179,"soonestReadout":392},[1809],{"nctId":1810,"briefTitle":1811,"status":170,"phases":1812,"primaryCompletion":392,"completion":392,"start":1813,"enrollment":426,"conditions":1814,"interventions":1815},"NCT06789705","Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls",[90],"2025-01-27",[570],[1083],{"intervention":1817,"totalTrials":411,"cells":1818},"N,N-Dimethyltryptamine",{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1842,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":98},[1823,1832],{"nctId":1824,"briefTitle":1825,"status":108,"phases":1826,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":9,"conditions":1830,"interventions":1831},"NCT05695495","Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)",[86],"2025-02-02","2025-03-04","2024-06-12",[15],[1817,1817,1817,1817,1817],{"nctId":1833,"briefTitle":1834,"status":108,"phases":1835,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":426,"conditions":1839,"interventions":1840},"NCT05384678","Acute Dose-dependent Effects of DMT in Healthy Subjects",[86],"2024-03-08","2024-03-13","2022-11-15",[15],[1817,1817,1817,1817,1841],"N,N-Dimethyltryptamine (108 mg) + dose titration",{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":179,"soonestReadout":1854},[1850],{"nctId":1851,"briefTitle":1852,"status":170,"phases":1853,"primaryCompletion":1854,"completion":1854,"start":1855,"enrollment":980,"conditions":1856,"interventions":1858},"NCT06927076","Antidepressant Response of DMT Masked With Propofol",[90],"2029-03","2025-08-05",[1136,1857],"Psychedelic Experiences",[1817],{"intervention":1860,"totalTrials":179,"cells":1861},"Low-dose corticosteroids for immune-related hepatitis grade 3",{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":98},[],{"trials":1869,"activeCount":98},[],{"trials":1871,"activeCount":98},[],{"trials":1873,"activeCount":179,"soonestReadout":644},[1874],{"nctId":1875,"briefTitle":1876,"status":170,"phases":1877,"primaryCompletion":644,"completion":644,"start":1878,"enrollment":125,"conditions":1879,"interventions":1883},"NCT07167251","Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids",[],"2025-08-25",[1880,1881,1882],"Immune Related Adverse Events","Immune-Mediated Hepatitis","Cancer",[1860,1884],"Low-dose corticosteroids for immune-related hepatitis grade 2",{"intervention":1884,"totalTrials":179,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":179,"soonestReadout":644},[1899],{"nctId":1875,"briefTitle":1876,"status":170,"phases":1900,"primaryCompletion":644,"completion":644,"start":1878,"enrollment":125,"conditions":1901,"interventions":1902},[],[1880,1881,1882],[1860,1884],{"intervention":1153,"totalTrials":179,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":98},[],{"trials":1914,"activeCount":98},[],{"trials":1916,"activeCount":179,"soonestReadout":1148},[1917],{"nctId":1145,"briefTitle":1146,"status":170,"phases":1918,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":426,"conditions":1919,"interventions":1920},[90],[1151],[1153,1005],{"intervention":1922,"totalTrials":179,"cells":1923},"Linezolid 600 mg",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":179,"soonestReadout":1940},[1936],{"nctId":1937,"briefTitle":1938,"status":170,"phases":1939,"primaryCompletion":1940,"completion":1940,"start":1941,"enrollment":1942,"conditions":1943,"interventions":1945},"NCT06958835","Linezolid Plus Standard of Care",[90],"2028-10","2025-10-06",606,[1944],"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)",[1922],{"intervention":1947,"totalTrials":179,"cells":1948},"estradiol valerate",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":179,"soonestReadout":337},[1961],{"nctId":1962,"briefTitle":1963,"status":170,"phases":1964,"primaryCompletion":337,"completion":337,"start":1965,"enrollment":1002,"conditions":1966,"interventions":1968},"NCT07361263","Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency",[90],"2026-01-09",[1967,562],"AVP Deficiency",[1947,1969],"esthinylestradiol",{"intervention":1969,"totalTrials":179,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":179,"soonestReadout":337},[1984],{"nctId":1962,"briefTitle":1963,"status":170,"phases":1985,"primaryCompletion":337,"completion":337,"start":1965,"enrollment":1002,"conditions":1986,"interventions":1987},[90],[1967,562],[1947,1969],{"intervention":73,"totalTrials":179,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":179,"soonestReadout":68},[2002],{"nctId":71,"briefTitle":72,"status":170,"phases":2003,"primaryCompletion":68,"completion":644,"start":2004,"enrollment":1238,"conditions":2005,"interventions":2008},[90],"2026-01-21",[2006,2007],"Brown Adipose Tissue (BAT) Physiology","Cold Exposure",[73],{"intervention":45,"totalTrials":179,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":2012,"activeCount":98},[],{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[],{"trials":2022,"activeCount":179,"soonestReadout":44},[2023],{"nctId":42,"briefTitle":43,"status":464,"phases":2024,"primaryCompletion":44,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2030},[90],"2027-12-31","2023-09-09",1354,[2029],"Arterial Hypertension",[45],{"intervention":130,"totalTrials":376,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2056},{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":98},[],{"trials":2040,"activeCount":98},[],{"trials":2042,"activeCount":98},[2043,2047],{"nctId":120,"briefTitle":121,"status":108,"phases":2044,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":2045,"interventions":2046},[89],[127,128],[130,131,93],{"nctId":2048,"briefTitle":2049,"status":108,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":227,"conditions":2054,"interventions":2055},"NCT00306397","Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients",[89],"2008-06","2008-12","2005-01",[140],[130],{"trials":2057,"activeCount":98},[],{"intervention":2059,"totalTrials":376,"cells":2060},"Ketamine",{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2082,"NA":2097},{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[2069],{"nctId":2070,"briefTitle":2071,"status":422,"phases":2072,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":1054,"conditions":2076,"interventions":2079},"NCT02591017","Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients",[88],"2017-07","2017-07-06","2015-02",[2077,2078],"Cancer: Breakthrough Pain","Cancer: Extreme Pain on Movement",[2080,2059,2081],"Morphine","Chitosan",{"trials":2083,"activeCount":98},[2084],{"nctId":2085,"briefTitle":2086,"status":108,"phases":2087,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":2091,"interventions":2093},"NCT02433041","Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial",[89],"2018-12-21","2013-07",200,[2092],"Postoperative Delirium",[2094,2059,2095,2096],"Haloperidol","Haloperidol + Ketamine","Saline solution",{"trials":2098,"activeCount":98},[],{"intervention":2100,"totalTrials":376,"cells":2101},"Propofol",{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2133},{"trials":2103,"activeCount":98},[],{"trials":2105,"activeCount":98},[],{"trials":2107,"activeCount":98},[],{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[2112,2121],{"nctId":2113,"briefTitle":2114,"status":108,"phases":2115,"primaryCompletion":2116,"completion":2116,"start":2117,"enrollment":16,"conditions":2118,"interventions":2120},"NCT03426462","Time to Peak Effect of Propofol in Children",[89],"2018-12-04","2018-04-23",[2100,2119],"Child",[2100],{"nctId":2122,"briefTitle":2123,"status":422,"phases":2124,"primaryCompletion":2125,"completion":2126,"start":2127,"enrollment":2128,"conditions":2129,"interventions":2131},"NCT02807467","Influence of Dexmedetomidine or Propofol on ICU Delirium",[89],"2022-03-03","2023-02-11","2019-03-01",37,[2130],"Delirium",[2132,2100],"Dexmedetomidine",{"trials":2134,"activeCount":98},[],{"intervention":2136,"totalTrials":376,"cells":2137},"Metformin",{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2168},{"trials":2139,"activeCount":98},[],{"trials":2141,"activeCount":98},[2142],{"nctId":2143,"briefTitle":2144,"status":108,"phases":2145,"primaryCompletion":2146,"completion":2146,"start":1673,"enrollment":991,"conditions":2147,"interventions":2149},"NCT02516085","Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin",[86],"2012-10",[2148],"Duchenne Muscular Dystrophy",[2136,2150],"L-Arginine",{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[2157],{"nctId":2158,"briefTitle":2159,"status":108,"phases":2160,"primaryCompletion":2161,"completion":2162,"start":2163,"enrollment":2164,"conditions":2165,"interventions":2167},"NCT01187849","Metformin to Prevent Metabolic Complications in Glucocorticoid Excess",[89],"2015-08","2015-12","2010-08",29,[2166],"Patients With Glucocorticoid Treatment",[2136],{"trials":2169,"activeCount":98},[],{"intervention":2171,"totalTrials":376,"cells":2172},"sevoflurane",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2181,"NA":2203},{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[],{"trials":2178,"activeCount":98},[],{"trials":2180,"activeCount":98},[],{"trials":2182,"activeCount":98},[2183,2192],{"nctId":2184,"briefTitle":2185,"status":422,"phases":2186,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":1305,"conditions":2189,"interventions":2191},"NCT00665418","Sevoflurane and Laryngeal Reflex Responses in Pediatric Patients",[89],"2008-08","2008-02",[2190],"Laryngospasm",[2171],{"nctId":2193,"briefTitle":2194,"status":108,"phases":2195,"primaryCompletion":2196,"completion":2196,"start":2197,"enrollment":621,"conditions":2198,"interventions":2200},"NCT01601795","Sevoflurane and Isoflurane - During Cardiopulmonary Bypass With the MECC System (Minimized Extracorporeal Circuit)",[89],"2014-01","2012-07",[2199],"Myocardial Reperfusion Injury",[2201,2202],"Sevoflurane","Isoflurane",{"trials":2204,"activeCount":98},[],{"intervention":131,"totalTrials":179,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2221},{"trials":2208,"activeCount":98},[],{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[2217],{"nctId":120,"briefTitle":121,"status":108,"phases":2218,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":2219,"interventions":2220},[89],[127,128],[130,131,93],{"trials":2222,"activeCount":98},[],{"intervention":2094,"totalTrials":179,"cells":2224},{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2239},{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[2235],{"nctId":2085,"briefTitle":2086,"status":108,"phases":2236,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":2237,"interventions":2238},[89],[2092],[2094,2059,2095,2096],{"trials":2240,"activeCount":98},[],{"intervention":2095,"totalTrials":179,"cells":2242},{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2257},{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[2253],{"nctId":2085,"briefTitle":2086,"status":108,"phases":2254,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":2255,"interventions":2256},[89],[2092],[2094,2059,2095,2096],{"trials":2258,"activeCount":98},[],{"intervention":2096,"totalTrials":179,"cells":2260},{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2269,"NA":2275},{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[2271],{"nctId":2085,"briefTitle":2086,"status":108,"phases":2272,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":2273,"interventions":2274},[89],[2092],[2094,2059,2095,2096],{"trials":2276,"activeCount":98},[],{"intervention":2278,"totalTrials":179,"cells":2279},"Succinylcholine",{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2286,"PHASE4":2288,"NA":2300},{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[],{"trials":2287,"activeCount":98},[],{"trials":2289,"activeCount":98},[2290],{"nctId":2291,"briefTitle":2292,"status":108,"phases":2293,"primaryCompletion":2294,"completion":1635,"start":2294,"enrollment":2295,"conditions":2296,"interventions":2298},"NCT00355368","Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care",[89],"2006-08",420,[2297],"Intubation",[2278,2299],"Rocuronium",{"trials":2301,"activeCount":98},[],{"intervention":2299,"totalTrials":179,"cells":2303},{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2318},{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[2314],{"nctId":2291,"briefTitle":2292,"status":108,"phases":2315,"primaryCompletion":2294,"completion":1635,"start":2294,"enrollment":2295,"conditions":2316,"interventions":2317},[89],[2297],[2278,2299],{"trials":2319,"activeCount":98},[],{"intervention":2321,"totalTrials":179,"cells":2322},"Propranolol",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2331,"NA":2343},{"trials":2324,"activeCount":98},[],{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[],{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[2333],{"nctId":2334,"briefTitle":2335,"status":108,"phases":2336,"primaryCompletion":2337,"completion":2337,"start":2338,"enrollment":2339,"conditions":2340,"interventions":2342},"NCT03379181","Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy",[89],"2020-02-12","2017-07-18",19,[2341],"Hyperthyroidism",[2321],{"trials":2344,"activeCount":98},[],{"intervention":2346,"totalTrials":179,"cells":2347},"Lamivudine",{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2367},{"trials":2349,"activeCount":98},[],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[],{"trials":2357,"activeCount":98},[2358],{"nctId":2359,"briefTitle":2360,"status":422,"phases":2361,"primaryCompletion":111,"start":2362,"enrollment":955,"conditions":2363,"interventions":2365},"NCT01005238","Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine",[89],"2009-09",[2364],"Hepatitis, Chronic",[2346,2366],"Telbivudine",{"trials":2368,"activeCount":98},[],{"intervention":2366,"totalTrials":179,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2385},{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[2381],{"nctId":2359,"briefTitle":2360,"status":422,"phases":2382,"primaryCompletion":111,"start":2362,"enrollment":955,"conditions":2383,"interventions":2384},[89],[2364],[2346,2366],{"trials":2386,"activeCount":98},[],{"intervention":2388,"totalTrials":179,"cells":2389},"AB",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2410},{"trials":2391,"activeCount":98},[],{"trials":2393,"activeCount":98},[],{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[2400],{"nctId":2401,"briefTitle":2402,"status":108,"phases":2403,"primaryCompletion":2404,"completion":2404,"start":2405,"enrollment":1238,"conditions":2406,"interventions":2408},"NCT03204578","Physiological Study of the Human CYP3A Activity (PiSA)",[89],"2017-09-25","2017-08-18",[2407],"Cytochrome P450 CYP3A Enzyme Deficiency",[2388,2409],"BA",{"trials":2411,"activeCount":98},[],{"intervention":2409,"totalTrials":179,"cells":2413},{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2428},{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[2424],{"nctId":2401,"briefTitle":2402,"status":108,"phases":2425,"primaryCompletion":2404,"completion":2404,"start":2405,"enrollment":1238,"conditions":2426,"interventions":2427},[89],[2407],[2388,2409],{"trials":2429,"activeCount":98},[],{"intervention":2431,"totalTrials":179,"cells":2432},"Vitamin D: liquid form, start weekly",{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2439,"PHASE4":2441,"NA":2456},{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[],{"trials":2442,"activeCount":98},[2443],{"nctId":2444,"briefTitle":2445,"status":108,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":2449,"conditions":2450,"interventions":2452},"NCT03141593","Oral Vitamin D Substitution Weekly or Monthly and Adherence",[89],"2018-10-31","2017-10-09",97,[2451],"Vitamin D Deficiency",[2431,2453,2454,2455],"Vitamin D: liquid form, start monthly","Vitamin D: solid form, start weekly","Vitamin D: solid form, start monthly",{"trials":2457,"activeCount":98},[],{"intervention":2453,"totalTrials":179,"cells":2459},{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2466,"PHASE4":2468,"NA":2474},{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[],{"trials":2465,"activeCount":98},[],{"trials":2467,"activeCount":98},[],{"trials":2469,"activeCount":98},[2470],{"nctId":2444,"briefTitle":2445,"status":108,"phases":2471,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":2449,"conditions":2472,"interventions":2473},[89],[2451],[2431,2453,2454,2455],{"trials":2475,"activeCount":98},[],{"intervention":2454,"totalTrials":179,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2484,"PHASE4":2486,"NA":2492},{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[],{"trials":2483,"activeCount":98},[],{"trials":2485,"activeCount":98},[],{"trials":2487,"activeCount":98},[2488],{"nctId":2444,"briefTitle":2445,"status":108,"phases":2489,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":2449,"conditions":2490,"interventions":2491},[89],[2451],[2431,2453,2454,2455],{"trials":2493,"activeCount":98},[],{"intervention":2455,"totalTrials":179,"cells":2495},{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2502,"PHASE4":2504,"NA":2510},{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[],{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[],{"trials":2505,"activeCount":98},[2506],{"nctId":2444,"briefTitle":2445,"status":108,"phases":2507,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":2449,"conditions":2508,"interventions":2509},[89],[2451],[2431,2453,2454,2455],{"trials":2511,"activeCount":98},[],{"intervention":2513,"totalTrials":179,"cells":2514},"travoprost 0.004%",{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2521,"PHASE4":2523,"NA":2535},{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[],{"trials":2520,"activeCount":98},[],{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[2525],{"nctId":2526,"briefTitle":2527,"status":108,"phases":2528,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":783,"conditions":2531,"interventions":2533},"NCT00308945","Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients",[89],"2005-02","2003-11",[2532],"Open-Angle Glaucoma",[2513,2534],"latanoprost 0.005%",{"trials":2536,"activeCount":98},[],{"intervention":2534,"totalTrials":179,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2547,"NA":2553},{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[],{"trials":2548,"activeCount":98},[2549],{"nctId":2526,"briefTitle":2527,"status":108,"phases":2550,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":783,"conditions":2551,"interventions":2552},[89],[2532],[2513,2534],{"trials":2554,"activeCount":98},[],{"intervention":2556,"totalTrials":179,"cells":2557},"Cholecalciferol",{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2564,"PHASE4":2566,"NA":2577},{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[],{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[2568],{"nctId":2569,"briefTitle":2570,"status":422,"phases":2571,"primaryCompletion":1655,"completion":2572,"start":2573,"enrollment":580,"conditions":2574,"interventions":2576},"NCT01559974","Vitamin D and Walking Ability in Patients With Peripheral Artery Occlusive Disease",[89],"2013-02","2011-11",[2575],"Peripheral Arterial Disease",[2556],{"trials":2578,"activeCount":98},[],{"intervention":2580,"totalTrials":179,"cells":2581},"Placebos",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2601},{"trials":2583,"activeCount":98},[],{"trials":2585,"activeCount":98},[],{"trials":2587,"activeCount":98},[],{"trials":2589,"activeCount":98},[],{"trials":2591,"activeCount":98},[2592],{"nctId":2593,"briefTitle":2594,"status":108,"phases":2595,"primaryCompletion":1795,"completion":1618,"start":2596,"enrollment":2597,"conditions":2598,"interventions":2599},"NCT00488540","Is Paracetamol an Effective Treatment for Chronic Moderate Pain in the Newborn After Operative Vaginal Delivery?",[89],"2007-06",280,[29],[2600,2580],"Paracetamol",{"trials":2602,"activeCount":98},[],{"intervention":2604,"totalTrials":179,"cells":2605},"ATG Fresenius",{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2612,"PHASE4":2614,"NA":2625},{"trials":2607,"activeCount":98},[],{"trials":2609,"activeCount":98},[],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[],{"trials":2615,"activeCount":98},[2616],{"nctId":2617,"briefTitle":2618,"status":108,"phases":2619,"primaryCompletion":2075,"completion":2075,"start":2620,"enrollment":1305,"conditions":2621,"interventions":2623},"NCT00861536","Comparison of ATG to Thymoglobuline in Renal Transplantation",[89],"2009-01",[2622],"Transplantation, Kidney",[2604,2624],"Thymoglobuline Genzyme",{"trials":2626,"activeCount":98},[],{"intervention":2624,"totalTrials":179,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2637,"NA":2643},{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[],{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[2639],{"nctId":2617,"briefTitle":2618,"status":108,"phases":2640,"primaryCompletion":2075,"completion":2075,"start":2620,"enrollment":1305,"conditions":2641,"interventions":2642},[89],[2622],[2604,2624],{"trials":2644,"activeCount":98},[],{"intervention":2646,"totalTrials":179,"cells":2647},"TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2669},{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[],{"trials":2653,"activeCount":98},[],{"trials":2655,"activeCount":98},[],{"trials":2657,"activeCount":98},[2658],{"nctId":2659,"briefTitle":2660,"status":422,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":271,"conditions":2664,"interventions":2667},"NCT00244517","DIAFAX I+II-Effects of Inhalative Anesthetics on Left Ventricular Diastolic Function",[89],"2010-04","2004-06",[2665,2666],"Young Healthy Adults","Ventricular Dysfunction",[2646,2668],"Sevoflurane, Isoflurane, Desflurane",{"trials":2670,"activeCount":98},[],{"intervention":2668,"totalTrials":179,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2681,"NA":2687},{"trials":2674,"activeCount":98},[],{"trials":2676,"activeCount":98},[],{"trials":2678,"activeCount":98},[],{"trials":2680,"activeCount":98},[],{"trials":2682,"activeCount":98},[2683],{"nctId":2659,"briefTitle":2660,"status":422,"phases":2684,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":271,"conditions":2685,"interventions":2686},[89],[2665,2666],[2646,2668],{"trials":2688,"activeCount":98},[],{"intervention":143,"totalTrials":179,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2699,"NA":2705},{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[2701],{"nctId":133,"briefTitle":134,"status":108,"phases":2702,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":2703,"interventions":2704},[89],[140,141],[143,144,93,145],{"trials":2706,"activeCount":98},[],{"intervention":144,"totalTrials":179,"cells":2708},{"EARLY_PHASE1":2709,"PHASE1":2711,"PHASE2":2713,"PHASE3":2715,"PHASE4":2717,"NA":2723},{"trials":2710,"activeCount":98},[],{"trials":2712,"activeCount":98},[],{"trials":2714,"activeCount":98},[],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[2719],{"nctId":133,"briefTitle":134,"status":108,"phases":2720,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":2721,"interventions":2722},[89],[140,141],[143,144,93,145],{"trials":2724,"activeCount":98},[],{"intervention":145,"totalTrials":179,"cells":2726},{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2741},{"trials":2728,"activeCount":98},[],{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[2737],{"nctId":133,"briefTitle":134,"status":108,"phases":2738,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":2739,"interventions":2740},[89],[140,141],[143,144,93,145],{"trials":2742,"activeCount":98},[],{"intervention":2744,"totalTrials":179,"cells":2745},"Darunavir",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2767},{"trials":2747,"activeCount":98},[],{"trials":2749,"activeCount":98},[],{"trials":2751,"activeCount":98},[],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[2756],{"nctId":2757,"briefTitle":2758,"status":422,"phases":2759,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":1744,"conditions":2762,"interventions":2764},"NCT02503462","Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals",[89],"2017-01","2015-07",[2763],"AIDS-related Dementia Complex",[2744,2765,2766],"ritonavir","cobicistat",{"trials":2768,"activeCount":98},[],{"intervention":2765,"totalTrials":179,"cells":2770},{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2775,"PHASE3":2777,"PHASE4":2779,"NA":2785},{"trials":2772,"activeCount":98},[],{"trials":2774,"activeCount":98},[],{"trials":2776,"activeCount":98},[],{"trials":2778,"activeCount":98},[],{"trials":2780,"activeCount":98},[2781],{"nctId":2757,"briefTitle":2758,"status":422,"phases":2782,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":1744,"conditions":2783,"interventions":2784},[89],[2763],[2744,2765,2766],{"trials":2786,"activeCount":98},[],{"intervention":2766,"totalTrials":179,"cells":2788},{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2793,"PHASE3":2795,"PHASE4":2797,"NA":2803},{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[],{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[2799],{"nctId":2757,"briefTitle":2758,"status":422,"phases":2800,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":1744,"conditions":2801,"interventions":2802},[89],[2763],[2744,2765,2766],{"trials":2804,"activeCount":98},[],{"intervention":2806,"totalTrials":179,"cells":2807},"40 mL Ropivacain 0.5%",{"EARLY_PHASE1":2808,"PHASE1":2810,"PHASE2":2812,"PHASE3":2814,"PHASE4":2816,"NA":2829},{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[],{"trials":2815,"activeCount":98},[],{"trials":2817,"activeCount":98},[2818],{"nctId":2819,"briefTitle":2820,"status":108,"phases":2821,"primaryCompletion":1069,"completion":1069,"start":2822,"enrollment":2823,"conditions":2824,"interventions":2828},"NCT03405922","Perianal Nerval Block in Proctological Interventions",[89],"2018-02-01",166,[2825,2826,2827],"Perianal Fistula","Fissure in Ano","Hemorrhoids",[2806],{"trials":2830,"activeCount":98},[],{"intervention":2832,"totalTrials":179,"cells":2833},"PRP",{"EARLY_PHASE1":2834,"PHASE1":2836,"PHASE2":2838,"PHASE3":2840,"PHASE4":2842,"NA":2853},{"trials":2835,"activeCount":98},[],{"trials":2837,"activeCount":98},[],{"trials":2839,"activeCount":98},[],{"trials":2841,"activeCount":98},[],{"trials":2843,"activeCount":98},[2844],{"nctId":2845,"briefTitle":2846,"status":2847,"phases":2848,"primaryCompletion":2849,"start":2849,"enrollment":98,"conditions":2850,"interventions":2852},"NCT02678936","Anal Fistula Repair With Platelet-rich Plasma","WITHDRAWN",[89],"2015-11",[2851],"Rectal Fistula",[2832],{"trials":2854,"activeCount":98},[],{"intervention":2856,"totalTrials":179,"cells":2857},"Inhalational anesthetic",{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2864,"PHASE4":2866,"NA":2879},{"trials":2859,"activeCount":98},[],{"trials":2861,"activeCount":98},[],{"trials":2863,"activeCount":98},[],{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[2868],{"nctId":2869,"briefTitle":2870,"status":108,"phases":2871,"primaryCompletion":2872,"completion":2573,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2877},"NCT00286585","TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality",[89],"2010-11","2006-02",385,[2876],"Coronary Artery Disease",[2856,2878],"Intravenous anesthetic, propofol",{"trials":2880,"activeCount":98},[],{"intervention":2878,"totalTrials":179,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2897},{"trials":2884,"activeCount":98},[],{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[2893],{"nctId":2869,"briefTitle":2870,"status":108,"phases":2894,"primaryCompletion":2872,"completion":2573,"start":2873,"enrollment":2874,"conditions":2895,"interventions":2896},[89],[2876],[2856,2878],{"trials":2898,"activeCount":98},[],{"intervention":2900,"totalTrials":179,"cells":2901},"n-3 fatty acids",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2922},{"trials":2903,"activeCount":98},[],{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":98},[],{"trials":2911,"activeCount":98},[2912],{"nctId":2913,"briefTitle":2914,"status":108,"phases":2915,"primaryCompletion":2916,"completion":2916,"start":2917,"enrollment":293,"conditions":2918,"interventions":2921},"NCT00772096","Septic Encephalopathy and Late Cognitive Dysfunction",[89],"2011-06","2008-10",[2919,2920],"Sepsis","Severe Sepsis",[2900],{"trials":2923,"activeCount":98},[],{"intervention":2925,"totalTrials":179,"cells":2926},"oral applications of TMP\u002FSMX 800\u002F160 mg",{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2931,"PHASE3":2933,"PHASE4":2935,"NA":2948},{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[],{"trials":2932,"activeCount":98},[],{"trials":2934,"activeCount":98},[],{"trials":2936,"activeCount":98},[2937],{"nctId":2938,"briefTitle":2939,"status":108,"phases":2940,"primaryCompletion":2941,"completion":2941,"start":2942,"enrollment":2943,"conditions":2944,"interventions":2946},"NCT03633643","Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate",[89],"2022-10-31","2018-10-29",728,[2945],"Antimicrobial Prophylaxis in Prostate Surgery",[2925,2947],"oral applications of Placebo",{"trials":2949,"activeCount":98},[],{"intervention":2947,"totalTrials":179,"cells":2951},{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2958,"PHASE4":2960,"NA":2966},{"trials":2953,"activeCount":98},[],{"trials":2955,"activeCount":98},[],{"trials":2957,"activeCount":98},[],{"trials":2959,"activeCount":98},[],{"trials":2961,"activeCount":98},[2962],{"nctId":2938,"briefTitle":2939,"status":108,"phases":2963,"primaryCompletion":2941,"completion":2941,"start":2942,"enrollment":2943,"conditions":2964,"interventions":2965},[89],[2945],[2925,2947],{"trials":2967,"activeCount":98},[],{"intervention":2969,"totalTrials":179,"cells":2970},"Goal-directed preload and afterload decrement",{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2977,"PHASE4":2979,"NA":2992},{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[],{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[],{"trials":2980,"activeCount":98},[2981],{"nctId":2982,"briefTitle":2983,"status":108,"phases":2984,"primaryCompletion":2985,"completion":2986,"start":2987,"enrollment":2988,"conditions":2989,"interventions":2991},"NCT00512759","Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study",[89],"2018-08-24","2019-02-21","2007-12-10",781,[2990],"Acute Heart Failure",[2969],{"trials":2993,"activeCount":98},[],{"intervention":2995,"totalTrials":179,"cells":2996},"Bryophyllum",{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3001,"PHASE3":3003,"PHASE4":3005,"NA":3019},{"trials":2998,"activeCount":98},[],{"trials":3000,"activeCount":98},[],{"trials":3002,"activeCount":98},[],{"trials":3004,"activeCount":98},[],{"trials":3006,"activeCount":98},[3007],{"nctId":3008,"briefTitle":3009,"status":108,"phases":3010,"primaryCompletion":3011,"completion":3011,"start":3012,"enrollment":3013,"conditions":3014,"interventions":3018},"NCT00163579","The Impact of Bryophyllum on Preterm Delivery",[89],"2009-07","2004-07",26,[3015,3016,3017],"Preterm Delivery","Preterm Contractions","Cervical Shortening",[2995],{"trials":3020,"activeCount":98},[],{"intervention":3022,"totalTrials":179,"cells":3023},"Lidocaine 10%",{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3028,"PHASE3":3030,"PHASE4":3032,"NA":3044},{"trials":3025,"activeCount":98},[],{"trials":3027,"activeCount":98},[],{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"trials":3033,"activeCount":98},[3034],{"nctId":3035,"briefTitle":3036,"status":108,"phases":3037,"primaryCompletion":1618,"completion":1618,"start":3038,"enrollment":3039,"conditions":3040,"interventions":3042},"NCT01081002","Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia",[89],"2009-08",294,[3041],"Conscious Sedation",[3022,3043],"Diluted gentian root solution",{"trials":3045,"activeCount":98},[],{"intervention":3043,"totalTrials":179,"cells":3047},{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3054,"PHASE4":3056,"NA":3062},{"trials":3049,"activeCount":98},[],{"trials":3051,"activeCount":98},[],{"trials":3053,"activeCount":98},[],{"trials":3055,"activeCount":98},[],{"trials":3057,"activeCount":98},[3058],{"nctId":3035,"briefTitle":3036,"status":108,"phases":3059,"primaryCompletion":1618,"completion":1618,"start":3038,"enrollment":3039,"conditions":3060,"interventions":3061},[89],[3041],[3022,3043],{"trials":3063,"activeCount":98},[],{"intervention":3065,"totalTrials":179,"cells":3066},"hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline",{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3073,"PHASE4":3075,"NA":3086},{"trials":3068,"activeCount":98},[],{"trials":3070,"activeCount":98},[],{"trials":3072,"activeCount":98},[],{"trials":3074,"activeCount":98},[],{"trials":3076,"activeCount":98},[3077],{"nctId":3078,"briefTitle":3079,"status":108,"phases":3080,"primaryCompletion":123,"completion":1694,"start":3081,"enrollment":3082,"conditions":3083,"interventions":3085},"NCT00273728","BaSES Trial: Basel Starch Evaluation in Sepsis",[89],"2005-05",231,[2919,2920,3084],"Septic Shock",[3065],{"trials":3087,"activeCount":98},[],{"intervention":3089,"totalTrials":179,"cells":3090},"romiplostim",{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3097,"PHASE4":3099,"NA":3111},{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[],{"trials":3100,"activeCount":98},[3101],{"nctId":3102,"briefTitle":3103,"status":108,"phases":3104,"primaryCompletion":3105,"completion":3106,"start":3107,"enrollment":19,"conditions":3108,"interventions":3110},"NCT02760251","Immunomodulation With Romiplostim in Young Adults With ITP",[89],"2019-07","2020-03","2016-04",[3109],"Immune Thrombocytopenia",[3089],{"trials":3112,"activeCount":98},[],{"intervention":3114,"totalTrials":179,"cells":3115},"bisacodyl",{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3120,"PHASE3":3122,"PHASE4":3124,"NA":3136},{"trials":3117,"activeCount":98},[],{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[],{"trials":3125,"activeCount":98},[3126],{"nctId":3127,"briefTitle":3128,"status":108,"phases":3129,"completion":3130,"start":3131,"enrollment":2090,"conditions":3132,"interventions":3134},"NCT00509327","Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery",[89],"2007-02","2004-11",[3133],"Postoperative Ileus",[3114,3135],"glucosemonohydricum",{"trials":3137,"activeCount":98},[],{"intervention":3135,"totalTrials":179,"cells":3139},{"EARLY_PHASE1":3140,"PHASE1":3142,"PHASE2":3144,"PHASE3":3146,"PHASE4":3148,"NA":3154},{"trials":3141,"activeCount":98},[],{"trials":3143,"activeCount":98},[],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[3150],{"nctId":3127,"briefTitle":3128,"status":108,"phases":3151,"completion":3130,"start":3131,"enrollment":2090,"conditions":3152,"interventions":3153},[89],[3133],[3114,3135],{"trials":3155,"activeCount":98},[],{"intervention":2132,"totalTrials":179,"cells":3157},{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3164,"PHASE4":3166,"NA":3172},{"trials":3159,"activeCount":98},[],{"trials":3161,"activeCount":98},[],{"trials":3163,"activeCount":98},[],{"trials":3165,"activeCount":98},[],{"trials":3167,"activeCount":98},[3168],{"nctId":2122,"briefTitle":2123,"status":422,"phases":3169,"primaryCompletion":2125,"completion":2126,"start":2127,"enrollment":2128,"conditions":3170,"interventions":3171},[89],[2130],[2132,2100],{"trials":3173,"activeCount":98},[],{"intervention":3175,"totalTrials":179,"cells":3176},"Metamizole and Ibuprofen",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3183,"PHASE4":3185,"NA":3198},{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[3187],{"nctId":3188,"briefTitle":3189,"status":108,"phases":3190,"primaryCompletion":3191,"completion":3191,"start":3192,"enrollment":9,"conditions":3193,"interventions":3195},"NCT02686021","Potential Benefit of the Combination of Metamizole and Ibuprofen After Third Lower Molar Extraction",[89],"2021-04-28","2016-02-15",[3194],"Pain, Postoperative",[3175,3196,3197],"Metamizole and Placebo","Ibuprofen and Placebo",{"trials":3199,"activeCount":98},[],{"intervention":3196,"totalTrials":179,"cells":3201},{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3208,"PHASE4":3210,"NA":3216},{"trials":3203,"activeCount":98},[],{"trials":3205,"activeCount":98},[],{"trials":3207,"activeCount":98},[],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[3212],{"nctId":3188,"briefTitle":3189,"status":108,"phases":3213,"primaryCompletion":3191,"completion":3191,"start":3192,"enrollment":9,"conditions":3214,"interventions":3215},[89],[3194],[3175,3196,3197],{"trials":3217,"activeCount":98},[],{"intervention":3197,"totalTrials":179,"cells":3219},{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3224,"PHASE3":3226,"PHASE4":3228,"NA":3234},{"trials":3221,"activeCount":98},[],{"trials":3223,"activeCount":98},[],{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":98},[],{"trials":3229,"activeCount":98},[3230],{"nctId":3188,"briefTitle":3189,"status":108,"phases":3231,"primaryCompletion":3191,"completion":3191,"start":3192,"enrollment":9,"conditions":3232,"interventions":3233},[89],[3194],[3175,3196,3197],{"trials":3235,"activeCount":98},[],{"intervention":3237,"totalTrials":179,"cells":3238},"cera, darbepoetin, epoetin-beta",{"EARLY_PHASE1":3239,"PHASE1":3241,"PHASE2":3243,"PHASE3":3245,"PHASE4":3247,"NA":3258},{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"trials":3246,"activeCount":98},[],{"trials":3248,"activeCount":98},[3249],{"nctId":3250,"briefTitle":3251,"status":108,"phases":3252,"primaryCompletion":1674,"completion":3253,"start":1695,"enrollment":27,"conditions":3254,"interventions":3256},"NCT01306409","Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)",[89],"2011-10",[3255],"Renal Anemia",[3237,3257],"ESA",{"trials":3259,"activeCount":98},[],{"intervention":3257,"totalTrials":179,"cells":3261},{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3266,"PHASE3":3268,"PHASE4":3270,"NA":3276},{"trials":3263,"activeCount":98},[],{"trials":3265,"activeCount":98},[],{"trials":3267,"activeCount":98},[],{"trials":3269,"activeCount":98},[],{"trials":3271,"activeCount":98},[3272],{"nctId":3250,"briefTitle":3251,"status":108,"phases":3273,"primaryCompletion":1674,"completion":3253,"start":1695,"enrollment":27,"conditions":3274,"interventions":3275},[89],[3255],[3237,3257],{"trials":3277,"activeCount":98},[],{"intervention":3279,"totalTrials":179,"cells":3280},"High Dose Clomiphencitrat",{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3287,"PHASE4":3289,"NA":3305},{"trials":3282,"activeCount":98},[],{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[3291],{"nctId":3292,"briefTitle":3293,"status":108,"phases":3294,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":3297,"conditions":3298,"interventions":3301},"NCT01577472","Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol",[89],"2017-11-14","2013-08",117,[3299,3300],"Female Infertility","Ovarian Insufficiency",[3279,3302,3303,3304],"Low Dose Clomiphencitrat","High Dose Placebo","Low dose Placebo",{"trials":3306,"activeCount":98},[],{"intervention":3302,"totalTrials":179,"cells":3308},{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3315,"PHASE4":3317,"NA":3323},{"trials":3310,"activeCount":98},[],{"trials":3312,"activeCount":98},[],{"trials":3314,"activeCount":98},[],{"trials":3316,"activeCount":98},[],{"trials":3318,"activeCount":98},[3319],{"nctId":3292,"briefTitle":3293,"status":108,"phases":3320,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":3297,"conditions":3321,"interventions":3322},[89],[3299,3300],[3279,3302,3303,3304],{"trials":3324,"activeCount":98},[],{"intervention":3303,"totalTrials":179,"cells":3326},{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3333,"PHASE4":3335,"NA":3341},{"trials":3328,"activeCount":98},[],{"trials":3330,"activeCount":98},[],{"trials":3332,"activeCount":98},[],{"trials":3334,"activeCount":98},[],{"trials":3336,"activeCount":98},[3337],{"nctId":3292,"briefTitle":3293,"status":108,"phases":3338,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":3297,"conditions":3339,"interventions":3340},[89],[3299,3300],[3279,3302,3303,3304],{"trials":3342,"activeCount":98},[],{"intervention":3304,"totalTrials":179,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3351,"PHASE4":3353,"NA":3359},{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[],{"trials":3352,"activeCount":98},[],{"trials":3354,"activeCount":98},[3355],{"nctId":3292,"briefTitle":3293,"status":108,"phases":3356,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":3297,"conditions":3357,"interventions":3358},[89],[3299,3300],[3279,3302,3303,3304],{"trials":3360,"activeCount":98},[],{"intervention":3362,"totalTrials":179,"cells":3363},"CHX disinfection",{"EARLY_PHASE1":3364,"PHASE1":3366,"PHASE2":3368,"PHASE3":3370,"PHASE4":3372,"NA":3385},{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"trials":3371,"activeCount":98},[],{"trials":3373,"activeCount":98},[3374],{"nctId":3375,"briefTitle":3376,"status":108,"phases":3377,"primaryCompletion":3378,"completion":3378,"start":3379,"enrollment":3380,"conditions":3381,"interventions":3383},"NCT03685604","PVP Iodine vs Chlorhexidine in Alcohol for Disinfection of the Surgical Site",[89],"2020-06-30","2018-09-10",3321,[3382],"Surgical Site Infections",[3362,3384],"PI Disinfection",{"trials":3386,"activeCount":98},[],{"intervention":3384,"totalTrials":179,"cells":3388},{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3393,"PHASE3":3395,"PHASE4":3397,"NA":3403},{"trials":3390,"activeCount":98},[],{"trials":3392,"activeCount":98},[],{"trials":3394,"activeCount":98},[],{"trials":3396,"activeCount":98},[],{"trials":3398,"activeCount":98},[3399],{"nctId":3375,"briefTitle":3376,"status":108,"phases":3400,"primaryCompletion":3378,"completion":3378,"start":3379,"enrollment":3380,"conditions":3401,"interventions":3402},[89],[3382],[3362,3384],{"trials":3404,"activeCount":98},[],{"intervention":3406,"totalTrials":179,"cells":3407},"Bupivacain\u002Flevobupivacaine",{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3412,"PHASE3":3414,"PHASE4":3416,"NA":3427},{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"trials":3413,"activeCount":98},[],{"trials":3415,"activeCount":98},[],{"trials":3417,"activeCount":98},[3418],{"nctId":3419,"briefTitle":3420,"status":422,"phases":3421,"primaryCompletion":2872,"completion":2872,"start":3038,"enrollment":3422,"conditions":3423,"interventions":3426},"NCT00970086","Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Groin Surgery",[89],22,[3424,3425],"Postoperative Pain","Reaction; Anesthesia",[3406],{"trials":3428,"activeCount":98},[],{"intervention":3430,"totalTrials":179,"cells":3431},"n-acetylcysteine",{"EARLY_PHASE1":3432,"PHASE1":3434,"PHASE2":3436,"PHASE3":3438,"PHASE4":3440,"NA":3451},{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[],{"trials":3439,"activeCount":98},[],{"trials":3441,"activeCount":98},[3442],{"nctId":3443,"briefTitle":3444,"status":108,"phases":3445,"primaryCompletion":124,"completion":2620,"start":3446,"enrollment":2164,"conditions":3447,"interventions":3449},"NCT00512265","Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer",[89],"2006-01",[3448],"Pulmonary Morbidity",[3430,3450],"250mL glucose 5%",{"trials":3452,"activeCount":98},[],{"intervention":3450,"totalTrials":179,"cells":3454},{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3459,"PHASE3":3461,"PHASE4":3463,"NA":3469},{"trials":3456,"activeCount":98},[],{"trials":3458,"activeCount":98},[],{"trials":3460,"activeCount":98},[],{"trials":3462,"activeCount":98},[],{"trials":3464,"activeCount":98},[3465],{"nctId":3443,"briefTitle":3444,"status":108,"phases":3466,"primaryCompletion":124,"completion":2620,"start":3446,"enrollment":2164,"conditions":3467,"interventions":3468},[89],[3448],[3430,3450],{"trials":3470,"activeCount":98},[],{"intervention":3472,"totalTrials":179,"cells":3473},"Oral administration of vitamin B12",{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3492},{"trials":3475,"activeCount":98},[],{"trials":3477,"activeCount":98},[],{"trials":3479,"activeCount":98},[],{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[3484],{"nctId":3485,"briefTitle":3486,"status":108,"phases":3487,"primaryCompletion":2162,"completion":2162,"start":1785,"enrollment":2128,"conditions":3488,"interventions":3490},"NCT01832129","Vitamin B12 Acceptance and Biomarker Response Study",[89],[3489],"Vitamin B 12 Deficiency",[3472,3491],"i.m. injection of vitamin B12",{"trials":3493,"activeCount":98},[],{"intervention":3491,"totalTrials":179,"cells":3495},{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3504,"NA":3510},{"trials":3497,"activeCount":98},[],{"trials":3499,"activeCount":98},[],{"trials":3501,"activeCount":98},[],{"trials":3503,"activeCount":98},[],{"trials":3505,"activeCount":98},[3506],{"nctId":3485,"briefTitle":3486,"status":108,"phases":3507,"primaryCompletion":2162,"completion":2162,"start":1785,"enrollment":2128,"conditions":3508,"interventions":3509},[89],[3489],[3472,3491],{"trials":3511,"activeCount":98},[],{"intervention":3513,"totalTrials":179,"cells":3514},"Ginkgo biloba",{"EARLY_PHASE1":3515,"PHASE1":3517,"PHASE2":3519,"PHASE3":3521,"PHASE4":3523,"NA":3533},{"trials":3516,"activeCount":98},[],{"trials":3518,"activeCount":98},[],{"trials":3520,"activeCount":98},[],{"trials":3522,"activeCount":98},[],{"trials":3524,"activeCount":98},[3525],{"nctId":3526,"briefTitle":3527,"status":108,"phases":3528,"primaryCompletion":2075,"completion":3529,"start":405,"enrollment":293,"conditions":3530,"interventions":3532},"NCT01046292","Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI",[89],"2015-10",[3531],"Mild Cognitive Impairment",[3513],{"trials":3534,"activeCount":98},[],{"intervention":3536,"totalTrials":179,"cells":3537},"epidural analgesia",{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3544,"PHASE4":3546,"NA":3555},{"trials":3539,"activeCount":98},[],{"trials":3541,"activeCount":98},[],{"trials":3543,"activeCount":98},[],{"trials":3545,"activeCount":98},[],{"trials":3547,"activeCount":98},[3548],{"nctId":3549,"briefTitle":3550,"status":108,"phases":3551,"completion":3552,"start":3131,"enrollment":691,"conditions":3553,"interventions":3554},"NCT00512395","Influence of Epidural Analgesia in Elective Laparoscopic Colorectal Resections",[89],"2007-01",[29],[3536],{"trials":3556,"activeCount":98},[],{"intervention":3558,"totalTrials":179,"cells":3559},"Carbetocin Short-infusion",{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3568,"NA":3581},{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[],{"trials":3565,"activeCount":98},[],{"trials":3567,"activeCount":98},[],{"trials":3569,"activeCount":98},[3570],{"nctId":3571,"briefTitle":3572,"status":108,"phases":3573,"primaryCompletion":2849,"completion":2849,"start":3574,"enrollment":3575,"conditions":3576,"interventions":3579},"NCT02221531","Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN",[89],"2014-08",140,[3577,3578],"Complications; Cesarean Section","Anesthesia; Reaction",[3558,3580],"Carbetocin Bolus application",{"trials":3582,"activeCount":98},[],{"intervention":3580,"totalTrials":179,"cells":3584},{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3591,"PHASE4":3593,"NA":3599},{"trials":3586,"activeCount":98},[],{"trials":3588,"activeCount":98},[],{"trials":3590,"activeCount":98},[],{"trials":3592,"activeCount":98},[],{"trials":3594,"activeCount":98},[3595],{"nctId":3571,"briefTitle":3572,"status":108,"phases":3596,"primaryCompletion":2849,"completion":2849,"start":3574,"enrollment":3575,"conditions":3597,"interventions":3598},[89],[3577,3578],[3558,3580],{"trials":3600,"activeCount":98},[],{"intervention":2202,"totalTrials":179,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3609,"PHASE4":3611,"NA":3617},{"trials":3604,"activeCount":98},[],{"trials":3606,"activeCount":98},[],{"trials":3608,"activeCount":98},[],{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[3613],{"nctId":2193,"briefTitle":2194,"status":108,"phases":3614,"primaryCompletion":2196,"completion":2196,"start":2197,"enrollment":621,"conditions":3615,"interventions":3616},[89],[2199],[2201,2202],{"trials":3618,"activeCount":98},[],{"intervention":3620,"totalTrials":376,"cells":3621},"Sodium Chloride 0.9%",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3640,"PHASE4":3654,"NA":3656},{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[3628],{"nctId":3629,"briefTitle":3630,"status":108,"phases":3631,"primaryCompletion":3632,"completion":3633,"start":2760,"enrollment":3634,"conditions":3635,"interventions":3637},"NCT02869347","Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects",[87],"2018-05","2018-07",80,[3636],"Acute Kidney Injury",[3638,3639],"Conestat alfa","Sodium chloride 0.9%",{"trials":3641,"activeCount":98},[3642],{"nctId":3643,"briefTitle":3644,"status":108,"phases":3645,"primaryCompletion":3646,"completion":3646,"start":3647,"enrollment":3648,"conditions":3649,"interventions":3652},"NCT02672592","Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome",[88],"2017-06","2016-01",70,[3650,3651,18],"Hypogonadism","Metabolic Syndrome X",[3653,3620],"Anakinra",{"trials":3655,"activeCount":98},[],{"trials":3657,"activeCount":98},[],{"intervention":3659,"totalTrials":376,"cells":3660},"Vitamin D3",{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3665,"PHASE3":3667,"PHASE4":3688,"NA":3690},{"trials":3662,"activeCount":98},[],{"trials":3664,"activeCount":98},[],{"trials":3666,"activeCount":98},[],{"trials":3668,"activeCount":98},[3669,3679],{"nctId":3670,"briefTitle":3671,"status":108,"phases":3672,"primaryCompletion":3673,"completion":3673,"start":3674,"enrollment":3675,"conditions":3676,"interventions":3677},"NCT03920150","Vitamin D 24'000 IU for Oral Intermittent Supplementation",[88],"2020-05-31","2019-09-30",58,[2451],[3659,3678,3678],"Vitamin D oily",{"nctId":3680,"briefTitle":3681,"status":108,"phases":3682,"primaryCompletion":3683,"completion":3683,"start":3684,"enrollment":760,"conditions":3685,"interventions":3687},"NCT04991324","Cholecalciferol Comedication in IBD - the 5C-study",[88],"2024-09-15","2022-09-21",[3686],"Inflammatory Bowel Diseases",[3659],{"trials":3689,"activeCount":98},[],{"trials":3691,"activeCount":98},[],{"intervention":3693,"totalTrials":376,"cells":3694},"tranexamic acid",{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3701,"PHASE4":3725,"NA":3727},{"trials":3696,"activeCount":98},[],{"trials":3698,"activeCount":98},[],{"trials":3700,"activeCount":98},[],{"trials":3702,"activeCount":98},[3703,3713],{"nctId":3704,"briefTitle":3705,"status":2847,"phases":3706,"primaryCompletion":644,"completion":644,"start":3707,"enrollment":98,"conditions":3708,"interventions":3710},"NCT04625530","Perioperative Management in Gynaecological Carcinoma Surgery",[88],"2021-08-01",[3709],"Gynaecological Carcinoma",[3711,3693,3712],"ferric carboxymaltose","ferric carboxymaltose and tranexamic acid",{"nctId":3714,"briefTitle":3715,"status":108,"phases":3716,"primaryCompletion":3717,"completion":3718,"start":424,"enrollment":3719,"conditions":3720,"interventions":3722},"NCT02866838","Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist",[87,88],"2021-09-30","2022-03-22",64,[3721],"Intracerebral Hemorrhage",[3723,3724],"Tranexamic acid","Saline 0.9%",{"trials":3726,"activeCount":98},[],{"trials":3728,"activeCount":98},[],{"intervention":3730,"totalTrials":179,"cells":3731},"NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o.",{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3738,"PHASE4":3749,"NA":3751},{"trials":3733,"activeCount":98},[],{"trials":3735,"activeCount":98},[],{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[3740],{"nctId":3741,"briefTitle":3742,"status":108,"phases":3743,"primaryCompletion":112,"completion":112,"start":3744,"enrollment":3745,"conditions":3746,"interventions":3748},"NCT00130598","PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION",[87,88],"2005-06",258,[3747],"Kidney Failure, Acute",[3730],{"trials":3750,"activeCount":98},[],{"trials":3752,"activeCount":98},[],{"intervention":2080,"totalTrials":179,"cells":3754},{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3767,"NA":3769},{"trials":3756,"activeCount":98},[],{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[],{"trials":3762,"activeCount":98},[3763],{"nctId":2070,"briefTitle":2071,"status":422,"phases":3764,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":1054,"conditions":3765,"interventions":3766},[88],[2077,2078],[2080,2059,2081],{"trials":3768,"activeCount":98},[],{"trials":3770,"activeCount":98},[],{"intervention":2081,"totalTrials":179,"cells":3772},{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3779,"PHASE4":3785,"NA":3787},{"trials":3774,"activeCount":98},[],{"trials":3776,"activeCount":98},[],{"trials":3778,"activeCount":98},[],{"trials":3780,"activeCount":98},[3781],{"nctId":2070,"briefTitle":2071,"status":422,"phases":3782,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":1054,"conditions":3783,"interventions":3784},[88],[2077,2078],[2080,2059,2081],{"trials":3786,"activeCount":98},[],{"trials":3788,"activeCount":98},[],{"intervention":3790,"totalTrials":179,"cells":3791},"intravitreal ranibizumab",{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3798,"PHASE4":3810,"NA":3812},{"trials":3793,"activeCount":98},[],{"trials":3795,"activeCount":98},[],{"trials":3797,"activeCount":98},[],{"trials":3799,"activeCount":98},[3800],{"nctId":3801,"briefTitle":3802,"status":108,"phases":3803,"primaryCompletion":2051,"completion":2051,"start":3804,"enrollment":1305,"conditions":3805,"interventions":3808},"NCT00429962","Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV",[88],"2006-07",[3806,3807],"Choroidal Neovascularization","Age-Related Macular Degeneration",[3790,3809],"intravitreal ranibizumab & photodynamic therapy",{"trials":3811,"activeCount":98},[],{"trials":3813,"activeCount":98},[],{"intervention":3809,"totalTrials":179,"cells":3815},{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3828,"NA":3830},{"trials":3817,"activeCount":98},[],{"trials":3819,"activeCount":98},[],{"trials":3821,"activeCount":98},[],{"trials":3823,"activeCount":98},[3824],{"nctId":3801,"briefTitle":3802,"status":108,"phases":3825,"primaryCompletion":2051,"completion":2051,"start":3804,"enrollment":1305,"conditions":3826,"interventions":3827},[88],[3806,3807],[3790,3809],{"trials":3829,"activeCount":98},[],{"trials":3831,"activeCount":98},[],{"intervention":3833,"totalTrials":179,"cells":3834},"Tamoxifen",{"EARLY_PHASE1":3835,"PHASE1":3837,"PHASE2":3839,"PHASE3":3841,"PHASE4":3853,"NA":3855},{"trials":3836,"activeCount":98},[],{"trials":3838,"activeCount":98},[],{"trials":3840,"activeCount":98},[],{"trials":3842,"activeCount":98},[3843],{"nctId":3844,"briefTitle":3845,"status":108,"phases":3846,"primaryCompletion":3847,"completion":3848,"start":3849,"enrollment":3850,"conditions":3851,"interventions":3852},"NCT03354039","Tamoxifen in Duchenne Muscular Dystrophy",[88],"2022-07-25","2022-10-18","2018-06-12",93,[2148],[3833],{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[],{"intervention":3858,"totalTrials":179,"cells":3859},"Ibandronate IV",{"EARLY_PHASE1":3860,"PHASE1":3862,"PHASE2":3864,"PHASE3":3866,"PHASE4":3877,"NA":3879},{"trials":3861,"activeCount":98},[],{"trials":3863,"activeCount":98},[],{"trials":3865,"activeCount":98},[],{"trials":3867,"activeCount":98},[3868],{"nctId":3869,"briefTitle":3870,"status":108,"phases":3871,"primaryCompletion":2161,"completion":2161,"start":3872,"enrollment":621,"conditions":3873,"interventions":3876},"NCT00532220","Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial",[88],"2007-12",[3874,3875],"Osteonecrosis of the Knee","Bone Marrow Edema of the Knee",[3858],{"trials":3878,"activeCount":98},[],{"trials":3880,"activeCount":98},[],{"intervention":3882,"totalTrials":179,"cells":3883},"moxonidine",{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3888,"PHASE3":3890,"PHASE4":3903,"NA":3905},{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[],{"trials":3889,"activeCount":98},[],{"trials":3891,"activeCount":98},[3892],{"nctId":3893,"briefTitle":3894,"status":422,"phases":3895,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":3898,"conditions":3899,"interventions":3902},"NCT00244504","Moxonidine in Patients Undergoing Vascular Surgery",[88],"2006-03","2002-11",141,[3900,3901],"Cardiac Disease","Vascular Surgery",[3882],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"intervention":3908,"totalTrials":179,"cells":3909},"Ropivacain",{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3916,"PHASE4":3928,"NA":3930},{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[],{"trials":3917,"activeCount":98},[3918],{"nctId":3919,"briefTitle":3920,"status":108,"phases":3921,"primaryCompletion":3922,"completion":3923,"start":1121,"enrollment":1031,"conditions":3924,"interventions":3926},"NCT04939545","Study of Postoperative ICC Analgesia",[88],"2023-03-20","2023-10-20",[3925],"Postoperative Analgesia",[3908,3927],"NaCl 0.9%",{"trials":3929,"activeCount":98},[],{"trials":3931,"activeCount":98},[],{"intervention":3927,"totalTrials":179,"cells":3933},{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3938,"PHASE3":3940,"PHASE4":3946,"NA":3948},{"trials":3935,"activeCount":98},[],{"trials":3937,"activeCount":98},[],{"trials":3939,"activeCount":98},[],{"trials":3941,"activeCount":98},[3942],{"nctId":3919,"briefTitle":3920,"status":108,"phases":3943,"primaryCompletion":3922,"completion":3923,"start":1121,"enrollment":1031,"conditions":3944,"interventions":3945},[88],[3925],[3908,3927],{"trials":3947,"activeCount":98},[],{"trials":3949,"activeCount":98},[],{"intervention":3951,"totalTrials":179,"cells":3952},"Empagliflozin (Jardiance®;",{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3959,"PHASE4":3969,"NA":3971},{"trials":3954,"activeCount":98},[],{"trials":3956,"activeCount":98},[],{"trials":3958,"activeCount":98},[],{"trials":3960,"activeCount":98},[3961],{"nctId":3962,"briefTitle":3963,"status":422,"phases":3964,"primaryCompletion":3965,"completion":3965,"start":3966,"enrollment":1305,"conditions":3967,"interventions":3968},"NCT05036317","Empagliflozin for the Treatment of Postprandial Hypoglycemia",[88],"2024-08-05","2022-03-11",[436],[3951],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"intervention":3974,"totalTrials":179,"cells":3975},"Lidocaine",{"EARLY_PHASE1":3976,"PHASE1":3978,"PHASE2":3980,"PHASE3":3982,"PHASE4":3994,"NA":3996},{"trials":3977,"activeCount":98},[],{"trials":3979,"activeCount":98},[],{"trials":3981,"activeCount":98},[],{"trials":3983,"activeCount":98},[3984],{"nctId":3985,"briefTitle":3986,"status":108,"phases":3987,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":3991,"interventions":3992},"NCT03677817","Perioperative Lidocaine Administration in Thoracoscopic Surgery for Improved Postoperative Pain Control",[88],"2022-08-28","2019-04-03",113,[3424],[3974,3993],"NaCl 0,9%",{"trials":3995,"activeCount":98},[],{"trials":3997,"activeCount":98},[],{"intervention":3993,"totalTrials":179,"cells":3999},{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4006,"PHASE4":4012,"NA":4014},{"trials":4001,"activeCount":98},[],{"trials":4003,"activeCount":98},[],{"trials":4005,"activeCount":98},[],{"trials":4007,"activeCount":98},[4008],{"nctId":3985,"briefTitle":3986,"status":108,"phases":4009,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":4010,"interventions":4011},[88],[3424],[3974,3993],{"trials":4013,"activeCount":98},[],{"trials":4015,"activeCount":98},[],{"intervention":3678,"totalTrials":179,"cells":4017},{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4022,"PHASE3":4024,"PHASE4":4030,"NA":4032},{"trials":4019,"activeCount":98},[],{"trials":4021,"activeCount":98},[],{"trials":4023,"activeCount":98},[],{"trials":4025,"activeCount":98},[4026],{"nctId":3670,"briefTitle":3671,"status":108,"phases":4027,"primaryCompletion":3673,"completion":3673,"start":3674,"enrollment":3675,"conditions":4028,"interventions":4029},[88],[2451],[3659,3678,3678],{"trials":4031,"activeCount":98},[],{"trials":4033,"activeCount":98},[],{"intervention":4035,"totalTrials":179,"cells":4036},"Rivastigmine prevention of delirium",{"EARLY_PHASE1":4037,"PHASE1":4039,"PHASE2":4041,"PHASE3":4043,"PHASE4":4052,"NA":4054},{"trials":4038,"activeCount":98},[],{"trials":4040,"activeCount":98},[],{"trials":4042,"activeCount":98},[],{"trials":4044,"activeCount":98},[4045],{"nctId":4046,"briefTitle":4047,"status":108,"phases":4048,"completion":4049,"start":3446,"enrollment":202,"conditions":4050,"interventions":4051},"NCT00257868","Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery",[88],"2007-07",[2130],[4035],{"trials":4053,"activeCount":98},[],{"trials":4055,"activeCount":98},[],{"intervention":3711,"totalTrials":179,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4064,"PHASE4":4070,"NA":4072},{"trials":4059,"activeCount":98},[],{"trials":4061,"activeCount":98},[],{"trials":4063,"activeCount":98},[],{"trials":4065,"activeCount":98},[4066],{"nctId":3704,"briefTitle":3705,"status":2847,"phases":4067,"primaryCompletion":644,"completion":644,"start":3707,"enrollment":98,"conditions":4068,"interventions":4069},[88],[3709],[3711,3693,3712],{"trials":4071,"activeCount":98},[],{"trials":4073,"activeCount":98},[],{"intervention":3712,"totalTrials":179,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4082,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":98},[],{"trials":4079,"activeCount":98},[],{"trials":4081,"activeCount":98},[],{"trials":4083,"activeCount":98},[4084],{"nctId":3704,"briefTitle":3705,"status":2847,"phases":4085,"primaryCompletion":644,"completion":644,"start":3707,"enrollment":98,"conditions":4086,"interventions":4087},[88],[3709],[3711,3693,3712],{"trials":4089,"activeCount":98},[],{"trials":4091,"activeCount":98},[],{"intervention":4093,"totalTrials":179,"cells":4094},"s-ketamine & midazolam",{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4099,"PHASE3":4101,"PHASE4":4112,"NA":4114},{"trials":4096,"activeCount":98},[],{"trials":4098,"activeCount":98},[],{"trials":4100,"activeCount":98},[],{"trials":4102,"activeCount":98},[4103],{"nctId":4104,"briefTitle":4105,"status":108,"phases":4106,"primaryCompletion":2916,"completion":1656,"start":1695,"enrollment":3422,"conditions":4107,"interventions":4110},"NCT01275547","The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam",[87,88],[4108,4109],"Analgesia, Patient-controlled","Spinal Stenosis",[4093,4111],"Morphine PCA",{"trials":4113,"activeCount":98},[],{"trials":4115,"activeCount":98},[],{"intervention":4111,"totalTrials":179,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4124,"PHASE4":4130,"NA":4132},{"trials":4119,"activeCount":98},[],{"trials":4121,"activeCount":98},[],{"trials":4123,"activeCount":98},[],{"trials":4125,"activeCount":98},[4126],{"nctId":4104,"briefTitle":4105,"status":108,"phases":4127,"primaryCompletion":2916,"completion":1656,"start":1695,"enrollment":3422,"conditions":4128,"interventions":4129},[87,88],[4108,4109],[4093,4111],{"trials":4131,"activeCount":98},[],{"trials":4133,"activeCount":98},[],{"intervention":3724,"totalTrials":179,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4148,"NA":4150},{"trials":4137,"activeCount":98},[],{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[],{"trials":4143,"activeCount":98},[4144],{"nctId":3714,"briefTitle":3715,"status":108,"phases":4145,"primaryCompletion":3717,"completion":3718,"start":424,"enrollment":3719,"conditions":4146,"interventions":4147},[87,88],[3721],[3723,3724],{"trials":4149,"activeCount":98},[],{"trials":4151,"activeCount":98},[],{"intervention":4153,"totalTrials":179,"cells":4154},"Empagliflozin 25mg Tbl",{"EARLY_PHASE1":4155,"PHASE1":4157,"PHASE2":4159,"PHASE3":4161,"PHASE4":4173,"NA":4175},{"trials":4156,"activeCount":98},[],{"trials":4158,"activeCount":98},[],{"trials":4160,"activeCount":98},[],{"trials":4162,"activeCount":98},[4163],{"nctId":4164,"briefTitle":4165,"status":108,"phases":4166,"primaryCompletion":4167,"completion":4168,"start":4169,"enrollment":19,"conditions":4170,"interventions":4172},"NCT02729766","Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study",[87,88],"2016-07","2016-08","2016-03",[4171],"Inappropriate ADH Syndrome",[4153],{"trials":4174,"activeCount":98},[],{"trials":4176,"activeCount":98},[],{"intervention":4178,"totalTrials":179,"cells":4179},"PREDNISON Galepharm Tabl. 20 mg",{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4197,"NA":4199},{"trials":4181,"activeCount":98},[],{"trials":4183,"activeCount":98},[],{"trials":4185,"activeCount":98},[],{"trials":4187,"activeCount":98},[4188],{"nctId":4189,"briefTitle":4190,"status":422,"phases":4191,"primaryCompletion":4192,"completion":4192,"start":4193,"enrollment":1031,"conditions":4194,"interventions":4196},"NCT04232449","Oral Corticosteroids for Post-infectious Cough in Adults",[88],"2024-04-30","2020-11-06",[4195],"Post-infectious Cough",[4178],{"trials":4198,"activeCount":98},[],{"trials":4200,"activeCount":98},[],{"intervention":4202,"totalTrials":179,"cells":4203},"glibenclamide",{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4219,"NA":4221},{"trials":4205,"activeCount":98},[],{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[4212],{"nctId":4213,"briefTitle":4214,"status":108,"phases":4215,"start":2596,"enrollment":646,"conditions":4216,"interventions":4218},"NCT00515801","Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM",[87,88],[4217],"Diabetes Mellitus, Type 1",[4202],{"trials":4220,"activeCount":98},[],{"trials":4222,"activeCount":98},[],{"intervention":4224,"totalTrials":179,"cells":4225},"Selenase",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4244,"NA":4246},{"trials":4227,"activeCount":98},[],{"trials":4229,"activeCount":98},[],{"trials":4231,"activeCount":98},[],{"trials":4233,"activeCount":98},[4234],{"nctId":4235,"briefTitle":4236,"status":108,"phases":4237,"primaryCompletion":2197,"completion":4238,"start":1634,"enrollment":4239,"conditions":4240,"interventions":4243},"NCT01141556","Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery",[88],"2012-09",410,[4241,4242],"Heart; Surgery, Heart, Functional Disturbance as Result","Self Efficacy",[4224],{"trials":4245,"activeCount":98},[],{"trials":4247,"activeCount":98},[],{"intervention":4249,"totalTrials":179,"cells":4250},"Moderna COVID-19 Vaccine, mRNA-1273",{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4269,"NA":4271},{"trials":4252,"activeCount":98},[],{"trials":4254,"activeCount":98},[],{"trials":4256,"activeCount":98},[],{"trials":4258,"activeCount":98},[4259],{"nctId":4260,"briefTitle":4261,"status":108,"phases":4262,"primaryCompletion":4263,"completion":4263,"start":4264,"enrollment":468,"conditions":4265,"interventions":4267},"NCT04805125","Immunocompromised Swiss Cohorts Based Trial Platform",[88],"2023-09-23","2021-04-19",[4266],"Immunocompromised Patients",[4249,4268],"Pfizer-BioNTech COVID-19 Vaccine BNT162b2",{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[],{"intervention":4268,"totalTrials":179,"cells":4274},{"EARLY_PHASE1":4275,"PHASE1":4277,"PHASE2":4279,"PHASE3":4281,"PHASE4":4287,"NA":4289},{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"trials":4280,"activeCount":98},[],{"trials":4282,"activeCount":98},[4283],{"nctId":4260,"briefTitle":4261,"status":108,"phases":4284,"primaryCompletion":4263,"completion":4263,"start":4264,"enrollment":468,"conditions":4285,"interventions":4286},[88],[4266],[4249,4268],{"trials":4288,"activeCount":98},[],{"trials":4290,"activeCount":98},[],{"intervention":4292,"totalTrials":179,"cells":4293},"750 mg metformin and 7.5 g L-citrulline daily p.o.",{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4300,"PHASE4":4310,"NA":4312},{"trials":4295,"activeCount":98},[],{"trials":4297,"activeCount":98},[],{"trials":4299,"activeCount":98},[],{"trials":4301,"activeCount":98},[4302],{"nctId":4303,"briefTitle":4304,"status":108,"phases":4305,"primaryCompletion":3529,"completion":4169,"start":1765,"enrollment":4306,"conditions":4307,"interventions":4309},"NCT01995032","L-citrulline and Metformin in Duchenne's Muscular Dystrophy",[88],47,[4308],"Duchenne's Muscular Dystrophy (DMD)",[4292],{"trials":4311,"activeCount":98},[],{"trials":4313,"activeCount":98},[],{"intervention":4315,"totalTrials":179,"cells":4316},"S-adenosyl-L-methionine",{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4323,"PHASE4":4335,"NA":4337},{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[],{"trials":4322,"activeCount":98},[],{"trials":4324,"activeCount":98},[4325],{"nctId":4326,"briefTitle":4327,"status":108,"phases":4328,"primaryCompletion":3038,"completion":2362,"start":2294,"enrollment":621,"conditions":4329,"interventions":4331},"NCT00310336","Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine",[87,88],[4330],"Hepatitis C",[4315,4332,4333,4334],"betaine","pegylated interferon alpha2b","ribavirin",{"trials":4336,"activeCount":98},[],{"trials":4338,"activeCount":98},[],{"intervention":4332,"totalTrials":179,"cells":4340},{"EARLY_PHASE1":4341,"PHASE1":4343,"PHASE2":4345,"PHASE3":4347,"PHASE4":4353,"NA":4355},{"trials":4342,"activeCount":98},[],{"trials":4344,"activeCount":98},[],{"trials":4346,"activeCount":98},[],{"trials":4348,"activeCount":98},[4349],{"nctId":4326,"briefTitle":4327,"status":108,"phases":4350,"primaryCompletion":3038,"completion":2362,"start":2294,"enrollment":621,"conditions":4351,"interventions":4352},[87,88],[4330],[4315,4332,4333,4334],{"trials":4354,"activeCount":98},[],{"trials":4356,"activeCount":98},[],{"intervention":4333,"totalTrials":179,"cells":4358},{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4365,"PHASE4":4371,"NA":4373},{"trials":4360,"activeCount":98},[],{"trials":4362,"activeCount":98},[],{"trials":4364,"activeCount":98},[],{"trials":4366,"activeCount":98},[4367],{"nctId":4326,"briefTitle":4327,"status":108,"phases":4368,"primaryCompletion":3038,"completion":2362,"start":2294,"enrollment":621,"conditions":4369,"interventions":4370},[87,88],[4330],[4315,4332,4333,4334],{"trials":4372,"activeCount":98},[],{"trials":4374,"activeCount":98},[],{"intervention":4334,"totalTrials":179,"cells":4376},{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4383,"PHASE4":4389,"NA":4391},{"trials":4378,"activeCount":98},[],{"trials":4380,"activeCount":98},[],{"trials":4382,"activeCount":98},[],{"trials":4384,"activeCount":98},[4385],{"nctId":4326,"briefTitle":4327,"status":108,"phases":4386,"primaryCompletion":3038,"completion":2362,"start":2294,"enrollment":621,"conditions":4387,"interventions":4388},[87,88],[4330],[4315,4332,4333,4334],{"trials":4390,"activeCount":98},[],{"trials":4392,"activeCount":98},[],{"intervention":4394,"totalTrials":179,"cells":4395},"Empagliflozin 25mg",{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4415,"NA":4417},{"trials":4397,"activeCount":98},[],{"trials":4399,"activeCount":98},[],{"trials":4401,"activeCount":98},[],{"trials":4403,"activeCount":98},[4404],{"nctId":4405,"briefTitle":4406,"status":108,"phases":4407,"primaryCompletion":4408,"completion":4409,"start":4410,"enrollment":4411,"conditions":4412,"interventions":4414},"NCT03202667","Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study",[87,88],"2021-08-26","2021-12-06","2017-12-15",17,[4413,33],"SIAD - Syndrome of Inappropriate Antidiuresis",[4394],{"trials":4416,"activeCount":98},[],{"trials":4418,"activeCount":98},[],{"intervention":4420,"totalTrials":580,"cells":4421},"Dulaglutide",{"EARLY_PHASE1":4422,"PHASE1":4424,"PHASE2":4426,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4423,"activeCount":98},[],{"trials":4425,"activeCount":98},[],{"trials":4427,"activeCount":98},[4428,4437,4448,4463],{"nctId":4429,"briefTitle":4430,"status":108,"phases":4431,"primaryCompletion":4432,"completion":4433,"start":4169,"enrollment":293,"conditions":4434,"interventions":4436},"NCT02770885","Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)",[87],"2019-05-17","2019-10-07",[4435],"Primary Polydipsia",[4420],{"nctId":4438,"briefTitle":4439,"status":108,"phases":4440,"primaryCompletion":4441,"completion":4442,"start":4443,"enrollment":4411,"conditions":4444,"interventions":4447},"NCT03141632","Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake",[87],"2017-05","2017-05-12","2016-10-17",[4445,4446],"Thirst","Water-Electrolyte Imbalance",[4420],{"nctId":4449,"briefTitle":4450,"status":108,"phases":4451,"primaryCompletion":4452,"completion":4453,"start":4454,"enrollment":4455,"conditions":4456,"interventions":4461},"NCT03204396","Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues",[87],"2022-07-30","2022-08-30","2017-06-26",256,[4457,4458,4459,4460],"Glucagon-like Peptide-1","Smoking Cessation","Weight Change, Body","Craving",[4420,4462],"0.5 ml normal saline",{"nctId":4464,"briefTitle":4465,"status":108,"phases":4466,"primaryCompletion":4467,"completion":4467,"start":4468,"enrollment":3013,"conditions":4469,"interventions":4471},"NCT04687514","Effects of Glucagon-Like Peptide-1 Analogs on Sexuality",[87],"2022-09-05","2021-05-05",[4470],"Sexual Functioning",[4420],{"trials":4473,"activeCount":98},[],{"trials":4475,"activeCount":98},[],{"trials":4477,"activeCount":98},[],{"intervention":3638,"totalTrials":411,"cells":4479},{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4484,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4481,"activeCount":98},[],{"trials":4483,"activeCount":98},[],{"trials":4485,"activeCount":98},[4486,4497,4506],{"nctId":4487,"briefTitle":4488,"status":108,"phases":4489,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":3898,"conditions":4492,"interventions":4495},"NCT05145283","Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation",[87],"2026-01-05","2022-03-16",[4493,4494],"Acute Ischemic Stroke","Acute Renal Injury",[3638,4496],"NaCl 0.9%)",{"nctId":4498,"briefTitle":4499,"status":422,"phases":4500,"primaryCompletion":4501,"completion":4501,"start":4502,"enrollment":3634,"conditions":4503,"interventions":4505},"NCT04414631","Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19",[87],"2021-09-15","2020-08-06",[4504],"Coronavirus Infections",[3638],{"nctId":3629,"briefTitle":3630,"status":108,"phases":4507,"primaryCompletion":3632,"completion":3633,"start":2760,"enrollment":3634,"conditions":4508,"interventions":4509},[87],[3636],[3638,3639],{"trials":4511,"activeCount":98},[],{"trials":4513,"activeCount":98},[],{"trials":4515,"activeCount":98},[],{"intervention":4517,"totalTrials":179,"cells":4518},"clostridium botulinum toxin type A neurotoxin complex",{"EARLY_PHASE1":4519,"PHASE1":4521,"PHASE2":4523,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4520,"activeCount":98},[],{"trials":4522,"activeCount":98},[],{"trials":4524,"activeCount":98},[4525],{"nctId":4526,"briefTitle":4527,"status":108,"phases":4528,"primaryCompletion":4529,"completion":4529,"start":3038,"enrollment":621,"conditions":4530,"interventions":4531},"NCT00934687","Botulinum Toxin for the Treatment of Depression",[87],"2010-10",[927],[4517],{"trials":4533,"activeCount":98},[],{"trials":4535,"activeCount":98},[],{"trials":4537,"activeCount":98},[],{"intervention":4539,"totalTrials":179,"cells":4540},"SonoVue",{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[4547],{"nctId":4548,"briefTitle":4549,"status":2847,"phases":4550,"completion":2052,"start":2294,"enrollment":98,"conditions":4551,"interventions":4552},"NCT00286559","Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)",[86,87],[2876],[4539,4553],"Optison",{"trials":4555,"activeCount":98},[],{"trials":4557,"activeCount":98},[],{"trials":4559,"activeCount":98},[],{"intervention":4553,"totalTrials":179,"cells":4561},{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4566,"PHASE3":4572,"PHASE4":4574,"NA":4576},{"trials":4563,"activeCount":98},[],{"trials":4565,"activeCount":98},[],{"trials":4567,"activeCount":98},[4568],{"nctId":4548,"briefTitle":4549,"status":2847,"phases":4569,"completion":2052,"start":2294,"enrollment":98,"conditions":4570,"interventions":4571},[86,87],[2876],[4539,4553],{"trials":4573,"activeCount":98},[],{"trials":4575,"activeCount":98},[],{"trials":4577,"activeCount":98},[],{"intervention":4496,"totalTrials":179,"cells":4579},{"EARLY_PHASE1":4580,"PHASE1":4582,"PHASE2":4584,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4581,"activeCount":98},[],{"trials":4583,"activeCount":98},[],{"trials":4585,"activeCount":98},[4586],{"nctId":4487,"briefTitle":4488,"status":108,"phases":4587,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":3898,"conditions":4588,"interventions":4589},[87],[4493,4494],[3638,4496],{"trials":4591,"activeCount":98},[],{"trials":4593,"activeCount":98},[],{"trials":4595,"activeCount":98},[],{"intervention":4597,"totalTrials":179,"cells":4598},"Everolimus 0.75 mg",{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4614,"PHASE4":4616,"NA":4618},{"trials":4600,"activeCount":98},[],{"trials":4602,"activeCount":98},[],{"trials":4604,"activeCount":98},[4605],{"nctId":4606,"briefTitle":4607,"status":108,"phases":4608,"primaryCompletion":4609,"completion":4609,"start":4610,"enrollment":1238,"conditions":4611,"interventions":4613},"NCT03174171","Open-label Study on Treatment of Primary Aldosteronism With Everolimus",[87],"2018-06-25","2017-05-22",[4612],"Primary Aldosteronism",[4597],{"trials":4615,"activeCount":98},[],{"trials":4617,"activeCount":98},[],{"trials":4619,"activeCount":98},[],{"intervention":4621,"totalTrials":179,"cells":4622},"DOTA-TOC Treatment",{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4627,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4624,"activeCount":98},[],{"trials":4626,"activeCount":98},[],{"trials":4628,"activeCount":98},[4629],{"nctId":4630,"briefTitle":4631,"status":108,"phases":4632,"primaryCompletion":1786,"completion":4633,"start":4634,"enrollment":4635,"conditions":4636,"interventions":4637},"NCT00978211","DOTA-TOC in Metastasized Neuroendocrine Tumors",[87],"2013-12","1997-09",1499,[957],[4621],{"trials":4639,"activeCount":98},[],{"trials":4641,"activeCount":98},[],{"trials":4643,"activeCount":98},[],{"intervention":4645,"totalTrials":179,"cells":4646},"first-line i\u002Fv-levetiracetam",{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4651,"PHASE3":4661,"PHASE4":4663,"NA":4665},{"trials":4648,"activeCount":98},[],{"trials":4650,"activeCount":98},[],{"trials":4652,"activeCount":98},[4653],{"nctId":4654,"briefTitle":4655,"status":2847,"phases":4656,"primaryCompletion":3011,"completion":1795,"start":4657,"enrollment":98,"conditions":4658,"interventions":4660},"NCT00603135","Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus",[87],"2008-01",[4659],"Status Epilepticus, Non-Convulsive",[4645],{"trials":4662,"activeCount":98},[],{"trials":4664,"activeCount":98},[],{"trials":4666,"activeCount":98},[],{"intervention":4668,"totalTrials":179,"cells":4669},"Anakinra Prefilled Syringe",{"EARLY_PHASE1":4670,"PHASE1":4672,"PHASE2":4674,"PHASE3":4688,"PHASE4":4690,"NA":4692},{"trials":4671,"activeCount":98},[],{"trials":4673,"activeCount":98},[],{"trials":4675,"activeCount":98},[4676],{"nctId":4677,"briefTitle":4678,"status":422,"phases":4679,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":646,"conditions":4682,"interventions":4687},"NCT04227769","IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes",[87],"2024-05-28","2020-01-13",[4683,4684,4685,4686],"Diabetes Mellitus Type 2 in Obese","Inflammation","Metabolic Disease","Glucose Metabolism Disorders (Including Diabetes Mellitus)",[4668],{"trials":4689,"activeCount":98},[],{"trials":4691,"activeCount":98},[],{"trials":4693,"activeCount":98},[],{"intervention":4695,"totalTrials":179,"cells":4696},"methoxy-polyethyleneglycol epoetin beta",{"EARLY_PHASE1":4697,"PHASE1":4699,"PHASE2":4701,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4698,"activeCount":98},[],{"trials":4700,"activeCount":98},[],{"trials":4702,"activeCount":98},[4703],{"nctId":4704,"briefTitle":4705,"status":108,"phases":4706,"primaryCompletion":4707,"completion":4529,"start":2662,"enrollment":34,"conditions":4708,"interventions":4710},"NCT01093820","Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction",[87],"2010-09",[4709],"Acute Myocardial Infarction",[4695],{"trials":4712,"activeCount":98},[],{"trials":4714,"activeCount":98},[],{"trials":4716,"activeCount":98},[],{"intervention":4718,"totalTrials":179,"cells":4719},"Nivolumab",{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4735,"PHASE4":4737,"NA":4739},{"trials":4721,"activeCount":98},[],{"trials":4723,"activeCount":98},[],{"trials":4725,"activeCount":98},[4726],{"nctId":4727,"briefTitle":4728,"status":422,"phases":4729,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":34,"conditions":4732,"interventions":4734},"NCT04212026","Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.",[87],"2023-07-12","2020-06-28",[4733],"Metastatic Pancreatic Cancer",[4718],{"trials":4736,"activeCount":98},[],{"trials":4738,"activeCount":98},[],{"trials":4740,"activeCount":98},[],{"intervention":4742,"totalTrials":179,"cells":4743},"Metformin and Metformin & L-Citrulline",{"EARLY_PHASE1":4744,"PHASE1":4746,"PHASE2":4748,"PHASE3":4759,"PHASE4":4761,"NA":4763},{"trials":4745,"activeCount":98},[],{"trials":4747,"activeCount":98},[],{"trials":4749,"activeCount":98},[4750],{"nctId":4751,"briefTitle":4752,"status":108,"phases":4753,"primaryCompletion":4754,"completion":2162,"start":425,"enrollment":783,"conditions":4755,"interventions":4757},"NCT02018731","L-citrulline and Metformin in Becker's Muscular Dystrophy",[87],"2014-09",[4756],"Becker's Muscular Dystrophy (BMD)",[4742,4758],"L-Citrulline and Metformin & L-Citrulline",{"trials":4760,"activeCount":98},[],{"trials":4762,"activeCount":98},[],{"trials":4764,"activeCount":98},[],{"intervention":4758,"totalTrials":179,"cells":4766},{"EARLY_PHASE1":4767,"PHASE1":4769,"PHASE2":4771,"PHASE3":4777,"PHASE4":4779,"NA":4781},{"trials":4768,"activeCount":98},[],{"trials":4770,"activeCount":98},[],{"trials":4772,"activeCount":98},[4773],{"nctId":4751,"briefTitle":4752,"status":108,"phases":4774,"primaryCompletion":4754,"completion":2162,"start":425,"enrollment":783,"conditions":4775,"interventions":4776},[87],[4756],[4742,4758],{"trials":4778,"activeCount":98},[],{"trials":4780,"activeCount":98},[],{"trials":4782,"activeCount":98},[],{"intervention":4784,"totalTrials":179,"cells":4785},"CD3-depleted\u002FCD56+ selected natural killer cells collected from apheresis products",{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4806,"PHASE4":4808,"NA":4810},{"trials":4787,"activeCount":98},[],{"trials":4789,"activeCount":98},[],{"trials":4791,"activeCount":98},[4792],{"nctId":4793,"briefTitle":4794,"status":108,"phases":4795,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":19,"conditions":4798,"interventions":4805},"NCT01386619","NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)",[86,87],"2011-03","2004-01",[4799,4800,4801,4802,4803,4804],"Leukemia, Myeloid, Acute","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Myelodysplastic Syndromes","Lymphoma","Neuroblastoma","Rhabdomyosarcoma",[4784],{"trials":4807,"activeCount":98},[],{"trials":4809,"activeCount":98},[],{"trials":4811,"activeCount":98},[],{"intervention":4462,"totalTrials":179,"cells":4813},{"EARLY_PHASE1":4814,"PHASE1":4816,"PHASE2":4818,"PHASE3":4824,"PHASE4":4826,"NA":4828},{"trials":4815,"activeCount":98},[],{"trials":4817,"activeCount":98},[],{"trials":4819,"activeCount":98},[4820],{"nctId":4449,"briefTitle":4450,"status":108,"phases":4821,"primaryCompletion":4452,"completion":4453,"start":4454,"enrollment":4455,"conditions":4822,"interventions":4823},[87],[4457,4458,4459,4460],[4420,4462],{"trials":4825,"activeCount":98},[],{"trials":4827,"activeCount":98},[],{"trials":4829,"activeCount":98},[],{"intervention":4831,"totalTrials":179,"cells":4832},"Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes",{"EARLY_PHASE1":4833,"PHASE1":4835,"PHASE2":4837,"PHASE3":4847,"PHASE4":4849,"NA":4851},{"trials":4834,"activeCount":98},[],{"trials":4836,"activeCount":98},[],{"trials":4838,"activeCount":98},[4839],{"nctId":4840,"briefTitle":4841,"status":108,"phases":4842,"primaryCompletion":4049,"completion":2052,"start":3897,"enrollment":19,"conditions":4843,"interventions":4845},"NCT00116597","Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma",[86,87],[4844],"Melanoma",[4831,4846],"Intranodal booster immunizations with synthetic melanoma associated epitopes",{"trials":4848,"activeCount":98},[],{"trials":4850,"activeCount":98},[],{"trials":4852,"activeCount":98},[],{"intervention":4846,"totalTrials":179,"cells":4854},{"EARLY_PHASE1":4855,"PHASE1":4857,"PHASE2":4859,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4856,"activeCount":98},[],{"trials":4858,"activeCount":98},[],{"trials":4860,"activeCount":98},[4861],{"nctId":4840,"briefTitle":4841,"status":108,"phases":4862,"primaryCompletion":4049,"completion":2052,"start":3897,"enrollment":19,"conditions":4863,"interventions":4864},[86,87],[4844],[4831,4846],{"trials":4866,"activeCount":98},[],{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":98},[],{"intervention":4872,"totalTrials":179,"cells":4873},"gemcitabine, oxaliplatin, capecitabine",{"EARLY_PHASE1":4874,"PHASE1":4876,"PHASE2":4878,"PHASE3":4889,"PHASE4":4891,"NA":4893},{"trials":4875,"activeCount":98},[],{"trials":4877,"activeCount":98},[],{"trials":4879,"activeCount":98},[4880],{"nctId":4881,"briefTitle":4882,"status":108,"phases":4883,"primaryCompletion":4884,"completion":112,"start":4885,"enrollment":1123,"conditions":4886,"interventions":4888},"NCT00744640","Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma",[86,87],"2009-02","2005-10",[4887,4733],"Locally Advanced Pancreatic Cancer",[4872],{"trials":4890,"activeCount":98},[],{"trials":4892,"activeCount":98},[],{"trials":4894,"activeCount":98},[],{"intervention":4896,"totalTrials":179,"cells":4897},"Ticagrelor",{"EARLY_PHASE1":4898,"PHASE1":4900,"PHASE2":4902,"PHASE3":4915,"PHASE4":4917,"NA":4919},{"trials":4899,"activeCount":98},[],{"trials":4901,"activeCount":98},[],{"trials":4903,"activeCount":98},[4904],{"nctId":4905,"briefTitle":4906,"status":108,"phases":4907,"primaryCompletion":4908,"completion":4908,"start":424,"enrollment":4909,"conditions":4910,"interventions":4912},"NCT02677545","Ticagrelor Versus Clopidogrel in Carotid Artery Stenting",[87],"2022-04-28",210,[4911],"Carotid Artery Stenosis",[4896,4913,4914],"Clopidogrel","Aspirin",{"trials":4916,"activeCount":98},[],{"trials":4918,"activeCount":98},[],{"trials":4920,"activeCount":98},[],{"intervention":4913,"totalTrials":179,"cells":4922},{"EARLY_PHASE1":4923,"PHASE1":4925,"PHASE2":4927,"PHASE3":4933,"PHASE4":4935,"NA":4937},{"trials":4924,"activeCount":98},[],{"trials":4926,"activeCount":98},[],{"trials":4928,"activeCount":98},[4929],{"nctId":4905,"briefTitle":4906,"status":108,"phases":4930,"primaryCompletion":4908,"completion":4908,"start":424,"enrollment":4909,"conditions":4931,"interventions":4932},[87],[4911],[4896,4913,4914],{"trials":4934,"activeCount":98},[],{"trials":4936,"activeCount":98},[],{"trials":4938,"activeCount":98},[],{"intervention":4914,"totalTrials":179,"cells":4940},{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4945,"PHASE3":4951,"PHASE4":4953,"NA":4955},{"trials":4942,"activeCount":98},[],{"trials":4944,"activeCount":98},[],{"trials":4946,"activeCount":98},[4947],{"nctId":4905,"briefTitle":4906,"status":108,"phases":4948,"primaryCompletion":4908,"completion":4908,"start":424,"enrollment":4909,"conditions":4949,"interventions":4950},[87],[4911],[4896,4913,4914],{"trials":4952,"activeCount":98},[],{"trials":4954,"activeCount":98},[],{"trials":4956,"activeCount":98},[],{"intervention":4958,"totalTrials":179,"cells":4959},"fingolimod",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4961,"activeCount":98},[],{"trials":4963,"activeCount":98},[],{"trials":4965,"activeCount":98},[4966],{"nctId":4967,"briefTitle":4968,"status":108,"phases":4969,"primaryCompletion":4970,"completion":4970,"start":3296,"enrollment":94,"conditions":4971,"interventions":4973},"NCT02061137","Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome",[86,87],"2018-04",[4972],"Rett's Syndrome",[4958],{"trials":4975,"activeCount":98},[],{"trials":4977,"activeCount":98},[],{"trials":4979,"activeCount":98},[],{"intervention":4981,"totalTrials":179,"cells":4982},"Sitagliptin",{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4987,"PHASE3":4999,"PHASE4":5001,"NA":5003},{"trials":4984,"activeCount":98},[],{"trials":4986,"activeCount":98},[],{"trials":4988,"activeCount":98},[4989],{"nctId":4990,"briefTitle":4991,"status":108,"phases":4992,"primaryCompletion":4167,"completion":4993,"start":4994,"enrollment":426,"conditions":4995,"interventions":4997},"NCT02127047","Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes",[87],"2016-08-05","2013-11",[4996],"Diabetes Mellitus Type 1",[4981,4998],"Exercise",{"trials":5000,"activeCount":98},[],{"trials":5002,"activeCount":98},[],{"trials":5004,"activeCount":98},[],{"intervention":4998,"totalTrials":179,"cells":5006},{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5011,"PHASE3":5017,"PHASE4":5019,"NA":5021},{"trials":5008,"activeCount":98},[],{"trials":5010,"activeCount":98},[],{"trials":5012,"activeCount":98},[5013],{"nctId":4990,"briefTitle":4991,"status":108,"phases":5014,"primaryCompletion":4167,"completion":4993,"start":4994,"enrollment":426,"conditions":5015,"interventions":5016},[87],[4996],[4981,4998],{"trials":5018,"activeCount":98},[],{"trials":5020,"activeCount":98},[],{"trials":5022,"activeCount":98},[],{"intervention":5024,"totalTrials":179,"cells":5025},"Oral GLP-1",{"EARLY_PHASE1":5026,"PHASE1":5028,"PHASE2":5030,"PHASE3":5040,"PHASE4":5042,"NA":5044},{"trials":5027,"activeCount":98},[],{"trials":5029,"activeCount":98},[],{"trials":5031,"activeCount":98},[5032],{"nctId":5033,"briefTitle":5034,"status":108,"phases":5035,"primaryCompletion":2051,"completion":5036,"start":2188,"enrollment":163,"conditions":5037,"interventions":5039},"NCT00822003","Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects",[86,87],"2008-09",[5038],"Glucose Homeostasis",[5024],{"trials":5041,"activeCount":98},[],{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"intervention":5047,"totalTrials":179,"cells":5048},"esketamine nasal spray",{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5053,"PHASE3":5064,"PHASE4":5066,"NA":5068},{"trials":5050,"activeCount":98},[],{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[5055],{"nctId":5056,"briefTitle":5057,"status":2847,"phases":5058,"primaryCompletion":5059,"completion":5059,"start":5060,"enrollment":98,"conditions":5061,"interventions":5063},"NCT04666623","Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain",[87],"2023-10-11","2020-11-25",[5062],"Cancer Pain",[5047],{"trials":5065,"activeCount":98},[],{"trials":5067,"activeCount":98},[],{"trials":5069,"activeCount":98},[],{"intervention":5071,"totalTrials":179,"cells":5072},"IL-1 receptor antagonist Anakinra",{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5074,"activeCount":98},[],{"trials":5076,"activeCount":98},[],{"trials":5078,"activeCount":98},[5079],{"nctId":5080,"briefTitle":5081,"status":108,"phases":5082,"primaryCompletion":5083,"completion":5083,"start":5084,"enrollment":646,"conditions":5085,"interventions":5087},"NCT03578497","Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome",[87],"2020-07-30","2018-08-31",[5086],"Polycystic Ovary Syndrome",[5071],{"trials":5089,"activeCount":98},[],{"trials":5091,"activeCount":98},[],{"trials":5093,"activeCount":98},[],{"intervention":5095,"totalTrials":179,"cells":5096},"misoprostol",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5101,"PHASE3":5112,"PHASE4":5114,"NA":5116},{"trials":5098,"activeCount":98},[],{"trials":5100,"activeCount":98},[],{"trials":5102,"activeCount":98},[5103],{"nctId":5104,"briefTitle":5105,"status":108,"phases":5106,"primaryCompletion":5107,"completion":5107,"start":5108,"enrollment":434,"conditions":5109,"interventions":5111},"NCT00107874","Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section",[87],"2002-02","1999-01",[5110],"Postpartum Hemorrhage",[5095],{"trials":5113,"activeCount":98},[],{"trials":5115,"activeCount":98},[],{"trials":5117,"activeCount":98},[],{"intervention":1607,"totalTrials":411,"cells":5119},{"EARLY_PHASE1":5120,"PHASE1":5130,"PHASE2":5136,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5121,"activeCount":98},[5122,5126],{"nctId":1762,"briefTitle":1763,"status":108,"phases":5123,"primaryCompletion":111,"completion":111,"start":1765,"enrollment":426,"conditions":5124,"interventions":5125},[85],[15,1767,1621],[1607,1769,1083],{"nctId":1598,"briefTitle":1599,"status":108,"phases":5127,"primaryCompletion":1601,"completion":1602,"start":1603,"enrollment":621,"conditions":5128,"interventions":5129},[85],[1605],[1013,1607],{"trials":5131,"activeCount":98},[5132],{"nctId":1652,"briefTitle":1653,"status":108,"phases":5133,"primaryCompletion":1601,"completion":1655,"start":1656,"enrollment":163,"conditions":5134,"interventions":5135},[86],[15],[1013,1607],{"trials":5137,"activeCount":98},[],{"trials":5139,"activeCount":98},[],{"trials":5141,"activeCount":98},[],{"trials":5143,"activeCount":98},[],{"intervention":5145,"totalTrials":376,"cells":5146},"metamizole",{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5169,"PHASE3":5171,"PHASE4":5173,"NA":5175},{"trials":5148,"activeCount":98},[],{"trials":5150,"activeCount":98},[5151,5159],{"nctId":5152,"briefTitle":5153,"status":108,"phases":5154,"primaryCompletion":5155,"completion":5155,"start":2196,"enrollment":19,"conditions":5156,"interventions":5157},"NCT01995006","Effect of Metamizole (Dipyrone) on Renal Function in Salt-depleted Healthy Subjects",[86],"2014-04",[15],[5145,5158],"Naproxen",{"nctId":5160,"briefTitle":5161,"status":108,"phases":5162,"primaryCompletion":2447,"completion":2447,"start":1079,"enrollment":1238,"conditions":5163,"interventions":5167},"NCT03990129","Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects",[86],[5164,5165,5166],"Inhibition","Induction","Drug-Drug Interaction",[5168],"Metamizole",{"trials":5170,"activeCount":98},[],{"trials":5172,"activeCount":98},[],{"trials":5174,"activeCount":98},[],{"trials":5176,"activeCount":98},[],{"intervention":1667,"totalTrials":376,"cells":5178},{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5195,"PHASE3":5197,"PHASE4":5199,"NA":5201},{"trials":5180,"activeCount":98},[],{"trials":5182,"activeCount":98},[5183,5187],{"nctId":1660,"briefTitle":1661,"status":108,"phases":5184,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":426,"conditions":5185,"interventions":5186},[86],[15],[604,1667,1668,1668],{"nctId":5188,"briefTitle":5189,"status":108,"phases":5190,"primaryCompletion":5191,"completion":5191,"start":5192,"enrollment":3013,"conditions":5193,"interventions":5194},"NCT06905652","Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants",[86],"2026-05-12","2025-07-29",[15],[1668,1667],{"trials":5196,"activeCount":98},[],{"trials":5198,"activeCount":98},[],{"trials":5200,"activeCount":98},[],{"trials":5202,"activeCount":98},[],{"intervention":1668,"totalTrials":376,"cells":5204},{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5217,"PHASE3":5219,"PHASE4":5221,"NA":5223},{"trials":5206,"activeCount":98},[],{"trials":5208,"activeCount":98},[5209,5213],{"nctId":1660,"briefTitle":1661,"status":108,"phases":5210,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":426,"conditions":5211,"interventions":5212},[86],[15],[604,1667,1668,1668],{"nctId":5188,"briefTitle":5189,"status":108,"phases":5214,"primaryCompletion":5191,"completion":5191,"start":5192,"enrollment":3013,"conditions":5215,"interventions":5216},[86],[15],[1668,1667],{"trials":5218,"activeCount":98},[],{"trials":5220,"activeCount":98},[],{"trials":5222,"activeCount":98},[],{"trials":5224,"activeCount":98},[],{"intervention":1780,"totalTrials":179,"cells":5226},{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5235,"PHASE3":5237,"PHASE4":5239,"NA":5241},{"trials":5228,"activeCount":98},[],{"trials":5230,"activeCount":98},[5231],{"nctId":1773,"briefTitle":1774,"status":108,"phases":5232,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":163,"conditions":5233,"interventions":5234},[86],[1621,1622,1623],[1083,1780],{"trials":5236,"activeCount":98},[],{"trials":5238,"activeCount":98},[],{"trials":5240,"activeCount":98},[],{"trials":5242,"activeCount":98},[],{"intervention":1625,"totalTrials":179,"cells":5244},{"EARLY_PHASE1":5245,"PHASE1":5247,"PHASE2":5253,"PHASE3":5255,"PHASE4":5257,"NA":5259},{"trials":5246,"activeCount":98},[],{"trials":5248,"activeCount":98},[5249],{"nctId":1615,"briefTitle":1616,"status":108,"phases":5250,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":163,"conditions":5251,"interventions":5252},[86],[1621,1622,1623],[1013,1625],{"trials":5254,"activeCount":98},[],{"trials":5256,"activeCount":98},[],{"trials":5258,"activeCount":98},[],{"trials":5260,"activeCount":98},[],{"intervention":5262,"totalTrials":179,"cells":5263},"Intravenous infusion of DMT",{"EARLY_PHASE1":5264,"PHASE1":5266,"PHASE2":5279,"PHASE3":5281,"PHASE4":5283,"NA":5285},{"trials":5265,"activeCount":98},[],{"trials":5267,"activeCount":98},[5268],{"nctId":5269,"briefTitle":5270,"status":108,"phases":5271,"primaryCompletion":5272,"completion":5273,"start":5274,"enrollment":4411,"conditions":5275,"interventions":5276},"NCT06180759","Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants",[86],"2025-09-29","2025-11-06","2025-01-23",[15],[5262,5277,5278],"Intravenous infusion of ketamine","Intravenous infusion of placebo",{"trials":5280,"activeCount":98},[],{"trials":5282,"activeCount":98},[],{"trials":5284,"activeCount":98},[],{"trials":5286,"activeCount":98},[],{"intervention":5277,"totalTrials":179,"cells":5288},{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5297,"PHASE3":5299,"PHASE4":5301,"NA":5303},{"trials":5290,"activeCount":98},[],{"trials":5292,"activeCount":98},[5293],{"nctId":5269,"briefTitle":5270,"status":108,"phases":5294,"primaryCompletion":5272,"completion":5273,"start":5274,"enrollment":4411,"conditions":5295,"interventions":5296},[86],[15],[5262,5277,5278],{"trials":5298,"activeCount":98},[],{"trials":5300,"activeCount":98},[],{"trials":5302,"activeCount":98},[],{"trials":5304,"activeCount":98},[],{"intervention":5278,"totalTrials":179,"cells":5306},{"EARLY_PHASE1":5307,"PHASE1":5309,"PHASE2":5315,"PHASE3":5317,"PHASE4":5319,"NA":5321},{"trials":5308,"activeCount":98},[],{"trials":5310,"activeCount":98},[5311],{"nctId":5269,"briefTitle":5270,"status":108,"phases":5312,"primaryCompletion":5272,"completion":5273,"start":5274,"enrollment":4411,"conditions":5313,"interventions":5314},[86],[15],[5262,5277,5278],{"trials":5316,"activeCount":98},[],{"trials":5318,"activeCount":98},[],{"trials":5320,"activeCount":98},[],{"trials":5322,"activeCount":98},[],{"intervention":5324,"totalTrials":179,"cells":5325},"diacetylmorphine",{"EARLY_PHASE1":5326,"PHASE1":5328,"PHASE2":5338,"PHASE3":5340,"PHASE4":5342,"NA":5344},{"trials":5327,"activeCount":98},[],{"trials":5329,"activeCount":98},[5330],{"nctId":5331,"briefTitle":5332,"status":108,"phases":5333,"primaryCompletion":1634,"completion":5334,"start":1795,"enrollment":271,"conditions":5335,"interventions":5337},"NCT01174927","Effects of Diacetylmorphine (DAM) on Brain Function and Stress Response",[86],"2012-02",[5336],"Opiate",[5324],{"trials":5339,"activeCount":98},[],{"trials":5341,"activeCount":98},[],{"trials":5343,"activeCount":98},[],{"trials":5345,"activeCount":98},[],{"intervention":5158,"totalTrials":179,"cells":5347},{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5356,"PHASE3":5358,"PHASE4":5360,"NA":5362},{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[5352],{"nctId":5152,"briefTitle":5153,"status":108,"phases":5353,"primaryCompletion":5155,"completion":5155,"start":2196,"enrollment":19,"conditions":5354,"interventions":5355},[86],[15],[5145,5158],{"trials":5357,"activeCount":98},[],{"trials":5359,"activeCount":98},[],{"trials":5361,"activeCount":98},[],{"trials":5363,"activeCount":98},[],{"intervention":5365,"totalTrials":179,"cells":5366},"Tissue engineered cartilage graft",{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5381,"PHASE3":5383,"PHASE4":5385,"NA":5387},{"trials":5368,"activeCount":98},[],{"trials":5370,"activeCount":98},[5371],{"nctId":5372,"briefTitle":5373,"status":108,"phases":5374,"primaryCompletion":5375,"completion":5375,"start":5376,"enrollment":646,"conditions":5377,"interventions":5380},"NCT01605201","Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage",[86],"2018-08-15","2012-08-29",[5378,5379],"Cartilage Lesion","Degenerative Lesion of Articular Cartilage of Knee",[5365],{"trials":5382,"activeCount":98},[],{"trials":5384,"activeCount":98},[],{"trials":5386,"activeCount":98},[],{"trials":5388,"activeCount":98},[],{"intervention":1110,"totalTrials":179,"cells":5390},{"EARLY_PHASE1":5391,"PHASE1":5393,"PHASE2":5399,"PHASE3":5401,"PHASE4":5403,"NA":5405},{"trials":5392,"activeCount":98},[],{"trials":5394,"activeCount":98},[5395],{"nctId":1103,"briefTitle":1104,"status":108,"phases":5396,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":783,"conditions":5397,"interventions":5398},[86],[15],[1005,1005,1005,1110],{"trials":5400,"activeCount":98},[],{"trials":5402,"activeCount":98},[],{"trials":5404,"activeCount":98},[],{"trials":5406,"activeCount":98},[],{"intervention":5408,"totalTrials":179,"cells":5409},"C225-ILs-dox",{"EARLY_PHASE1":5410,"PHASE1":5412,"PHASE2":5423,"PHASE3":5425,"PHASE4":5427,"NA":5429},{"trials":5411,"activeCount":98},[],{"trials":5413,"activeCount":98},[5414],{"nctId":5415,"briefTitle":5416,"status":108,"phases":5417,"primaryCompletion":5418,"completion":5418,"start":5419,"enrollment":27,"conditions":5420,"interventions":5422},"NCT03603379","Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas",[86],"2020-11-01","2018-11-16",[5421],"Glioblastoma",[5408],{"trials":5424,"activeCount":98},[],{"trials":5426,"activeCount":98},[],{"trials":5428,"activeCount":98},[],{"trials":5430,"activeCount":98},[],{"intervention":595,"totalTrials":179,"cells":5432},{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5441,"PHASE3":5443,"PHASE4":5445,"NA":5447},{"trials":5434,"activeCount":98},[],{"trials":5436,"activeCount":98},[5437],{"nctId":587,"briefTitle":588,"status":108,"phases":5438,"primaryCompletion":590,"completion":591,"start":592,"enrollment":426,"conditions":5439,"interventions":5440},[86],[15],[595,55],{"trials":5442,"activeCount":98},[],{"trials":5444,"activeCount":98},[],{"trials":5446,"activeCount":98},[],{"trials":5448,"activeCount":98},[],{"intervention":5450,"totalTrials":179,"cells":5451},"engineered nasal cartilage graft",{"EARLY_PHASE1":5452,"PHASE1":5454,"PHASE2":5463,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5453,"activeCount":98},[],{"trials":5455,"activeCount":98},[5456],{"nctId":5457,"briefTitle":5458,"status":108,"phases":5459,"primaryCompletion":2572,"start":4529,"enrollment":991,"conditions":5460,"interventions":5462},"NCT01242618","Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule",[86],[5461],"Skin Carcinoma",[5450],{"trials":5464,"activeCount":98},[],{"trials":5466,"activeCount":98},[],{"trials":5468,"activeCount":98},[],{"trials":5470,"activeCount":98},[],{"intervention":5472,"totalTrials":179,"cells":5473},"anti-EGFR immunoliposomes loaded with doxorubicin",{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5485,"PHASE3":5487,"PHASE4":5489,"NA":5491},{"trials":5475,"activeCount":98},[],{"trials":5477,"activeCount":98},[5478],{"nctId":5479,"briefTitle":5480,"status":108,"phases":5481,"primaryCompletion":1795,"completion":1795,"start":3552,"enrollment":3013,"conditions":5482,"interventions":5484},"NCT01702129","Anti-EGFR Immunoliposomes in Solid Tumors",[86],[5483],"Solid Tumors",[5472],{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[],{"trials":5490,"activeCount":98},[],{"trials":5492,"activeCount":98},[],{"intervention":5494,"totalTrials":179,"cells":5495},"Bortezomib",{"EARLY_PHASE1":5496,"PHASE1":5498,"PHASE2":5508,"PHASE3":5510,"PHASE4":5512,"NA":5514},{"trials":5497,"activeCount":98},[],{"trials":5499,"activeCount":98},[5500],{"nctId":5501,"briefTitle":5502,"status":422,"phases":5503,"primaryCompletion":5504,"completion":5504,"start":1601,"enrollment":411,"conditions":5505,"interventions":5507},"NCT01863004","Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin",[86],"2017-09-15",[5506],"Dysferlinopathy",[5494],{"trials":5509,"activeCount":98},[],{"trials":5511,"activeCount":98},[],{"trials":5513,"activeCount":98},[],{"trials":5515,"activeCount":98},[],{"intervention":5517,"totalTrials":179,"cells":5518},"ACEI-ARB-RI",{"EARLY_PHASE1":5519,"PHASE1":5521,"PHASE2":5533,"PHASE3":5535,"PHASE4":5537,"NA":5539},{"trials":5520,"activeCount":98},[],{"trials":5522,"activeCount":98},[5523],{"nctId":5524,"briefTitle":5525,"status":108,"phases":5526,"primaryCompletion":1602,"start":5527,"enrollment":1238,"conditions":5528,"interventions":5530},"NCT01771783","RAS-Peptide-Profile Study in Healthy Male Subjects",[86],"2012-11",[5529],"RAS Peptide Profile in Healthy Volunteers",[5517,5531,5532],"ARB-RI-ACEI","RI-ACEI-ARB",{"trials":5534,"activeCount":98},[],{"trials":5536,"activeCount":98},[],{"trials":5538,"activeCount":98},[],{"trials":5540,"activeCount":98},[],{"intervention":5531,"totalTrials":179,"cells":5542},{"EARLY_PHASE1":5543,"PHASE1":5545,"PHASE2":5551,"PHASE3":5553,"PHASE4":5555,"NA":5557},{"trials":5544,"activeCount":98},[],{"trials":5546,"activeCount":98},[5547],{"nctId":5524,"briefTitle":5525,"status":108,"phases":5548,"primaryCompletion":1602,"start":5527,"enrollment":1238,"conditions":5549,"interventions":5550},[86],[5529],[5517,5531,5532],{"trials":5552,"activeCount":98},[],{"trials":5554,"activeCount":98},[],{"trials":5556,"activeCount":98},[],{"trials":5558,"activeCount":98},[],{"intervention":5532,"totalTrials":179,"cells":5560},{"EARLY_PHASE1":5561,"PHASE1":5563,"PHASE2":5569,"PHASE3":5571,"PHASE4":5573,"NA":5575},{"trials":5562,"activeCount":98},[],{"trials":5564,"activeCount":98},[5565],{"nctId":5524,"briefTitle":5525,"status":108,"phases":5566,"primaryCompletion":1602,"start":5527,"enrollment":1238,"conditions":5567,"interventions":5568},[86],[5529],[5517,5531,5532],{"trials":5570,"activeCount":98},[],{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":98},[],{"intervention":614,"totalTrials":179,"cells":5578},{"EARLY_PHASE1":5579,"PHASE1":5581,"PHASE2":5587,"PHASE3":5589,"PHASE4":5591,"NA":5593},{"trials":5580,"activeCount":98},[],{"trials":5582,"activeCount":98},[5583],{"nctId":606,"briefTitle":607,"status":108,"phases":5584,"primaryCompletion":609,"completion":610,"start":611,"enrollment":426,"conditions":5585,"interventions":5586},[86],[15],[55,614,615],{"trials":5588,"activeCount":98},[],{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[],{"trials":5594,"activeCount":98},[],{"intervention":615,"totalTrials":179,"cells":5596},{"EARLY_PHASE1":5597,"PHASE1":5599,"PHASE2":5605,"PHASE3":5607,"PHASE4":5609,"NA":5611},{"trials":5598,"activeCount":98},[],{"trials":5600,"activeCount":98},[5601],{"nctId":606,"briefTitle":607,"status":108,"phases":5602,"primaryCompletion":609,"completion":610,"start":611,"enrollment":426,"conditions":5603,"interventions":5604},[86],[15],[55,614,615],{"trials":5606,"activeCount":98},[],{"trials":5608,"activeCount":98},[],{"trials":5610,"activeCount":98},[],{"trials":5612,"activeCount":98},[],{"intervention":5614,"totalTrials":179,"cells":5615},"esketamine hydrochloride",{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5626,"PHASE3":5628,"PHASE4":5630,"NA":5632},{"trials":5617,"activeCount":98},[],{"trials":5619,"activeCount":98},[5620],{"nctId":5621,"briefTitle":5622,"status":108,"phases":5623,"completion":150,"start":4884,"conditions":5624,"interventions":5625},"NCT00847418","Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine",[86],[29],[5614],{"trials":5627,"activeCount":98},[],{"trials":5629,"activeCount":98},[],{"trials":5631,"activeCount":98},[],{"trials":5633,"activeCount":98},[],{"intervention":5635,"totalTrials":179,"cells":5636},"Mescaline 100mg",{"EARLY_PHASE1":5637,"PHASE1":5639,"PHASE2":5653,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5638,"activeCount":98},[],{"trials":5640,"activeCount":98},[5641],{"nctId":5642,"briefTitle":5643,"status":108,"phases":5644,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":163,"conditions":5647,"interventions":5648},"NCT04849013","Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness",[86],"2023-03-27","2021-08-11",[15],[5635,5649,5650,5651,5652],"Mescaline 200mg","Mescaline 400mg","Mescaline 800mg","Mescaline 800mg + Ketanserin 40mg",{"trials":5654,"activeCount":98},[],{"trials":5656,"activeCount":98},[],{"trials":5658,"activeCount":98},[],{"trials":5660,"activeCount":98},[],{"intervention":5649,"totalTrials":179,"cells":5662},{"EARLY_PHASE1":5663,"PHASE1":5665,"PHASE2":5671,"PHASE3":5673,"PHASE4":5675,"NA":5677},{"trials":5664,"activeCount":98},[],{"trials":5666,"activeCount":98},[5667],{"nctId":5642,"briefTitle":5643,"status":108,"phases":5668,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":163,"conditions":5669,"interventions":5670},[86],[15],[5635,5649,5650,5651,5652],{"trials":5672,"activeCount":98},[],{"trials":5674,"activeCount":98},[],{"trials":5676,"activeCount":98},[],{"trials":5678,"activeCount":98},[],{"intervention":5650,"totalTrials":179,"cells":5680},{"EARLY_PHASE1":5681,"PHASE1":5683,"PHASE2":5689,"PHASE3":5691,"PHASE4":5693,"NA":5695},{"trials":5682,"activeCount":98},[],{"trials":5684,"activeCount":98},[5685],{"nctId":5642,"briefTitle":5643,"status":108,"phases":5686,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":163,"conditions":5687,"interventions":5688},[86],[15],[5635,5649,5650,5651,5652],{"trials":5690,"activeCount":98},[],{"trials":5692,"activeCount":98},[],{"trials":5694,"activeCount":98},[],{"trials":5696,"activeCount":98},[],{"intervention":5651,"totalTrials":179,"cells":5698},{"EARLY_PHASE1":5699,"PHASE1":5701,"PHASE2":5707,"PHASE3":5709,"PHASE4":5711,"NA":5713},{"trials":5700,"activeCount":98},[],{"trials":5702,"activeCount":98},[5703],{"nctId":5642,"briefTitle":5643,"status":108,"phases":5704,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":163,"conditions":5705,"interventions":5706},[86],[15],[5635,5649,5650,5651,5652],{"trials":5708,"activeCount":98},[],{"trials":5710,"activeCount":98},[],{"trials":5712,"activeCount":98},[],{"trials":5714,"activeCount":98},[],{"intervention":5652,"totalTrials":179,"cells":5716},{"EARLY_PHASE1":5717,"PHASE1":5719,"PHASE2":5725,"PHASE3":5727,"PHASE4":5729,"NA":5731},{"trials":5718,"activeCount":98},[],{"trials":5720,"activeCount":98},[5721],{"nctId":5642,"briefTitle":5643,"status":108,"phases":5722,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":163,"conditions":5723,"interventions":5724},[86],[15],[5635,5649,5650,5651,5652],{"trials":5726,"activeCount":98},[],{"trials":5728,"activeCount":98},[],{"trials":5730,"activeCount":98},[],{"trials":5732,"activeCount":98},[],{"intervention":1790,"totalTrials":179,"cells":5734},{"EARLY_PHASE1":5735,"PHASE1":5737,"PHASE2":5743,"PHASE3":5745,"PHASE4":5747,"NA":5749},{"trials":5736,"activeCount":98},[],{"trials":5738,"activeCount":98},[5739],{"nctId":1782,"briefTitle":1783,"status":108,"phases":5740,"primaryCompletion":1785,"completion":1786,"start":1655,"enrollment":163,"conditions":5741,"interventions":5742},[86],[15,1788],[1083,1790],{"trials":5744,"activeCount":98},[],{"trials":5746,"activeCount":98},[],{"trials":5748,"activeCount":98},[],{"trials":5750,"activeCount":98},[],{"intervention":5752,"totalTrials":179,"cells":5753},"Ivermectin",{"EARLY_PHASE1":5754,"PHASE1":5756,"PHASE2":5766,"PHASE3":5768,"PHASE4":5770,"NA":5772},{"trials":5755,"activeCount":98},[],{"trials":5757,"activeCount":98},[5758],{"nctId":5759,"briefTitle":5760,"status":108,"phases":5761,"primaryCompletion":424,"completion":2760,"start":5762,"enrollment":1238,"conditions":5763,"interventions":5765},"NCT02963324","Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers",[86],"2016-11",[5764],"Malaria",[5752],{"trials":5767,"activeCount":98},[],{"trials":5769,"activeCount":98},[],{"trials":5771,"activeCount":98},[],{"trials":5773,"activeCount":98},[],{"intervention":5775,"totalTrials":179,"cells":5776},"rVV-740CTA",{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5789,"PHASE3":5791,"PHASE4":5793,"NA":5795},{"trials":5778,"activeCount":98},[],{"trials":5780,"activeCount":98},[5781],{"nctId":5782,"briefTitle":5783,"status":2847,"phases":5784,"primaryCompletion":5785,"completion":5785,"start":3106,"enrollment":98,"conditions":5786,"interventions":5788},"NCT03110445","Cancer\u002FTestis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus",[86],"2021-09",[5787],"Breast Carcinoma",[5775],{"trials":5790,"activeCount":98},[],{"trials":5792,"activeCount":98},[],{"trials":5794,"activeCount":98},[],{"trials":5796,"activeCount":98},[],{"intervention":1841,"totalTrials":179,"cells":5798},{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5807,"PHASE3":5809,"PHASE4":5811,"NA":5813},{"trials":5800,"activeCount":98},[],{"trials":5802,"activeCount":98},[5803],{"nctId":1833,"briefTitle":1834,"status":108,"phases":5804,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":426,"conditions":5805,"interventions":5806},[86],[15],[1817,1817,1817,1817,1841],{"trials":5808,"activeCount":98},[],{"trials":5810,"activeCount":98},[],{"trials":5812,"activeCount":98},[],{"trials":5814,"activeCount":98},[],{"intervention":1638,"totalTrials":179,"cells":5816},{"EARLY_PHASE1":5817,"PHASE1":5819,"PHASE2":5825,"PHASE3":5827,"PHASE4":5829,"NA":5831},{"trials":5818,"activeCount":98},[],{"trials":5820,"activeCount":98},[5821],{"nctId":1631,"briefTitle":1632,"status":108,"phases":5822,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":163,"conditions":5823,"interventions":5824},[86],[1621,1622,1623],[1013,1638],{"trials":5826,"activeCount":98},[],{"trials":5828,"activeCount":98},[],{"trials":5830,"activeCount":98},[],{"trials":5832,"activeCount":98},[],{"intervention":5834,"totalTrials":179,"cells":5835},"Increasing doses of GLP-1",{"EARLY_PHASE1":5836,"PHASE1":5838,"PHASE2":5848,"PHASE3":5850,"PHASE4":5852,"NA":5854},{"trials":5837,"activeCount":98},[],{"trials":5839,"activeCount":98},[5840],{"nctId":5841,"briefTitle":5842,"status":108,"phases":5843,"completion":3130,"start":5844,"enrollment":1238,"conditions":5845,"interventions":5846},"NCT00468884","Oral Administration of Peptides; Absorption From Gastrointestinal Tract",[86],"2006-10",[15],[5834,5847],"PYY3-36",{"trials":5849,"activeCount":98},[],{"trials":5851,"activeCount":98},[],{"trials":5853,"activeCount":98},[],{"trials":5855,"activeCount":98},[],{"intervention":5847,"totalTrials":179,"cells":5857},{"EARLY_PHASE1":5858,"PHASE1":5860,"PHASE2":5866,"PHASE3":5868,"PHASE4":5870,"NA":5872},{"trials":5859,"activeCount":98},[],{"trials":5861,"activeCount":98},[5862],{"nctId":5841,"briefTitle":5842,"status":108,"phases":5863,"completion":3130,"start":5844,"enrollment":1238,"conditions":5864,"interventions":5865},[86],[15],[5834,5847],{"trials":5867,"activeCount":98},[],{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[],{"trials":5873,"activeCount":98},[],{"intervention":1800,"totalTrials":179,"cells":5875},{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5884,"PHASE3":5886,"PHASE4":5888,"NA":5890},{"trials":5877,"activeCount":98},[],{"trials":5879,"activeCount":98},[5880],{"nctId":1792,"briefTitle":1793,"status":108,"phases":5881,"primaryCompletion":112,"completion":1795,"start":1796,"enrollment":163,"conditions":5882,"interventions":5883},[86],[1621,1788,1798],[1083,1800],{"trials":5885,"activeCount":98},[],{"trials":5887,"activeCount":98},[],{"trials":5889,"activeCount":98},[],{"trials":5891,"activeCount":98},[],{"intervention":5893,"totalTrials":179,"cells":5894},"caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam",{"EARLY_PHASE1":5895,"PHASE1":5897,"PHASE2":5908,"PHASE3":5910,"PHASE4":5912,"NA":5914},{"trials":5896,"activeCount":98},[],{"trials":5898,"activeCount":98},[5899],{"nctId":5900,"briefTitle":5901,"status":108,"phases":5902,"primaryCompletion":5903,"start":1635,"enrollment":163,"conditions":5904,"interventions":5907},"NCT01187862","Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes",[86],"2011-02",[5905,5906],"Cytochrome","Pharmacokinetics",[5893],{"trials":5909,"activeCount":98},[],{"trials":5911,"activeCount":98},[],{"trials":5913,"activeCount":98},[],{"trials":5915,"activeCount":98},[],{"intervention":5917,"totalTrials":179,"cells":5918},"Basel cocktail+",{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5932,"PHASE3":5934,"PHASE4":5936,"NA":5938},{"trials":5920,"activeCount":98},[],{"trials":5922,"activeCount":98},[5923],{"nctId":5924,"briefTitle":5925,"status":108,"phases":5926,"primaryCompletion":1673,"completion":1673,"start":1694,"enrollment":163,"conditions":5927,"interventions":5929},"NCT01386593","Pharmacokinetic Study to Characterize Phenotyping Metrics of the \"Basel\" Cocktail After CYP Induction or Inhibition",[86],[5928],"Metabolic Detoxication, Phase I",[5917,5930,5931],"\"Basel\" Cocktail","Basel cocktail + Rifampicin",{"trials":5933,"activeCount":98},[],{"trials":5935,"activeCount":98},[],{"trials":5937,"activeCount":98},[],{"trials":5939,"activeCount":98},[],{"intervention":5930,"totalTrials":179,"cells":5941},{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5950,"PHASE3":5952,"PHASE4":5954,"NA":5956},{"trials":5943,"activeCount":98},[],{"trials":5945,"activeCount":98},[5946],{"nctId":5924,"briefTitle":5925,"status":108,"phases":5947,"primaryCompletion":1673,"completion":1673,"start":1694,"enrollment":163,"conditions":5948,"interventions":5949},[86],[5928],[5917,5930,5931],{"trials":5951,"activeCount":98},[],{"trials":5953,"activeCount":98},[],{"trials":5955,"activeCount":98},[],{"trials":5957,"activeCount":98},[],{"intervention":5931,"totalTrials":179,"cells":5959},{"EARLY_PHASE1":5960,"PHASE1":5962,"PHASE2":5968,"PHASE3":5970,"PHASE4":5972,"NA":5974},{"trials":5961,"activeCount":98},[],{"trials":5963,"activeCount":98},[5964],{"nctId":5924,"briefTitle":5925,"status":108,"phases":5965,"primaryCompletion":1673,"completion":1673,"start":1694,"enrollment":163,"conditions":5966,"interventions":5967},[86],[5928],[5917,5930,5931],{"trials":5969,"activeCount":98},[],{"trials":5971,"activeCount":98},[],{"trials":5973,"activeCount":98},[],{"trials":5975,"activeCount":98},[],{"intervention":1034,"totalTrials":179,"cells":5977},{"EARLY_PHASE1":5978,"PHASE1":5980,"PHASE2":5986,"PHASE3":5988,"PHASE4":5990,"NA":5992},{"trials":5979,"activeCount":98},[],{"trials":5981,"activeCount":98},[5982],{"nctId":1026,"briefTitle":1027,"status":108,"phases":5983,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":1031,"conditions":5984,"interventions":5985},[86],[15],[1005,78,1034],{"trials":5987,"activeCount":98},[],{"trials":5989,"activeCount":98},[],{"trials":5991,"activeCount":98},[],{"trials":5993,"activeCount":98},[],{"intervention":5995,"totalTrials":179,"cells":5996},"Stem cell therapy",{"EARLY_PHASE1":5997,"PHASE1":5999,"PHASE2":6012,"PHASE3":6014,"PHASE4":6016,"NA":6018},{"trials":5998,"activeCount":98},[],{"trials":6000,"activeCount":98},[6001],{"nctId":6002,"briefTitle":6003,"status":6004,"phases":6005,"completion":3872,"start":3552,"conditions":6006,"interventions":6011},"NCT00535548","Hematopoietic Stem Cell Therapy in Chronic Wounds Using a Pressure Sore Model","UNKNOWN",[86],[6007,6008,6009,6010],"Chronic Wounds","Pressure Sores","Hematopoietic Stem Cells","Wound Healing",[5995],{"trials":6013,"activeCount":98},[],{"trials":6015,"activeCount":98},[],{"trials":6017,"activeCount":98},[],{"trials":6019,"activeCount":98},[],{"intervention":1648,"totalTrials":179,"cells":6021},{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6030,"PHASE3":6032,"PHASE4":6034,"NA":6036},{"trials":6023,"activeCount":98},[],{"trials":6025,"activeCount":98},[6026],{"nctId":1640,"briefTitle":1641,"status":108,"phases":6027,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":6028,"interventions":6029},[86],[15],[604,1648,1649,1650],{"trials":6031,"activeCount":98},[],{"trials":6033,"activeCount":98},[],{"trials":6035,"activeCount":98},[],{"trials":6037,"activeCount":98},[],{"intervention":1649,"totalTrials":179,"cells":6039},{"EARLY_PHASE1":6040,"PHASE1":6042,"PHASE2":6048,"PHASE3":6050,"PHASE4":6052,"NA":6054},{"trials":6041,"activeCount":98},[],{"trials":6043,"activeCount":98},[6044],{"nctId":1640,"briefTitle":1641,"status":108,"phases":6045,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":6046,"interventions":6047},[86],[15],[604,1648,1649,1650],{"trials":6049,"activeCount":98},[],{"trials":6051,"activeCount":98},[],{"trials":6053,"activeCount":98},[],{"trials":6055,"activeCount":98},[],{"intervention":1650,"totalTrials":179,"cells":6057},{"EARLY_PHASE1":6058,"PHASE1":6060,"PHASE2":6066,"PHASE3":6068,"PHASE4":6070,"NA":6072},{"trials":6059,"activeCount":98},[],{"trials":6061,"activeCount":98},[6062],{"nctId":1640,"briefTitle":1641,"status":108,"phases":6063,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":6064,"interventions":6065},[86],[15],[604,1648,1649,1650],{"trials":6067,"activeCount":98},[],{"trials":6069,"activeCount":98},[],{"trials":6071,"activeCount":98},[],{"trials":6073,"activeCount":98},[],{"intervention":6075,"totalTrials":179,"cells":6076},"EP1572 (ghrelin agonist) oral and duodenal application",{"EARLY_PHASE1":6077,"PHASE1":6079,"PHASE2":6089,"PHASE3":6091,"PHASE4":6093,"NA":6095},{"trials":6078,"activeCount":98},[],{"trials":6080,"activeCount":98},[6081],{"nctId":6082,"briefTitle":6083,"status":108,"phases":6084,"completion":3804,"start":6085,"enrollment":559,"conditions":6086,"interventions":6088},"NCT00377377","Oral Ghrelin Agonist in Healthy Subjects",[86],"2005-11",[6087],"Healthy Subjects",[6075],{"trials":6090,"activeCount":98},[],{"trials":6092,"activeCount":98},[],{"trials":6094,"activeCount":98},[],{"trials":6096,"activeCount":98},[],{"intervention":6098,"totalTrials":179,"cells":6099},"Novalgin",{"EARLY_PHASE1":6100,"PHASE1":6102,"PHASE2":6113,"PHASE3":6115,"PHASE4":6117,"NA":6119},{"trials":6101,"activeCount":98},[],{"trials":6103,"activeCount":98},[6104],{"nctId":6105,"briefTitle":6106,"status":108,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":1238,"conditions":6110,"interventions":6112},"NCT04621253","Inhibition Metamizole 2020",[86],"2020-10-02","2020-04-29",[6111],"Drug-drug Interaction",[6098],{"trials":6114,"activeCount":98},[],{"trials":6116,"activeCount":98},[],{"trials":6118,"activeCount":98},[],{"trials":6120,"activeCount":98},[],{"intervention":6122,"totalTrials":179,"cells":6123},"Escitalopram",{"EARLY_PHASE1":6124,"PHASE1":6126,"PHASE2":6136,"PHASE3":6138,"PHASE4":6140,"NA":6142},{"trials":6125,"activeCount":98},[],{"trials":6127,"activeCount":98},[6128],{"nctId":6129,"briefTitle":6130,"status":108,"phases":6131,"primaryCompletion":6132,"completion":6132,"start":6133,"enrollment":955,"conditions":6134,"interventions":6135},"NCT03912974","Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects",[86],"2020-11-26","2019-07-04",[15],[6122],{"trials":6137,"activeCount":98},[],{"trials":6139,"activeCount":98},[],{"trials":6141,"activeCount":98},[],{"trials":6143,"activeCount":98},[],{"intervention":6145,"totalTrials":179,"cells":6146},"N-TEC: Autologous nasal chondrocytes and ECM proteins",{"EARLY_PHASE1":6147,"PHASE1":6149,"PHASE2":6160,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6148,"activeCount":98},[],{"trials":6150,"activeCount":98},[6151],{"nctId":6152,"briefTitle":6153,"status":108,"phases":6154,"primaryCompletion":6155,"completion":6155,"start":6156,"enrollment":991,"conditions":6157,"interventions":6159},"NCT04633928","Nasal Septum Perforation Treatment Using Tissue Engineered Cartilage Graft",[86],"2023-04-24","2021-04-09",[6158],"Nasal Cartilage Septum Perforations",[6145],{"trials":6161,"activeCount":98},[],{"trials":6163,"activeCount":98},[],{"trials":6165,"activeCount":98},[],{"trials":6167,"activeCount":98},[],{"intervention":6169,"totalTrials":179,"cells":6170},"Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2",{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6183,"PHASE3":6185,"PHASE4":6187,"NA":6189},{"trials":6172,"activeCount":98},[],{"trials":6174,"activeCount":98},[6175],{"nctId":6176,"briefTitle":6177,"status":108,"phases":6178,"primaryCompletion":6179,"completion":6179,"start":6180,"enrollment":27,"conditions":6181,"interventions":6182},"NCT04165967","Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma",[86],"2023-03-30","2020-09-17",[1264],[6169],{"trials":6184,"activeCount":98},[],{"trials":6186,"activeCount":98},[],{"trials":6188,"activeCount":98},[],{"trials":6190,"activeCount":98},[],{"intervention":6192,"totalTrials":179,"cells":6193},"Exendin 9-39",{"EARLY_PHASE1":6194,"PHASE1":6196,"PHASE2":6206,"PHASE3":6208,"PHASE4":6210,"NA":6212},{"trials":6195,"activeCount":98},[],{"trials":6197,"activeCount":98},[6198],{"nctId":6199,"briefTitle":6200,"status":108,"phases":6201,"primaryCompletion":1601,"completion":1601,"start":2573,"enrollment":1238,"conditions":6202,"interventions":6204},"NCT01900340","Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans",[86],[6203],"Appetite and General Nutritional Disorders",[6192,6205],"Exendin(9-39) plus ID nutrient",{"trials":6207,"activeCount":98},[],{"trials":6209,"activeCount":98},[],{"trials":6211,"activeCount":98},[],{"trials":6213,"activeCount":98},[],{"intervention":6205,"totalTrials":179,"cells":6215},{"EARLY_PHASE1":6216,"PHASE1":6218,"PHASE2":6224,"PHASE3":6226,"PHASE4":6228,"NA":6230},{"trials":6217,"activeCount":98},[],{"trials":6219,"activeCount":98},[6220],{"nctId":6199,"briefTitle":6200,"status":108,"phases":6221,"primaryCompletion":1601,"completion":1601,"start":2573,"enrollment":1238,"conditions":6222,"interventions":6223},[86],[6203],[6192,6205],{"trials":6225,"activeCount":98},[],{"trials":6227,"activeCount":98},[],{"trials":6229,"activeCount":98},[],{"trials":6231,"activeCount":98},[],{"intervention":1677,"totalTrials":179,"cells":6233},{"EARLY_PHASE1":6234,"PHASE1":6236,"PHASE2":6242,"PHASE3":6244,"PHASE4":6246,"NA":6248},{"trials":6235,"activeCount":98},[],{"trials":6237,"activeCount":98},[6238],{"nctId":1670,"briefTitle":1671,"status":108,"phases":6239,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":163,"conditions":6240,"interventions":6241},[86],[1621,1622,1623],[1013,1677],{"trials":6243,"activeCount":98},[],{"trials":6245,"activeCount":98},[],{"trials":6247,"activeCount":98},[],{"trials":6249,"activeCount":98},[],{"intervention":6251,"totalTrials":179,"cells":6252},"MDMA 120 mg + MDMA 60 mg",{"EARLY_PHASE1":6253,"PHASE1":6255,"PHASE2":6266,"PHASE3":6268,"PHASE4":6270,"NA":6272},{"trials":6254,"activeCount":98},[],{"trials":6256,"activeCount":98},[6257],{"nctId":6258,"briefTitle":6259,"status":108,"phases":6260,"primaryCompletion":6261,"completion":6261,"start":6262,"enrollment":1480,"conditions":6263,"interventions":6264},"NCT05809271","Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose",[86],"2025-03-07","2023-11-17",[15],[6251,6265],"MDMA 120 mg + placebo",{"trials":6267,"activeCount":98},[],{"trials":6269,"activeCount":98},[],{"trials":6271,"activeCount":98},[],{"trials":6273,"activeCount":98},[],{"intervention":6265,"totalTrials":179,"cells":6275},{"EARLY_PHASE1":6276,"PHASE1":6278,"PHASE2":6284,"PHASE3":6286,"PHASE4":6288,"NA":6290},{"trials":6277,"activeCount":98},[],{"trials":6279,"activeCount":98},[6280],{"nctId":6258,"briefTitle":6259,"status":108,"phases":6281,"primaryCompletion":6261,"completion":6261,"start":6262,"enrollment":1480,"conditions":6282,"interventions":6283},[86],[15],[6251,6265],{"trials":6285,"activeCount":98},[],{"trials":6287,"activeCount":98},[],{"trials":6289,"activeCount":98},[],{"trials":6291,"activeCount":98},[],{"intervention":6293,"totalTrials":179,"cells":6294},"Lisdexamfetamine, d-amphetamine, Placebo",{"EARLY_PHASE1":6295,"PHASE1":6297,"PHASE2":6308,"PHASE3":6310,"PHASE4":6312,"NA":6314},{"trials":6296,"activeCount":98},[],{"trials":6298,"activeCount":98},[6299],{"nctId":6300,"briefTitle":6301,"status":108,"phases":6302,"primaryCompletion":6303,"completion":424,"start":6304,"enrollment":426,"conditions":6305,"interventions":6306},"NCT02668926","Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.",[86],"2016-06","2016-05",[15],[6293,6307],"d-amphetamine, Placebo, Lisdexamfetamine",{"trials":6309,"activeCount":98},[],{"trials":6311,"activeCount":98},[],{"trials":6313,"activeCount":98},[],{"trials":6315,"activeCount":98},[],{"intervention":6307,"totalTrials":179,"cells":6317},{"EARLY_PHASE1":6318,"PHASE1":6320,"PHASE2":6326,"PHASE3":6328,"PHASE4":6330,"NA":6332},{"trials":6319,"activeCount":98},[],{"trials":6321,"activeCount":98},[6322],{"nctId":6300,"briefTitle":6301,"status":108,"phases":6323,"primaryCompletion":6303,"completion":424,"start":6304,"enrollment":426,"conditions":6324,"interventions":6325},[86],[15],[6293,6307],{"trials":6327,"activeCount":98},[],{"trials":6329,"activeCount":98},[],{"trials":6331,"activeCount":98},[],{"trials":6333,"activeCount":98},[],{"intervention":2150,"totalTrials":179,"cells":6335},{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6344,"PHASE3":6346,"PHASE4":6348,"NA":6350},{"trials":6337,"activeCount":98},[],{"trials":6339,"activeCount":98},[6340],{"nctId":2143,"briefTitle":2144,"status":108,"phases":6341,"primaryCompletion":2146,"completion":2146,"start":1673,"enrollment":991,"conditions":6342,"interventions":6343},[86],[2148],[2136,2150],{"trials":6345,"activeCount":98},[],{"trials":6347,"activeCount":98},[],{"trials":6349,"activeCount":98},[],{"trials":6351,"activeCount":98},[],{"intervention":1044,"totalTrials":179,"cells":6353},{"EARLY_PHASE1":6354,"PHASE1":6356,"PHASE2":6362,"PHASE3":6364,"PHASE4":6366,"NA":6368},{"trials":6355,"activeCount":98},[],{"trials":6357,"activeCount":98},[6358],{"nctId":1036,"briefTitle":1037,"status":108,"phases":6359,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":426,"conditions":6360,"interventions":6361},[86],[15],[1044,1044,1044,604,78],{"trials":6363,"activeCount":98},[],{"trials":6365,"activeCount":98},[],{"trials":6367,"activeCount":98},[],{"trials":6369,"activeCount":98},[],{"intervention":6371,"totalTrials":179,"cells":6372},"Lysergic Acid Diethylamide Base oral drinking solution",{"EARLY_PHASE1":6373,"PHASE1":6375,"PHASE2":6387,"PHASE3":6389,"PHASE4":6391,"NA":6393},{"trials":6374,"activeCount":98},[],{"trials":6376,"activeCount":98},[6377],{"nctId":6378,"briefTitle":6379,"status":108,"phases":6380,"primaryCompletion":5059,"completion":5059,"start":6381,"enrollment":783,"conditions":6382,"interventions":6383},"NCT04865653","LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects",[86],"2022-03-17",[15],[6371,6384,6385,6386],"Lysergic Acid Diethylamide Base solid orodispersible film","Lysergic Acid Diethylamide Tartrate oral drinking solution","Lysergic Acid Diethylamide Tartrate intravenous administration",{"trials":6388,"activeCount":98},[],{"trials":6390,"activeCount":98},[],{"trials":6392,"activeCount":98},[],{"trials":6394,"activeCount":98},[],{"intervention":6384,"totalTrials":179,"cells":6396},{"EARLY_PHASE1":6397,"PHASE1":6399,"PHASE2":6405,"PHASE3":6407,"PHASE4":6409,"NA":6411},{"trials":6398,"activeCount":98},[],{"trials":6400,"activeCount":98},[6401],{"nctId":6378,"briefTitle":6379,"status":108,"phases":6402,"primaryCompletion":5059,"completion":5059,"start":6381,"enrollment":783,"conditions":6403,"interventions":6404},[86],[15],[6371,6384,6385,6386],{"trials":6406,"activeCount":98},[],{"trials":6408,"activeCount":98},[],{"trials":6410,"activeCount":98},[],{"trials":6412,"activeCount":98},[],{"intervention":6385,"totalTrials":179,"cells":6414},{"EARLY_PHASE1":6415,"PHASE1":6417,"PHASE2":6423,"PHASE3":6425,"PHASE4":6427,"NA":6429},{"trials":6416,"activeCount":98},[],{"trials":6418,"activeCount":98},[6419],{"nctId":6378,"briefTitle":6379,"status":108,"phases":6420,"primaryCompletion":5059,"completion":5059,"start":6381,"enrollment":783,"conditions":6421,"interventions":6422},[86],[15],[6371,6384,6385,6386],{"trials":6424,"activeCount":98},[],{"trials":6426,"activeCount":98},[],{"trials":6428,"activeCount":98},[],{"trials":6430,"activeCount":98},[],{"intervention":6386,"totalTrials":179,"cells":6432},{"EARLY_PHASE1":6433,"PHASE1":6435,"PHASE2":6441,"PHASE3":6443,"PHASE4":6445,"NA":6447},{"trials":6434,"activeCount":98},[],{"trials":6436,"activeCount":98},[6437],{"nctId":6378,"briefTitle":6379,"status":108,"phases":6438,"primaryCompletion":5059,"completion":5059,"start":6381,"enrollment":783,"conditions":6439,"interventions":6440},[86],[15],[6371,6384,6385,6386],{"trials":6442,"activeCount":98},[],{"trials":6444,"activeCount":98},[],{"trials":6446,"activeCount":98},[],{"trials":6448,"activeCount":98},[],{"intervention":6450,"totalTrials":179,"cells":6451},"Dimethyltryptamine",{"EARLY_PHASE1":6452,"PHASE1":6454,"PHASE2":6467,"PHASE3":6469,"PHASE4":6471,"NA":6473},{"trials":6453,"activeCount":98},[],{"trials":6455,"activeCount":98},[6456],{"nctId":6457,"briefTitle":6458,"status":108,"phases":6459,"primaryCompletion":6460,"completion":6461,"start":6462,"enrollment":6463,"conditions":6464,"interventions":6465},"NCT04353024","Effects of Dimethyltryptamine in Healthy Subjects",[86],"2022-08-29","2022-09-22","2021-06-18",31,[15],[6450,6466],"Saline",{"trials":6468,"activeCount":98},[],{"trials":6470,"activeCount":98},[],{"trials":6472,"activeCount":98},[],{"trials":6474,"activeCount":98},[],{"intervention":6466,"totalTrials":179,"cells":6476},{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6485,"PHASE3":6487,"PHASE4":6489,"NA":6491},{"trials":6478,"activeCount":98},[],{"trials":6480,"activeCount":98},[6481],{"nctId":6457,"briefTitle":6458,"status":108,"phases":6482,"primaryCompletion":6460,"completion":6461,"start":6462,"enrollment":6463,"conditions":6483,"interventions":6484},[86],[15],[6450,6466],{"trials":6486,"activeCount":98},[],{"trials":6488,"activeCount":98},[],{"trials":6490,"activeCount":98},[],{"trials":6492,"activeCount":98},[],{"intervention":6494,"totalTrials":179,"cells":6495},"Glyceroltrinitrat",{"EARLY_PHASE1":6496,"PHASE1":6506,"PHASE2":6508,"PHASE3":6510,"PHASE4":6512,"NA":6514},{"trials":6497,"activeCount":98},[6498],{"nctId":6499,"briefTitle":6500,"status":108,"phases":6501,"primaryCompletion":6502,"completion":1106,"start":6503,"enrollment":621,"conditions":6504,"interventions":6505},"NCT05711199","Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis",[85],"2025-06-11","2023-03-01",[165],[6494],{"trials":6507,"activeCount":98},[],{"trials":6509,"activeCount":98},[],{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[],{"trials":6515,"activeCount":98},[],{"intervention":6517,"totalTrials":179,"cells":6518},"Fenoterol",{"EARLY_PHASE1":6519,"PHASE1":6530,"PHASE2":6532,"PHASE3":6534,"PHASE4":6536,"NA":6538},{"trials":6520,"activeCount":98},[6521],{"nctId":6522,"briefTitle":6523,"status":108,"phases":6524,"primaryCompletion":6525,"completion":6525,"start":6526,"enrollment":1238,"conditions":6527,"interventions":6529},"NCT05294965","Beta 2 Adrenergic Stimulation vs Cold Exposure to Activate Human Brown Adipose Tissue",[85],"2023-03-06","2022-04-27",[6528],"Thermogenesis",[6517],{"trials":6531,"activeCount":98},[],{"trials":6533,"activeCount":98},[],{"trials":6535,"activeCount":98},[],{"trials":6537,"activeCount":98},[],{"trials":6539,"activeCount":98},[],{"intervention":1168,"totalTrials":179,"cells":6541},{"EARLY_PHASE1":6542,"PHASE1":6548,"PHASE2":6550,"PHASE3":6552,"PHASE4":6554,"NA":6556},{"trials":6543,"activeCount":98},[6544],{"nctId":1160,"briefTitle":1161,"status":108,"phases":6545,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":34,"conditions":6546,"interventions":6547},[85],[1166],[1155,1168],{"trials":6549,"activeCount":98},[],{"trials":6551,"activeCount":98},[],{"trials":6553,"activeCount":98},[],{"trials":6555,"activeCount":98},[],{"trials":6557,"activeCount":98},[],{"intervention":1084,"totalTrials":179,"cells":6559},{"EARLY_PHASE1":6560,"PHASE1":6566,"PHASE2":6568,"PHASE3":6570,"PHASE4":6572,"NA":6574},{"trials":6561,"activeCount":98},[6562],{"nctId":1075,"briefTitle":1076,"status":108,"phases":6563,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1002,"conditions":6564,"interventions":6565},[85],[15],[1005,1083,1084],{"trials":6567,"activeCount":98},[],{"trials":6569,"activeCount":98},[],{"trials":6571,"activeCount":98},[],{"trials":6573,"activeCount":98},[],{"trials":6575,"activeCount":98},[],{"intervention":6577,"totalTrials":179,"cells":6578},"161Tb-DOTA-LM3",{"EARLY_PHASE1":6579,"PHASE1":6591,"PHASE2":6593,"PHASE3":6595,"PHASE4":6597,"NA":6599},{"trials":6580,"activeCount":98},[6581],{"nctId":6582,"briefTitle":6583,"status":6004,"phases":6584,"primaryCompletion":54,"completion":54,"start":6585,"enrollment":163,"conditions":6586,"interventions":6589},"NCT05359146","Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)",[85],"2023-03-28",[6587,6588],"Neuroendocrine Neoplasia's (NENs)","Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)",[6577,6590],"177Lu-DOTATOC",{"trials":6592,"activeCount":98},[],{"trials":6594,"activeCount":98},[],{"trials":6596,"activeCount":98},[],{"trials":6598,"activeCount":98},[],{"trials":6600,"activeCount":98},[],{"intervention":6590,"totalTrials":179,"cells":6602},{"EARLY_PHASE1":6603,"PHASE1":6609,"PHASE2":6611,"PHASE3":6613,"PHASE4":6615,"NA":6617},{"trials":6604,"activeCount":98},[6605],{"nctId":6582,"briefTitle":6583,"status":6004,"phases":6606,"primaryCompletion":54,"completion":54,"start":6585,"enrollment":163,"conditions":6607,"interventions":6608},[85],[6587,6588],[6577,6590],{"trials":6610,"activeCount":98},[],{"trials":6612,"activeCount":98},[],{"trials":6614,"activeCount":98},[],{"trials":6616,"activeCount":98},[],{"trials":6618,"activeCount":98},[],{"intervention":1769,"totalTrials":179,"cells":6620},{"EARLY_PHASE1":6621,"PHASE1":6627,"PHASE2":6629,"PHASE3":6631,"PHASE4":6633,"NA":6635},{"trials":6622,"activeCount":98},[6623],{"nctId":1762,"briefTitle":1763,"status":108,"phases":6624,"primaryCompletion":111,"completion":111,"start":1765,"enrollment":426,"conditions":6625,"interventions":6626},[85],[15,1767,1621],[1607,1769,1083],{"trials":6628,"activeCount":98},[],{"trials":6630,"activeCount":98},[],{"trials":6632,"activeCount":98},[],{"trials":6634,"activeCount":98},[],{"trials":6636,"activeCount":98},[],{"intervention":6638,"totalTrials":179,"cells":6639},"wound dressing with VAC and sNAG under Antiaggregation",{"EARLY_PHASE1":6640,"PHASE1":6650,"PHASE2":6652,"PHASE3":6654,"PHASE4":6656,"NA":6658},{"trials":6641,"activeCount":98},[6642],{"nctId":6643,"briefTitle":6644,"status":422,"phases":6645,"primaryCompletion":1603,"completion":1603,"start":5903,"enrollment":426,"conditions":6646,"interventions":6649},"NCT02237287","Combination of Taliderm® and Vacuum-assisted Closure (VAC) for Treatment of Pressure Ulcers",[85],[6647,6648],"Wounds","Pressure Ulcer",[6638],{"trials":6651,"activeCount":98},[],{"trials":6653,"activeCount":98},[],{"trials":6655,"activeCount":98},[],{"trials":6657,"activeCount":98},[],{"trials":6659,"activeCount":98},[],{"intervention":6661,"totalTrials":179,"cells":6662},"Digoxin",{"EARLY_PHASE1":6663,"PHASE1":6674,"PHASE2":6676,"PHASE3":6678,"PHASE4":6680,"NA":6682},{"trials":6664,"activeCount":98},[6665],{"nctId":6666,"briefTitle":6667,"status":108,"phases":6668,"primaryCompletion":6669,"completion":6669,"start":6670,"enrollment":3675,"conditions":6671,"interventions":6673},"NCT03928210","Digoxin Induced Dissolution of CTC Clusters",[85],"2023-12-01","2020-07-08",[26,6672],"Circulating Tumor Cells (CTCs)",[6661],{"trials":6675,"activeCount":98},[],{"trials":6677,"activeCount":98},[],{"trials":6679,"activeCount":98},[],{"trials":6681,"activeCount":98},[],{"trials":6683,"activeCount":98},[],{"intervention":6685,"totalTrials":179,"cells":6686},"chenodeoxycholic acid",{"EARLY_PHASE1":6687,"PHASE1":6699,"PHASE2":6701,"PHASE3":6703,"PHASE4":6705,"NA":6707},{"trials":6688,"activeCount":98},[6689],{"nctId":6690,"briefTitle":6691,"status":108,"phases":6692,"start":6693,"enrollment":621,"conditions":6694,"interventions":6698},"NCT00465751","Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism",[85],"2004-10",[6695,6696,6697],"Metabolic Syndrome","Familial Hypertriglyceridemia","Familial Combined Hyperlipidemia",[6685],{"trials":6700,"activeCount":98},[],{"trials":6702,"activeCount":98},[],{"trials":6704,"activeCount":98},[],{"trials":6706,"activeCount":98},[],{"trials":6708,"activeCount":98},[],{"intervention":3653,"totalTrials":94,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6737,"PHASE4":6752,"NA":6754},{"trials":6712,"activeCount":98},[],{"trials":6714,"activeCount":98},[],{"trials":6716,"activeCount":98},[6717,6727],{"nctId":6718,"briefTitle":6719,"status":108,"phases":6720,"primaryCompletion":6721,"completion":6721,"start":6722,"enrollment":783,"conditions":6723,"interventions":6726},"NCT05854251","Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β",[87],"2024-05-17","2023-06-15",[6724,6725],"Hyperinsulinemia","PreDiabetes",[3653],{"nctId":6728,"briefTitle":6729,"status":2847,"phases":6730,"primaryCompletion":6731,"completion":6731,"start":6732,"enrollment":98,"conditions":6733,"interventions":6734},"NCT05174507","Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes",[87],"2026-05-01","2022-06-24",[436],[6735,6736],"empagliflozin","anakinra",{"trials":6738,"activeCount":98},[6739,6743],{"nctId":3643,"briefTitle":3644,"status":108,"phases":6740,"primaryCompletion":3646,"completion":3646,"start":3647,"enrollment":3648,"conditions":6741,"interventions":6742},[88],[3650,3651,18],[3653,3620],{"nctId":6744,"briefTitle":6745,"status":108,"phases":6746,"primaryCompletion":4169,"completion":4167,"start":6747,"enrollment":6748,"conditions":6749,"interventions":6751},"NCT02227420","Effects of IL-1 Beta on the HPA-axis in Obese Persons",[88],"2014-10",76,[6695,6750],"Hypersecretion; Cortisol",[3653],{"trials":6753,"activeCount":98},[],{"trials":6755,"activeCount":98},[6756,6767],{"nctId":6757,"briefTitle":6758,"status":108,"phases":6759,"primaryCompletion":6760,"completion":6760,"start":6761,"enrollment":1238,"conditions":6762,"interventions":6765},"NCT03200782","Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study",[90],"2018-09-21","2017-05-30",[436,6763,6764],"Bariatric Surgery","Late Dumping Syndrome",[6766,3653],"Empagliflozin",{"nctId":6768,"briefTitle":6769,"status":108,"phases":6770,"primaryCompletion":6771,"completion":6772,"start":4168,"enrollment":163,"conditions":6773,"interventions":6775},"NCT02916355","Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study",[90],"2017-04","2017-04-03",[6774],"Adiposity",[3653,6776],"NaCl",{"intervention":2600,"totalTrials":411,"cells":6778},{"EARLY_PHASE1":6779,"PHASE1":6781,"PHASE2":6783,"PHASE3":6785,"PHASE4":6787,"NA":6793},{"trials":6780,"activeCount":98},[],{"trials":6782,"activeCount":98},[],{"trials":6784,"activeCount":98},[],{"trials":6786,"activeCount":98},[],{"trials":6788,"activeCount":98},[6789],{"nctId":2593,"briefTitle":2594,"status":108,"phases":6790,"primaryCompletion":1795,"completion":1618,"start":2596,"enrollment":2597,"conditions":6791,"interventions":6792},[89],[29],[2600,2580],{"trials":6794,"activeCount":98},[6795,6805],{"nctId":6796,"briefTitle":6797,"status":108,"phases":6798,"primaryCompletion":3872,"completion":3872,"start":6799,"enrollment":6800,"conditions":6801,"interventions":6803},"NCT01637818","Long-term Follow-up of Lichtenstein's Operation Versus Mesh Plug Repair",[90],"1999-09",594,[6802],"Inguinal Hernia",[5336,2600,6804],"non-steroidal anti-inflammatory drug",{"nctId":6806,"briefTitle":6807,"status":108,"phases":6808,"primaryCompletion":1795,"completion":2662,"start":1619,"enrollment":163,"conditions":6809,"interventions":6811},"NCT00970450","The Central Analgesic Effects of Paracetamol on Serotonergic Pathways",[90],[6810],"Analgesia",[2600,6812],"Tropisetron",{"intervention":6766,"totalTrials":411,"cells":6814},{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6825,"PHASE4":6837,"NA":6839},{"trials":6816,"activeCount":98},[],{"trials":6818,"activeCount":98},[],{"trials":6820,"activeCount":98},[6821],{"nctId":6728,"briefTitle":6729,"status":2847,"phases":6822,"primaryCompletion":6731,"completion":6731,"start":6732,"enrollment":98,"conditions":6823,"interventions":6824},[87],[436],[6735,6736],{"trials":6826,"activeCount":98},[6827],{"nctId":6828,"briefTitle":6829,"status":108,"phases":6830,"primaryCompletion":6831,"completion":6832,"start":6833,"enrollment":6834,"conditions":6835,"interventions":6836},"NCT02874807","Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study",[87,88],"2018-12-14","2019-01-14","2016-09-05",88,[341],[6766],{"trials":6838,"activeCount":98},[],{"trials":6840,"activeCount":98},[6841],{"nctId":6757,"briefTitle":6758,"status":108,"phases":6842,"primaryCompletion":6760,"completion":6760,"start":6761,"enrollment":1238,"conditions":6843,"interventions":6844},[90],[436,6763,6764],[6766,3653],{"intervention":5336,"totalTrials":179,"cells":6846},{"EARLY_PHASE1":6847,"PHASE1":6849,"PHASE2":6851,"PHASE3":6853,"PHASE4":6855,"NA":6857},{"trials":6848,"activeCount":98},[],{"trials":6850,"activeCount":98},[],{"trials":6852,"activeCount":98},[],{"trials":6854,"activeCount":98},[],{"trials":6856,"activeCount":98},[],{"trials":6858,"activeCount":98},[6859],{"nctId":6796,"briefTitle":6797,"status":108,"phases":6860,"primaryCompletion":3872,"completion":3872,"start":6799,"enrollment":6800,"conditions":6861,"interventions":6862},[90],[6802],[5336,2600,6804],{"intervention":6804,"totalTrials":179,"cells":6864},{"EARLY_PHASE1":6865,"PHASE1":6867,"PHASE2":6869,"PHASE3":6871,"PHASE4":6873,"NA":6875},{"trials":6866,"activeCount":98},[],{"trials":6868,"activeCount":98},[],{"trials":6870,"activeCount":98},[],{"trials":6872,"activeCount":98},[],{"trials":6874,"activeCount":98},[],{"trials":6876,"activeCount":98},[6877],{"nctId":6796,"briefTitle":6797,"status":108,"phases":6878,"primaryCompletion":3872,"completion":3872,"start":6799,"enrollment":6800,"conditions":6879,"interventions":6880},[90],[6802],[5336,2600,6804],{"intervention":6882,"totalTrials":179,"cells":6883},"Macimorelin 0.5mg\u002Fkg body weight",{"EARLY_PHASE1":6884,"PHASE1":6886,"PHASE2":6888,"PHASE3":6890,"PHASE4":6892,"NA":6894},{"trials":6885,"activeCount":98},[],{"trials":6887,"activeCount":98},[],{"trials":6889,"activeCount":98},[],{"trials":6891,"activeCount":98},[],{"trials":6893,"activeCount":98},[],{"trials":6895,"activeCount":98},[6896],{"nctId":6897,"briefTitle":6898,"status":108,"phases":6899,"primaryCompletion":6900,"completion":6900,"start":6901,"enrollment":1002,"conditions":6902,"interventions":6904},"NCT03844217","Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers",[90],"2019-07-16","2019-03-07",[6903],"Polyuria-polydipsia Syndrome",[6882,6905],"Macimorelin 0.75mg\u002Fkg body weight",{"intervention":6905,"totalTrials":179,"cells":6907},{"EARLY_PHASE1":6908,"PHASE1":6910,"PHASE2":6912,"PHASE3":6914,"PHASE4":6916,"NA":6918},{"trials":6909,"activeCount":98},[],{"trials":6911,"activeCount":98},[],{"trials":6913,"activeCount":98},[],{"trials":6915,"activeCount":98},[],{"trials":6917,"activeCount":98},[],{"trials":6919,"activeCount":98},[6920],{"nctId":6897,"briefTitle":6898,"status":108,"phases":6921,"primaryCompletion":6900,"completion":6900,"start":6901,"enrollment":1002,"conditions":6922,"interventions":6923},[90],[6903],[6882,6905],{"intervention":6925,"totalTrials":179,"cells":6926},"dalteparine",{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6931,"PHASE3":6933,"PHASE4":6935,"NA":6937},{"trials":6928,"activeCount":98},[],{"trials":6930,"activeCount":98},[],{"trials":6932,"activeCount":98},[],{"trials":6934,"activeCount":98},[],{"trials":6936,"activeCount":98},[],{"trials":6938,"activeCount":98},[6939],{"nctId":6940,"briefTitle":6941,"status":108,"phases":6942,"primaryCompletion":3872,"completion":3872,"start":6943,"enrollment":6944,"conditions":6945,"interventions":6947},"NCT00681785","Thrombophylaxis in Transurethral Surgery With Dalteparine",[90],"2006-06",250,[6946],"Thrombophylaxis in Transurethral Surgery",[6925],{"intervention":6949,"totalTrials":179,"cells":6950},"Acetylsalicylic acid",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6955,"PHASE3":6957,"PHASE4":6959,"NA":6961},{"trials":6952,"activeCount":98},[],{"trials":6954,"activeCount":98},[],{"trials":6956,"activeCount":98},[],{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[],{"trials":6962,"activeCount":98},[6963],{"nctId":6964,"briefTitle":6965,"status":108,"phases":6966,"primaryCompletion":6967,"completion":6967,"start":6968,"enrollment":760,"conditions":6969,"interventions":6971},"NCT03120182","Chronic Subdural Hematoma and Aspirin",[90],"2023-12-31","2018-02-19",[6970],"Chronic Subdural Hematoma",[6949],{"intervention":6973,"totalTrials":179,"cells":6974},"Rejection treatment according to clinical standard-of-care",{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6981,"PHASE4":6983,"NA":6985},{"trials":6976,"activeCount":98},[],{"trials":6978,"activeCount":98},[],{"trials":6980,"activeCount":98},[],{"trials":6982,"activeCount":98},[],{"trials":6984,"activeCount":98},[],{"trials":6986,"activeCount":98},[6987],{"nctId":6988,"briefTitle":6989,"status":108,"phases":6990,"primaryCompletion":6991,"completion":6991,"start":6992,"enrollment":6993,"conditions":6994,"interventions":6996},"NCT03140514","Urine CXCL10 Chemokine Monitoring Post-renal Transplant",[90],"2022-07-15","2017-09-28",241,[6995],"Renal Transplant Rejection",[6973],{"intervention":6998,"totalTrials":179,"cells":6999},"Iberogast",{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7004,"PHASE3":7006,"PHASE4":7008,"NA":7010},{"trials":7001,"activeCount":98},[],{"trials":7003,"activeCount":98},[],{"trials":7005,"activeCount":98},[],{"trials":7007,"activeCount":98},[],{"trials":7009,"activeCount":98},[],{"trials":7011,"activeCount":98},[7012],{"nctId":7013,"briefTitle":7014,"status":108,"phases":7015,"primaryCompletion":7016,"completion":7016,"start":3647,"enrollment":434,"conditions":7017,"interventions":7019},"NCT02660970","Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea",[90],"2020-09-16",[7018],"Functional Nausea",[6998],{"intervention":7021,"totalTrials":179,"cells":7022},"\"Basel phenotyping cocktail\"",{"EARLY_PHASE1":7023,"PHASE1":7025,"PHASE2":7027,"PHASE3":7029,"PHASE4":7031,"NA":7033},{"trials":7024,"activeCount":98},[],{"trials":7026,"activeCount":98},[],{"trials":7028,"activeCount":98},[],{"trials":7030,"activeCount":98},[],{"trials":7032,"activeCount":98},[],{"trials":7034,"activeCount":98},[7035],{"nctId":7036,"briefTitle":7037,"status":108,"phases":7038,"primaryCompletion":7039,"completion":7040,"start":7041,"enrollment":16,"conditions":7042,"interventions":7044},"NCT03337945","In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis",[90],"2021-06-30","2021-12-31","2018-04-04",[7043],"Liver Cirrhosis",[7021],{"intervention":7046,"totalTrials":179,"cells":7047},"Hot-melt extruded amorphous solid dispersion of Efavirenz",{"EARLY_PHASE1":7048,"PHASE1":7050,"PHASE2":7052,"PHASE3":7054,"PHASE4":7056,"NA":7058},{"trials":7049,"activeCount":98},[],{"trials":7051,"activeCount":98},[],{"trials":7053,"activeCount":98},[],{"trials":7055,"activeCount":98},[],{"trials":7057,"activeCount":98},[],{"trials":7059,"activeCount":98},[7060],{"nctId":7061,"briefTitle":7062,"status":108,"phases":7063,"primaryCompletion":7064,"completion":7064,"start":7065,"enrollment":163,"conditions":7066,"interventions":7069},"NCT03886766","Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions",[90],"2020-03-19","2019-04-30",[7067,7068],"Biological Availability","Amorphous Solid Dispersions",[7046,7070,7071],"Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles","Efavirenz solution",{"intervention":7070,"totalTrials":179,"cells":7073},{"EARLY_PHASE1":7074,"PHASE1":7076,"PHASE2":7078,"PHASE3":7080,"PHASE4":7082,"NA":7084},{"trials":7075,"activeCount":98},[],{"trials":7077,"activeCount":98},[],{"trials":7079,"activeCount":98},[],{"trials":7081,"activeCount":98},[],{"trials":7083,"activeCount":98},[],{"trials":7085,"activeCount":98},[7086],{"nctId":7061,"briefTitle":7062,"status":108,"phases":7087,"primaryCompletion":7064,"completion":7064,"start":7065,"enrollment":163,"conditions":7088,"interventions":7089},[90],[7067,7068],[7046,7070,7071],{"intervention":7071,"totalTrials":179,"cells":7091},{"EARLY_PHASE1":7092,"PHASE1":7094,"PHASE2":7096,"PHASE3":7098,"PHASE4":7100,"NA":7102},{"trials":7093,"activeCount":98},[],{"trials":7095,"activeCount":98},[],{"trials":7097,"activeCount":98},[],{"trials":7099,"activeCount":98},[],{"trials":7101,"activeCount":98},[],{"trials":7103,"activeCount":98},[7104],{"nctId":7061,"briefTitle":7062,"status":108,"phases":7105,"primaryCompletion":7064,"completion":7064,"start":7065,"enrollment":163,"conditions":7106,"interventions":7107},[90],[7067,7068],[7046,7070,7071],{"intervention":7109,"totalTrials":179,"cells":7110},"Whole genome small nucleotide polymorphism genotyping",{"EARLY_PHASE1":7111,"PHASE1":7113,"PHASE2":7115,"PHASE3":7117,"PHASE4":7119,"NA":7121},{"trials":7112,"activeCount":98},[],{"trials":7114,"activeCount":98},[],{"trials":7116,"activeCount":98},[],{"trials":7118,"activeCount":98},[],{"trials":7120,"activeCount":98},[],{"trials":7122,"activeCount":98},[7123],{"nctId":7124,"briefTitle":7125,"status":108,"phases":7126,"primaryCompletion":3253,"completion":3253,"start":7127,"enrollment":125,"conditions":7128,"interventions":7130},"NCT02864173","Whole Genome Single Nucleotide Polymorphisms in Elderly Patients With Postoperative Cognitive Dysfunction",[],"2007-08",[7129],"Postoperative Cognitive Dysfunction",[7109],{"intervention":7132,"totalTrials":179,"cells":7133},"collection of salivary cytokines",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7140,"PHASE4":7142,"NA":7144},{"trials":7135,"activeCount":98},[],{"trials":7137,"activeCount":98},[],{"trials":7139,"activeCount":98},[],{"trials":7141,"activeCount":98},[],{"trials":7143,"activeCount":98},[],{"trials":7145,"activeCount":98},[7146],{"nctId":7147,"briefTitle":7148,"status":108,"phases":7149,"primaryCompletion":7150,"completion":7151,"start":424,"enrollment":7152,"conditions":7153,"interventions":7155},"NCT02807519","Salivary Cytokines as Biomarker for Oral Health",[],"2020-08","2021-01",128,[7154],"Neoplasms",[7132],{"intervention":7157,"totalTrials":179,"cells":7158},"Fentanyl",{"EARLY_PHASE1":7159,"PHASE1":7161,"PHASE2":7163,"PHASE3":7165,"PHASE4":7167,"NA":7169},{"trials":7160,"activeCount":98},[],{"trials":7162,"activeCount":98},[],{"trials":7164,"activeCount":98},[],{"trials":7166,"activeCount":98},[],{"trials":7168,"activeCount":98},[],{"trials":7170,"activeCount":98},[7171],{"nctId":7172,"briefTitle":7173,"status":108,"phases":7174,"primaryCompletion":7175,"completion":7175,"start":3574,"enrollment":7176,"conditions":7177,"interventions":7178},"NCT02252458","Can Fentanyl Lead to Opioid-induced Hyperalgesia in Healthy Volunteers?",[90],"2015-01",21,[15],[7157],{"intervention":7180,"totalTrials":179,"cells":7181},"influenza A\u002FB vaccine",{"EARLY_PHASE1":7182,"PHASE1":7184,"PHASE2":7186,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7183,"activeCount":98},[],{"trials":7185,"activeCount":98},[],{"trials":7187,"activeCount":98},[],{"trials":7189,"activeCount":98},[],{"trials":7191,"activeCount":98},[],{"trials":7193,"activeCount":98},[7194],{"nctId":7195,"briefTitle":7196,"status":108,"phases":7197,"primaryCompletion":7198,"completion":7199,"start":7200,"enrollment":2090,"conditions":7201,"interventions":7204},"NCT03467074","Role of Interferon-λ and Vaccine Response",[],"2017-08-31","2017-12-31","2014-09-01",[7202,7203],"Vaccine Response Impaired","Allogeneic Stem Cell Transplantation",[7180],{"intervention":7206,"totalTrials":179,"cells":7207},"Phenylephrine",{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7209,"activeCount":98},[],{"trials":7211,"activeCount":98},[],{"trials":7213,"activeCount":98},[],{"trials":7215,"activeCount":98},[],{"trials":7217,"activeCount":98},[],{"trials":7219,"activeCount":98},[7220],{"nctId":7221,"briefTitle":7222,"status":108,"phases":7223,"primaryCompletion":7224,"completion":7224,"start":7225,"enrollment":7226,"conditions":7227,"interventions":7229},"NCT04026685","Maternal Haemodynamic Changes After Crystalloid Co-loading and Phenylephrine Versus Phenylephrine Alone During Spinal Anaesthesia for Elective Caesarean Delivery",[90],"2021-02-05","2020-01-09",66,[7228],"Maternal Haemodynamic Stability",[7206,7230],"Phenylephrine infusion and Ringer-Acetate bolus",{"intervention":7230,"totalTrials":179,"cells":7232},{"EARLY_PHASE1":7233,"PHASE1":7235,"PHASE2":7237,"PHASE3":7239,"PHASE4":7241,"NA":7243},{"trials":7234,"activeCount":98},[],{"trials":7236,"activeCount":98},[],{"trials":7238,"activeCount":98},[],{"trials":7240,"activeCount":98},[],{"trials":7242,"activeCount":98},[],{"trials":7244,"activeCount":98},[7245],{"nctId":7221,"briefTitle":7222,"status":108,"phases":7246,"primaryCompletion":7224,"completion":7224,"start":7225,"enrollment":7226,"conditions":7247,"interventions":7248},[90],[7228],[7206,7230],{"intervention":7250,"totalTrials":179,"cells":7251},"Radioiodine",{"EARLY_PHASE1":7252,"PHASE1":7254,"PHASE2":7256,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7253,"activeCount":98},[],{"trials":7255,"activeCount":98},[],{"trials":7257,"activeCount":98},[],{"trials":7259,"activeCount":98},[],{"trials":7261,"activeCount":98},[],{"trials":7263,"activeCount":98},[7264],{"nctId":7265,"briefTitle":7266,"status":108,"phases":7267,"completion":7268,"start":7269,"enrollment":7270,"conditions":7271,"interventions":7273},"NCT00439478","Dental Safety Profile of High-Dose Radioiodine Therapy",[],"2006-09","2004-09",202,[7272],"Thyroid Cancer",[7250],{"intervention":7275,"totalTrials":179,"cells":7276},"Pergoveris in long protocol with GnRH agonist",{"EARLY_PHASE1":7277,"PHASE1":7279,"PHASE2":7281,"PHASE3":7283,"PHASE4":7285,"NA":7287},{"trials":7278,"activeCount":98},[],{"trials":7280,"activeCount":98},[],{"trials":7282,"activeCount":98},[],{"trials":7284,"activeCount":98},[],{"trials":7286,"activeCount":98},[],{"trials":7288,"activeCount":98},[7289],{"nctId":7290,"briefTitle":7291,"status":108,"phases":7292,"primaryCompletion":1601,"completion":4633,"start":7293,"enrollment":991,"conditions":7294,"interventions":7297},"NCT01565265","Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression",[90],"2012-04",[7295,7296],"Female Infertility Due to Nonimplantation of Ovum","Complications Associated With Artificial Fertilization",[7275,7298],"Pergoveris in GnRH antagonist protocol",{"intervention":7298,"totalTrials":179,"cells":7300},{"EARLY_PHASE1":7301,"PHASE1":7303,"PHASE2":7305,"PHASE3":7307,"PHASE4":7309,"NA":7311},{"trials":7302,"activeCount":98},[],{"trials":7304,"activeCount":98},[],{"trials":7306,"activeCount":98},[],{"trials":7308,"activeCount":98},[],{"trials":7310,"activeCount":98},[],{"trials":7312,"activeCount":98},[7313],{"nctId":7290,"briefTitle":7291,"status":108,"phases":7314,"primaryCompletion":1601,"completion":4633,"start":7293,"enrollment":991,"conditions":7315,"interventions":7316},[90],[7295,7296],[7275,7298],{"intervention":7318,"totalTrials":179,"cells":7319},"radionuclide therapy with 177Lu-PSMA-I&T",{"EARLY_PHASE1":7320,"PHASE1":7322,"PHASE2":7324,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7321,"activeCount":98},[],{"trials":7323,"activeCount":98},[],{"trials":7325,"activeCount":98},[],{"trials":7327,"activeCount":98},[],{"trials":7329,"activeCount":98},[],{"trials":7331,"activeCount":98},[7332],{"nctId":7333,"briefTitle":7334,"status":108,"phases":7335,"primaryCompletion":7336,"completion":7337,"start":7338,"enrollment":6944,"conditions":7339,"interventions":7341},"NCT06830408","Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study",[],"2024-11-12","2025-01-13","2020-07-06",[7340],"mCRPC",[7318],{"intervention":1698,"totalTrials":179,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7348,"PHASE3":7350,"PHASE4":7352,"NA":7354},{"trials":7345,"activeCount":98},[],{"trials":7347,"activeCount":98},[],{"trials":7349,"activeCount":98},[],{"trials":7351,"activeCount":98},[],{"trials":7353,"activeCount":98},[],{"trials":7355,"activeCount":98},[7356],{"nctId":1691,"briefTitle":1692,"status":108,"phases":7357,"primaryCompletion":1694,"completion":1694,"start":1695,"enrollment":163,"conditions":7358,"interventions":7359},[90],[1621,1622,1623],[1013,1698],{"intervention":7361,"totalTrials":179,"cells":7362},"LSD 10 μg",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7371,"NA":7373},{"trials":7364,"activeCount":98},[],{"trials":7366,"activeCount":98},[],{"trials":7368,"activeCount":98},[],{"trials":7370,"activeCount":98},[],{"trials":7372,"activeCount":98},[],{"trials":7374,"activeCount":98},[7375],{"nctId":7376,"briefTitle":7377,"status":108,"phases":7378,"primaryCompletion":7379,"completion":7379,"start":7380,"enrollment":621,"conditions":7381,"interventions":7382},"NCT05976698","LSD-Perceptual-Choice-Study",[90],"2025-02-25","2024-02-26",[1151],[7361,7383],"LSD 20 μg",{"intervention":7383,"totalTrials":179,"cells":7385},{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7390,"PHASE3":7392,"PHASE4":7394,"NA":7396},{"trials":7387,"activeCount":98},[],{"trials":7389,"activeCount":98},[],{"trials":7391,"activeCount":98},[],{"trials":7393,"activeCount":98},[],{"trials":7395,"activeCount":98},[],{"trials":7397,"activeCount":98},[7398],{"nctId":7376,"briefTitle":7377,"status":108,"phases":7399,"primaryCompletion":7379,"completion":7379,"start":7380,"enrollment":621,"conditions":7400,"interventions":7401},[90],[1151],[7361,7383],{"intervention":6776,"totalTrials":179,"cells":7403},{"EARLY_PHASE1":7404,"PHASE1":7406,"PHASE2":7408,"PHASE3":7410,"PHASE4":7412,"NA":7414},{"trials":7405,"activeCount":98},[],{"trials":7407,"activeCount":98},[],{"trials":7409,"activeCount":98},[],{"trials":7411,"activeCount":98},[],{"trials":7413,"activeCount":98},[],{"trials":7415,"activeCount":98},[7416],{"nctId":6768,"briefTitle":6769,"status":108,"phases":7417,"primaryCompletion":6771,"completion":6772,"start":4168,"enrollment":163,"conditions":7418,"interventions":7419},[90],[6774],[3653,6776],{"intervention":6812,"totalTrials":179,"cells":7421},{"EARLY_PHASE1":7422,"PHASE1":7424,"PHASE2":7426,"PHASE3":7428,"PHASE4":7430,"NA":7432},{"trials":7423,"activeCount":98},[],{"trials":7425,"activeCount":98},[],{"trials":7427,"activeCount":98},[],{"trials":7429,"activeCount":98},[],{"trials":7431,"activeCount":98},[],{"trials":7433,"activeCount":98},[7434],{"nctId":6806,"briefTitle":6807,"status":108,"phases":7435,"primaryCompletion":1795,"completion":2662,"start":1619,"enrollment":163,"conditions":7436,"interventions":7437},[90],[6810],[2600,6812],{"intervention":7439,"totalTrials":179,"cells":7440},"Apelin Low Dose",{"EARLY_PHASE1":7441,"PHASE1":7443,"PHASE2":7445,"PHASE3":7447,"PHASE4":7449,"NA":7451},{"trials":7442,"activeCount":98},[],{"trials":7444,"activeCount":98},[],{"trials":7446,"activeCount":98},[],{"trials":7448,"activeCount":98},[],{"trials":7450,"activeCount":98},[],{"trials":7452,"activeCount":98},[7453],{"nctId":7454,"briefTitle":7455,"status":108,"phases":7456,"primaryCompletion":7457,"completion":7457,"start":7458,"enrollment":19,"conditions":7459,"interventions":7460},"NCT06277336","Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD",[90],"2025-03-18","2024-03-01",[4413,33],[7439,7461,7462],"Apelin High Dose","Selected Apelin Dose",{"intervention":7461,"totalTrials":179,"cells":7464},{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7471,"PHASE4":7473,"NA":7475},{"trials":7466,"activeCount":98},[],{"trials":7468,"activeCount":98},[],{"trials":7470,"activeCount":98},[],{"trials":7472,"activeCount":98},[],{"trials":7474,"activeCount":98},[],{"trials":7476,"activeCount":98},[7477],{"nctId":7454,"briefTitle":7455,"status":108,"phases":7478,"primaryCompletion":7457,"completion":7457,"start":7458,"enrollment":19,"conditions":7479,"interventions":7480},[90],[4413,33],[7439,7461,7462],{"intervention":7462,"totalTrials":179,"cells":7482},{"EARLY_PHASE1":7483,"PHASE1":7485,"PHASE2":7487,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7484,"activeCount":98},[],{"trials":7486,"activeCount":98},[],{"trials":7488,"activeCount":98},[],{"trials":7490,"activeCount":98},[],{"trials":7492,"activeCount":98},[],{"trials":7494,"activeCount":98},[7495],{"nctId":7454,"briefTitle":7455,"status":108,"phases":7496,"primaryCompletion":7457,"completion":7457,"start":7458,"enrollment":19,"conditions":7497,"interventions":7498},[90],[4413,33],[7439,7461,7462],{"intervention":7500,"totalTrials":179,"cells":7501},"Brimonidine",{"EARLY_PHASE1":7502,"PHASE1":7504,"PHASE2":7506,"PHASE3":7508,"PHASE4":7510,"NA":7512},{"trials":7503,"activeCount":98},[],{"trials":7505,"activeCount":98},[],{"trials":7507,"activeCount":98},[],{"trials":7509,"activeCount":98},[],{"trials":7511,"activeCount":98},[],{"trials":7513,"activeCount":98},[7514],{"nctId":7515,"briefTitle":7516,"status":108,"phases":7517,"primaryCompletion":4994,"completion":4994,"start":2916,"enrollment":1305,"conditions":7518,"interventions":7520},"NCT01201551","Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature",[90],[7519],"Primary Vascular Dysregulation",[7500,7521],"Latanoprost",{"intervention":7521,"totalTrials":179,"cells":7523},{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7528,"PHASE3":7530,"PHASE4":7532,"NA":7534},{"trials":7525,"activeCount":98},[],{"trials":7527,"activeCount":98},[],{"trials":7529,"activeCount":98},[],{"trials":7531,"activeCount":98},[],{"trials":7533,"activeCount":98},[],{"trials":7535,"activeCount":98},[7536],{"nctId":7515,"briefTitle":7516,"status":108,"phases":7537,"primaryCompletion":4994,"completion":4994,"start":2916,"enrollment":1305,"conditions":7538,"interventions":7539},[90],[7519],[7500,7521],{"intervention":7541,"totalTrials":179,"cells":7542},"biomarker-enhanced disposition decision with proADM",{"EARLY_PHASE1":7543,"PHASE1":7545,"PHASE2":7547,"PHASE3":7549,"PHASE4":7551,"NA":7553},{"trials":7544,"activeCount":98},[],{"trials":7546,"activeCount":98},[],{"trials":7548,"activeCount":98},[],{"trials":7550,"activeCount":98},[],{"trials":7552,"activeCount":98},[],{"trials":7554,"activeCount":98},[7555],{"nctId":7556,"briefTitle":7557,"status":108,"phases":7558,"primaryCompletion":110,"completion":110,"start":1674,"enrollment":7559,"conditions":7560,"interventions":7562},"NCT00920491","Biomarker-enhanced ED Disposition Decisions",[],400,[7561],"Non-specific Complaints",[7541],{"intervention":7564,"totalTrials":179,"cells":7565},"Leflunomide 20 mg",{"EARLY_PHASE1":7566,"PHASE1":7568,"PHASE2":7570,"PHASE3":7572,"PHASE4":7574,"NA":7576},{"trials":7567,"activeCount":98},[],{"trials":7569,"activeCount":98},[],{"trials":7571,"activeCount":98},[],{"trials":7573,"activeCount":98},[],{"trials":7575,"activeCount":98},[],{"trials":7577,"activeCount":98},[7578],{"nctId":7579,"briefTitle":7580,"status":422,"phases":7581,"primaryCompletion":7582,"completion":7582,"start":7583,"enrollment":411,"conditions":7584,"interventions":7586},"NCT05605587","Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial",[90],"2026-01-13","2023-05-02",[7585],"MEN1 Gene Mutation",[7564],{"intervention":7588,"totalTrials":179,"cells":7589},"CBD",{"EARLY_PHASE1":7590,"PHASE1":7592,"PHASE2":7594,"PHASE3":7596,"PHASE4":7598,"NA":7600},{"trials":7591,"activeCount":98},[],{"trials":7593,"activeCount":98},[],{"trials":7595,"activeCount":98},[],{"trials":7597,"activeCount":98},[],{"trials":7599,"activeCount":98},[],{"trials":7601,"activeCount":98},[7602],{"nctId":7603,"briefTitle":7604,"status":108,"phases":7605,"primaryCompletion":7606,"completion":7606,"start":7607,"enrollment":7176,"conditions":7608,"interventions":7613},"NCT04059978","Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults",[90],"2020-10-15","2020-05-26",[7609,7610,7611,7612],"Acute Nociceptive Pain","Hyperalgesia","Allodynia","Opioid-induced Hyperalgesia",[7588,7614],"Remifentanil",{"intervention":7614,"totalTrials":179,"cells":7616},{"EARLY_PHASE1":7617,"PHASE1":7619,"PHASE2":7621,"PHASE3":7623,"PHASE4":7625,"NA":7627},{"trials":7618,"activeCount":98},[],{"trials":7620,"activeCount":98},[],{"trials":7622,"activeCount":98},[],{"trials":7624,"activeCount":98},[],{"trials":7626,"activeCount":98},[],{"trials":7628,"activeCount":98},[7629],{"nctId":7603,"briefTitle":7604,"status":108,"phases":7630,"primaryCompletion":7606,"completion":7606,"start":7607,"enrollment":7176,"conditions":7631,"interventions":7632},[90],[7609,7610,7611,7612],[7588,7614],{"intervention":7634,"totalTrials":179,"cells":7635},"Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation",{"EARLY_PHASE1":7636,"PHASE1":7638,"PHASE2":7640,"PHASE3":7642,"PHASE4":7644,"NA":7646},{"trials":7637,"activeCount":98},[],{"trials":7639,"activeCount":98},[],{"trials":7641,"activeCount":98},[],{"trials":7643,"activeCount":98},[],{"trials":7645,"activeCount":98},[],{"trials":7647,"activeCount":98},[7648],{"nctId":7649,"briefTitle":7650,"status":108,"phases":7651,"primaryCompletion":7652,"completion":7652,"start":1655,"enrollment":7653,"conditions":7654,"interventions":7658},"NCT01779882","Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT",[90],"2018-01-06",72,[7655,7656,7657],"Myeloid Leukemia","Precursor Myeloid Neoplasms","Lymphoid Neoplasms",[7634,7659],"Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation",{"intervention":7659,"totalTrials":179,"cells":7661},{"EARLY_PHASE1":7662,"PHASE1":7664,"PHASE2":7666,"PHASE3":7668,"PHASE4":7670,"NA":7672},{"trials":7663,"activeCount":98},[],{"trials":7665,"activeCount":98},[],{"trials":7667,"activeCount":98},[],{"trials":7669,"activeCount":98},[],{"trials":7671,"activeCount":98},[],{"trials":7673,"activeCount":98},[7674],{"nctId":7649,"briefTitle":7650,"status":108,"phases":7675,"primaryCompletion":7652,"completion":7652,"start":1655,"enrollment":7653,"conditions":7676,"interventions":7677},[90],[7655,7656,7657],[7634,7659],{"intervention":7679,"totalTrials":179,"cells":7680},"Tocilizumab",{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7685,"PHASE3":7687,"PHASE4":7689,"NA":7691},{"trials":7682,"activeCount":98},[],{"trials":7684,"activeCount":98},[],{"trials":7686,"activeCount":98},[],{"trials":7688,"activeCount":98},[],{"trials":7690,"activeCount":98},[],{"trials":7692,"activeCount":98},[7693],{"nctId":7694,"briefTitle":7695,"status":108,"phases":7696,"primaryCompletion":7697,"completion":7697,"start":7698,"enrollment":3013,"conditions":7699,"interventions":7702},"NCT06721910","Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis",[90],"2025-09-18","2025-01-15",[15,7700,7701],"Glucagon Resistance","Amino Acid Change",[7679],{"intervention":7704,"totalTrials":179,"cells":7705},"lidocaine-ketamine infusions",{"EARLY_PHASE1":7706,"PHASE1":7708,"PHASE2":7710,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7707,"activeCount":98},[],{"trials":7709,"activeCount":98},[],{"trials":7711,"activeCount":98},[],{"trials":7713,"activeCount":98},[],{"trials":7715,"activeCount":98},[],{"trials":7717,"activeCount":98},[7718],{"nctId":7719,"briefTitle":7720,"status":108,"phases":7721,"primaryCompletion":7722,"completion":7722,"start":7723,"enrollment":19,"conditions":7724,"interventions":7726},"NCT05906121","Lidocaine and Ketamine Levels in Plasma After Simultaneous Lidocaine\u002FKetamine Infusions",[],"2024-08-31","2023-05-16",[7725],"Chronic Pain",[7704],{"intervention":7728,"totalTrials":179,"cells":7729},"conventional opioid-based group",{"EARLY_PHASE1":7730,"PHASE1":7732,"PHASE2":7734,"PHASE3":7736,"PHASE4":7738,"NA":7740},{"trials":7731,"activeCount":98},[],{"trials":7733,"activeCount":98},[],{"trials":7735,"activeCount":98},[],{"trials":7737,"activeCount":98},[],{"trials":7739,"activeCount":98},[],{"trials":7741,"activeCount":98},[7742],{"nctId":7743,"briefTitle":7744,"status":108,"phases":7745,"primaryCompletion":7746,"completion":7746,"start":7747,"enrollment":3648,"conditions":7748,"interventions":7749},"NCT05485480","Nociception Level During Opioid-sparing Anaesthesia Versus Conventional Opioid-based Anaesthesia",[90],"2024-02-08","2022-11-17",[6810],[7728,7750],"opioid-sparing group",{"intervention":7750,"totalTrials":179,"cells":7752},{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7757,"PHASE3":7759,"PHASE4":7761,"NA":7763},{"trials":7754,"activeCount":98},[],{"trials":7756,"activeCount":98},[],{"trials":7758,"activeCount":98},[],{"trials":7760,"activeCount":98},[],{"trials":7762,"activeCount":98},[],{"trials":7764,"activeCount":98},[7765],{"nctId":7743,"briefTitle":7744,"status":108,"phases":7766,"primaryCompletion":7746,"completion":7746,"start":7747,"enrollment":3648,"conditions":7767,"interventions":7768},[90],[6810],[7728,7750],{"intervention":7770,"totalTrials":179,"cells":7771},"CBD 800 mg p.o",{"EARLY_PHASE1":7772,"PHASE1":7774,"PHASE2":7776,"PHASE3":7778,"PHASE4":7780,"NA":7782},{"trials":7773,"activeCount":98},[],{"trials":7775,"activeCount":98},[],{"trials":7777,"activeCount":98},[],{"trials":7779,"activeCount":98},[],{"trials":7781,"activeCount":98},[],{"trials":7783,"activeCount":98},[7784],{"nctId":7785,"briefTitle":7786,"status":108,"phases":7787,"primaryCompletion":7788,"completion":7788,"start":7789,"enrollment":783,"conditions":7790,"interventions":7792},"NCT03985995","Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults",[90],"2019-12-23","2019-09-16",[7791,7610,7611],"Pain Sensation",[7770],{"intervention":7794,"totalTrials":179,"cells":7795},"semaglutide",{"EARLY_PHASE1":7796,"PHASE1":7798,"PHASE2":7800,"PHASE3":7802,"PHASE4":7804,"NA":7806},{"trials":7797,"activeCount":98},[],{"trials":7799,"activeCount":98},[],{"trials":7801,"activeCount":98},[],{"trials":7803,"activeCount":98},[],{"trials":7805,"activeCount":98},[],{"trials":7807,"activeCount":98},[7808],{"nctId":7809,"briefTitle":7810,"status":108,"phases":7811,"primaryCompletion":7812,"completion":7813,"start":7814,"enrollment":3422,"conditions":7815,"interventions":7820},"NCT06608433","Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function",[90],"2025-10-31","2025-11-30","2025-01-16",[7816,7817,7818,7819],"Healthy Volunteer Study","HPA","Cortisol Deficiency","Adrenal Insufficiency",[7794],{"intervention":7822,"totalTrials":179,"cells":7823},"Pamidronate",{"EARLY_PHASE1":7824,"PHASE1":7826,"PHASE2":7828,"PHASE3":7830,"PHASE4":7832,"NA":7834},{"trials":7825,"activeCount":98},[],{"trials":7827,"activeCount":98},[],{"trials":7829,"activeCount":98},[],{"trials":7831,"activeCount":98},[],{"trials":7833,"activeCount":98},[],{"trials":7835,"activeCount":98},[7836],{"nctId":7837,"briefTitle":7838,"status":2847,"phases":7839,"primaryCompletion":123,"completion":123,"start":3744,"enrollment":98,"conditions":7840,"interventions":7842},"NCT00262392","Study of Pamidronate for the Prevention of Heterotopic Ossification",[90],[7841],"Heterotopic Ossification",[7822],{"intervention":7844,"totalTrials":179,"cells":7845},"transurethral surgery with or without aspirin",{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7847,"activeCount":98},[],{"trials":7849,"activeCount":98},[],{"trials":7851,"activeCount":98},[],{"trials":7853,"activeCount":98},[],{"trials":7855,"activeCount":98},[],{"trials":7857,"activeCount":98},[7858],{"nctId":7859,"briefTitle":7860,"status":2847,"phases":7861,"primaryCompletion":2620,"completion":2620,"start":5036,"enrollment":98,"conditions":7862,"interventions":7866},"NCT00861367","Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate",[90],[7863,7864,7865],"Blood Loss, Surgical","Intraoperative Complications","Re-operation Rates in Patients With Aspirin Treatment",[7844],{"intervention":7868,"totalTrials":179,"cells":7869},"Open-Label Placebo",{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7874,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7871,"activeCount":98},[],{"trials":7873,"activeCount":98},[],{"trials":7875,"activeCount":98},[],{"trials":7877,"activeCount":98},[],{"trials":7879,"activeCount":98},[],{"trials":7881,"activeCount":98},[7882],{"nctId":7883,"briefTitle":7884,"status":108,"phases":7885,"primaryCompletion":7886,"completion":7886,"start":7887,"enrollment":6748,"conditions":7888,"interventions":7889},"NCT04339023","Open-Label Placebo Treatment for Acute Postoperative Pain",[90],"2023-01-31","2020-05-12",[3424],[7868],{"intervention":7891,"totalTrials":179,"cells":7892},"Novorapid ®, Novo Nordisk, Denmark",{"EARLY_PHASE1":7893,"PHASE1":7895,"PHASE2":7897,"PHASE3":7899,"PHASE4":7901,"NA":7903},{"trials":7894,"activeCount":98},[],{"trials":7896,"activeCount":98},[],{"trials":7898,"activeCount":98},[],{"trials":7900,"activeCount":98},[],{"trials":7902,"activeCount":98},[],{"trials":7904,"activeCount":98},[7905],{"nctId":7906,"briefTitle":7907,"status":108,"phases":7908,"primaryCompletion":2662,"completion":4529,"start":7909,"enrollment":7910,"conditions":7911,"interventions":7913},"NCT00353431","Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia",[90],"2006-12",130,[7912],"Hyperglycemias",[7891],{"intervention":7915,"totalTrials":179,"cells":7916},"Influenza Vaccination",{"EARLY_PHASE1":7917,"PHASE1":7919,"PHASE2":7921,"PHASE3":7923,"PHASE4":7925,"NA":7927},{"trials":7918,"activeCount":98},[],{"trials":7920,"activeCount":98},[],{"trials":7922,"activeCount":98},[],{"trials":7924,"activeCount":98},[],{"trials":7926,"activeCount":98},[],{"trials":7928,"activeCount":98},[7929],{"nctId":7930,"briefTitle":7931,"status":108,"phases":7932,"primaryCompletion":7933,"completion":7933,"start":7934,"enrollment":760,"conditions":7935,"interventions":7936},"NCT04059991","Antibodies in Repeated Influenza Vaccination (ARIVA) Study",[],"2021-03-31","2017-11-01",[7202],[7915],{"intervention":7938,"totalTrials":179,"cells":7939},"immunisation",{"EARLY_PHASE1":7940,"PHASE1":7942,"PHASE2":7944,"PHASE3":7946,"PHASE4":7948,"NA":7950},{"trials":7941,"activeCount":98},[],{"trials":7943,"activeCount":98},[],{"trials":7945,"activeCount":98},[],{"trials":7947,"activeCount":98},[],{"trials":7949,"activeCount":98},[],{"trials":7951,"activeCount":98},[7952],{"nctId":7953,"briefTitle":7954,"status":108,"phases":7955,"primaryCompletion":7956,"completion":7956,"start":7957,"enrollment":7958,"conditions":7959,"interventions":7961},"NCT04303494","Predictive Value of Heart Rate Variability on Cardiorespiratory Events",[],"2022-11-05","2018-07-01",292,[7960],"Post-immunisation Apnoea and Bradycardia of Prematurity (AOP)",[7938],{"intervention":7963,"totalTrials":179,"cells":7964},"Exenatide",{"EARLY_PHASE1":7965,"PHASE1":7967,"PHASE2":7969,"PHASE3":7971,"PHASE4":7973,"NA":7975},{"trials":7966,"activeCount":98},[],{"trials":7968,"activeCount":98},[],{"trials":7970,"activeCount":98},[],{"trials":7972,"activeCount":98},[],{"trials":7974,"activeCount":98},[],{"trials":7976,"activeCount":98},[7977],{"nctId":7978,"briefTitle":7979,"status":108,"phases":7980,"primaryCompletion":4192,"completion":4192,"start":7981,"enrollment":2164,"conditions":7982,"interventions":7984},"NCT04909333","Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia",[90],"2021-04-29",[7983],"Endogenous Hyperinsulinism",[7963,7985],"0.9% saline solution",{"intervention":7985,"totalTrials":179,"cells":7987},{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":7992,"PHASE3":7994,"PHASE4":7996,"NA":7998},{"trials":7989,"activeCount":98},[],{"trials":7991,"activeCount":98},[],{"trials":7993,"activeCount":98},[],{"trials":7995,"activeCount":98},[],{"trials":7997,"activeCount":98},[],{"trials":7999,"activeCount":98},[8000],{"nctId":7978,"briefTitle":7979,"status":108,"phases":8001,"primaryCompletion":4192,"completion":4192,"start":7981,"enrollment":2164,"conditions":8002,"interventions":8003},[90],[7983],[7963,7985]]